{"text_format":"1","workbook":"xlsx","n_sheets":31,"sheets":["CoverSheet","Data","Impact Outcome Indicators_1A","Coverage Indicators_1B","ImpactOutcomeDisaggData","Impactoutcome","Coverage Indicators","CoverageDisaggregationData","WPTM_1C","Intervention By Modules old","Intervention By Modules","PR Cash Reconciliation_2A,B,C","SR_Cash Reconciliation_2D","Budget Variance_2E","Procurement_3","Grant Management_4","PR-LFA Evaluation_5","LFA_Findings&Recommendations_6","PR EFR_7A","LFA EFR_7B","Annual Cash Forecast_8A"," Request and Recommendation_8B","PR Authorization_9A","LFA Authorization_9B","PR_Disbursement Request_7","Modules","EFR Data","Checklist","Memo HIV","Memo TB","Memo Malaria"],"not_rendered":{"charts":0,"images":2,"macros":1,"external_links":11,"defined_names":554,"comments":2,"pivot_tables":0},"unopened":[],"bounds":{"document_bytes":16777216,"sheet_cells":100000,"rows_first":2000,"rows_last":500,"rows_between":2000,"halvings":0,"cell_chars":16384,"cell_head_chars":4096},"cells_cut":0,"cells_raw":0,"read":"whole","date_system":"1900"}

{"sheet":"CoverSheet","index":0,"n_rows":15,"n_cols":12,"rows_kept":15,"cut":false,"hidden":false,"merged":[[14,3,14,5],[9,0,9,2],[10,0,10,2],[0,0,0,11],[4,0,4,2],[5,0,5,2],[6,0,6,2],[7,0,7,2],[8,0,8,2],[1,0,2,14],[0,12,0,14],[8,5,8,11]]}
["Ongoing Progress Update and Disbursement Request"]
["Cover Sheet: Instructions\n\n• This template is compatible with MS Excel 2013 and later versions. Some drop-downs and formulae may not work with earlier versions and specifically MS Excel 2010. Hence, PRs with earlier MS versions are requested to upgrade to MS Excel 2013 to have the full functionalities of the tool.\n\n• Principal Recipients are first required to complete the Cover Sheet with the General Grant Information listed in the boxes below. They can refer to their Grant Face Sheet/Grant Confirmation to fill part of this information.\n\n• Principal Recipients are required to fill in the information related to the periods covered by the progress update and disbursement request.\n\n• Principal Recipients are required to select the type of submission, i.e. whether they are submitting a Mid-Year (or Quarterly) Progress Update or a Year-End Progress Update/Disbursement Request. This is important as the forms will change depending on the type of submission selected."]
[]
["GENERAL GRANT INFORMATION"]
["Country:",null,null,"Georgia",null,"PROGRESS UPDATE PERIOD FOR PROGRAMMATIC REPORTING"]
["(Disease) Component",null,null,"Tuberculosis",null,"Progress Update - Reporting Period:",null,null,"Cycle:","Annual","Number:",5]
["Grant Name/Number:",null,null,"GEO-T-NCDC",null,"Progress Update - Period Covered:",null,null,"Beginning Date:","2016-01-01","End Date:","2016-12-31"]
["Principal Recipient:",null,null,"NCDC"]
["LFA Name:",null,null,"UNOPS",null,"PROGRESS UPDATE PERIOD FOR FINANCIAL REPORTING"]
["Program Start Date:",null,null,"2014-04-01",null,"Progress Update - Period Covered:",null,null,"Beginning Date:","2016-01-01","End Date:","2016-12-31"]
["Currency:",null,null,"EUR"]
[null,null,null,null,null,"DISBURSEMENT REQUEST "]
[null,null,null,null,null,"Disbursement Request  - Disbursement Period:",null,null,"Cycle:",null,"Number:","N/A"]
[null,null,null,null,null,"Disbursement Request  - Period Covered:",null,null,"Beginning Date:","N/A","End Date:","N/A"]
[null,null,null,"Are you submitting:\n•    A Progress Update (PU); or \n•    A Progress Update/Disbursement Request (PU/DR)."]

{"sheet":"Data","index":1,"n_rows":307,"n_cols":19,"rows_kept":307,"cut":false,"hidden":true,"merged":[]}
["Component","Catalog Module Name","Intervention Name","Old Component","Module - Intervention",null,null,null,"Component",null,null,"Component","Catalog Module Name",null,"Component","Impact/Outcome",null,null,"Data Sources "]
["Malaria","Specific prevention interventions (SPI)","Intermittent preventive treatment (IPT) - In pregnancy","Malaria",{"$f":"CONCATENATE(B2,\"  -  \",C2)","v":"Specific prevention interventions (SPI)  -  Intermittent preventive treatment (IPT) - In pregnancy"},null,null,null,"Malaria",null,null,"Malaria","Specific prevention interventions (SPI)","Module1","Malaria","Impact",{"$f":"CONCATENATE(O2,P2)","v":"MalariaImpact"},"Type1","HMIS"]
["Malaria","Specific prevention interventions (SPI)","Intermittent preventive treatment (IPT) - In infancy","Malaria",{"$f":"CONCATENATE(B3,\"  -  \",C3)","v":"Specific prevention interventions (SPI)  -  Intermittent preventive treatment (IPT) - In infancy"},null,null,null,"Tuberculosis",null,null,"Malaria","Vector control","Module2","Tuberculosis","Impact",{"$f":"CONCATENATE(O3,P3)","v":"TuberculosisImpact"},"Type2","Patient records"]
["Malaria","Specific prevention interventions (SPI)","Seasonal malaria chemoprevention","Malaria","Specific prevention interventions (SPI)  -  Seasonal malaria chemoprevention",null,null,null,"HIV/TB",null,null,"Malaria","Case management","Module3","HIV/TB","Impact","HIV/TBImpact","Type3","Training records"]
["Malaria","Specific prevention interventions (SPI)","IEC/BCC","Malaria","Specific prevention interventions (SPI)  -  IEC/BCC",null,null,null,"HIV/AIDS",null,null,"Tuberculosis","TB care and prevention","Module4","HIV/AIDS","Impact","HIV/AIDSImpact","Type4","MICS (Multiple Indicator Cluster Survey)"]
["Malaria","Vector control","Long-lasting insecticidal nets (LLIN) - Mass campaign","Malaria","Vector control  -  Long-lasting insecticidal nets (LLIN) - Mass campaign",null,null,null,"Health Systems Strengthening",null,null,"Tuberculosis","MDR-TB","Module5","Health Systems Strengthening","Impact","Health Systems StrengtheningImpact","Type5","DHS/DHS+ (Demographic and Health\nSurvey)"]
["Malaria","Vector control","Long-lasting insecticidal nets (LLIN) - Continuous distribution","Malaria","Vector control  -  Long-lasting insecticidal nets (LLIN) - Continuous distribution",null,null,null,null,null,null,"HIV/TB","TB care and prevention","Module6","Malaria","Outcome","MalariaOutcome","Type6","AIS (AIDS Indicator Survey)"]
["Malaria","Vector control","Indoor residual spraying (IRS)","Malaria","Vector control  -  Indoor residual spraying (IRS)",null,null,null,null,null,null,"HIV/TB","MDR-TB","Module7","Tuberculosis","Outcome","TuberculosisOutcome","Type7","BSS (Behavioral Surveillance Survey)"]
["Malaria","Vector control","Other vector vontrol measures","Malaria","Vector control  -  Other vector vontrol measures",null,null,null,null,null,null,"HIV/TB","Prevention programs for general population","Module8","HIV/TB","Outcome","HIV/TBOutcome","Type8","Health Facility survey"]
["Malaria","Vector control","Entomological monitoring","Malaria","Vector control  -  Entomological monitoring",null,null,null,null,null,null,"HIV/TB","Prevention programs for MSM and TGs","Module9","HIV/AIDS","Outcome","HIV/AIDSOutcome","Type9","SAMS (Service Availability Mapping\nSurvey)"]
["Malaria","Case management","Facility-based treatment","Malaria","Case management  -  Facility-based treatment",null,null,null,null,null,null,"HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners","Module10","Health Systems Strengthening","Outcome","Health Systems StrengtheningOutcome","Type10","Households survey"]
["Malaria","Case management","Epidemic preparedness and response","Malaria","Case management  -  Epidemic preparedness and response",null,null,null,null,null,null,"HIV/TB","Prevention programs for other vulnerable populations (please specify)","Module11",null,null,null,null,"Specific surveys and research (specify)"]
["Malaria","Case management","Integrated community case management (ICCM)","Malaria","Case management  -  Integrated community case management (ICCM)",null,null,null,null,null,null,"HIV/TB","Prevention programs for adolescents and youth, in and out of school","Module12",null,null,null,null,"Reports (specify)"]
["Malaria","Case management","Active case detection and investigation (elimination phase)","Malaria","Case management  -  Active case detection and investigation (elimination phase)",null,null,null,null,null,null,"HIV/TB","Prevention programs for sex workers and their clients","Module13",null,null,null,null,"Vital and disease-specific registry"]
["Malaria","Case management","Therapeutic efficacy surveillance","Malaria","Case management  -  Therapeutic efficacy surveillance",null,null,null,null,null,null,"HIV/TB","PMTCT","Module14",null,null,null,null,"Operational Research"]
["Malaria","Case management","Severe malaria","Malaria","Case management  -  Severe malaria",null,null,null,null,null,null,"HIV/TB","Treatment, care and support","Module15",null,null,null,null,"Health Provider survey"]
["Malaria","Case management","Private sector co-payment mechanism","Malaria","Case management  -  Private sector co-payment mechanism",null,null,null,null,null,null,"HIV/AIDS","Prevention programs for general population","Module16",null,null,null,null,"National Health Account"]
["Malaria","Case management","Private sector case management (other)","Malaria","Case management  -  Private sector case management (other)",null,null,null,null,null,null,"HIV/AIDS","Prevention programs for MSM and TGs","Module17",null,null,null,null,"Administrative records"]
["Malaria","Case management","Ensuring drug quality","Malaria","Case management  -  Ensuring drug quality",null,null,null,null,null,null,"HIV/AIDS","Prevention programs for people who inject drugs (PWID) and their partners","Module18",null,null,null,null,"R&R TB system, quarterly reports"]
["Tuberculosis","TB care and prevention","Case detection and diagnosis","Tuberculosis; HIV/TB","TB care and prevention  -  Case detection and diagnosis",null,null,null,null,null,null,"HIV/AIDS","Prevention programs for other vulnerable populations (please specify)","Module19",null,null,null,null,"R&R TB system, yearly management report "]
["Tuberculosis","TB care and prevention","Treatment","Tuberculosis; HIV/TB","TB care and prevention  -  Treatment",null,null,null,null,null,null,"HIV/AIDS","Prevention programs for adolescents and youth, in and out of school","Module20",null,null,null,null,"TB prevalence survey"]
["Tuberculosis","TB care and prevention","Prevention","Tuberculosis; HIV/TB","TB care and prevention  -  Prevention",null,null,null,null,null,null,"HIV/AIDS","Prevention programs for sex workers and their clients","Module21",null,null,null,null,"TB patient register"]
["Tuberculosis","MDR-TB","Case detection and diagnosis: MDR-TB","Tuberculosis; HIV/TB","MDR-TB  -  Case detection and diagnosis: MDR-TB",null,null,null,null,null,null,"HIV/AIDS","PMTCT","Module22",null,null,null,null,"TB laboratory register"]
["Tuberculosis","MDR-TB","Treatment: MDR-TB","Tuberculosis; HIV/TB","MDR-TB  -  Treatment: MDR-TB",null,null,null,null,null,null,"HIV/AIDS","Treatment, care and support","Module23",null,null,null,null,"TB treatment card"]
["Tuberculosis","MDR-TB","Prevention for MDR-TB","Tuberculosis; HIV/TB","MDR-TB  -  Prevention for MDR-TB",null,null,null,null,null,null,"HIV/AIDS","TB/HIV","Module24",null,null,null,null,"Specify- Reports, Surveys, Questionnaires etc."]
["HIV/TB","TB care and prevention","Case detection and diagnosis","Tuberculosis; HIV/TB","TB care and prevention  -  Case detection and diagnosis",null,null,null,null,null,null,"Tuberculosis","TB/HIV","Module25",null,null,null,null,"MIS (Malaria Indicator Survey)"]
["HIV/TB","TB care and prevention","Treatment","Tuberculosis; HIV/TB","TB care and prevention  -  Treatment",null,null,null,null,null,null,"HIV/TB","TB/HIV","Module26",null,null,null,null,"Situation Analysis"]
["HIV/TB","TB care and prevention","Prevention","Tuberculosis; HIV/TB","TB care and prevention  -  Prevention",null,null,null,null,null,null,"HIV/AIDS","Removing legal barriers to access","Module27",null,null,null,null,"Key informant survey"]
["HIV/TB","MDR-TB","Case detection and diagnosis: MDR-TB","Tuberculosis; HIV/TB","MDR-TB  -  Case detection and diagnosis: MDR-TB",null,null,null,null,null,null,"HIV/AIDS","HSS - Service delivery","Module28",null,null,null,null,"Surveillance systems"]
["HIV/TB","MDR-TB","Treatment: MDR-TB","Tuberculosis; HIV/TB","MDR-TB  -  Treatment: MDR-TB",null,null,null,null,null,null,"HIV/AIDS","HSS - Health and community workforce","Module29",null,null,null,null,"Modelled"]
["HIV/TB","MDR-TB","Prevention for MDR-TB","Tuberculosis; HIV/TB","MDR-TB  -  Prevention for MDR-TB",null,null,null,null,null,null,"HIV/AIDS","HSS - Health information systems and M&E","Module30",null,null,null,null,"Other survey, specify"]
["HIV/TB","Prevention programs for general population","RMNCH linkages and gender-based violence (GBV)","HIV/AIDS; HIV/TB","Prevention programs for general population  -  RMNCH linkages and gender-based violence (GBV)",null,null,null,null,null,null,"HIV/AIDS","Program management","Module31",null,null,null,null,"IBBS"]
["HIV/TB","Prevention programs for general population","Other interventions for general population - Please specify","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Other interventions for general population - Please specify",null,null,null,null,null,null,"HIV/AIDS","HSS - Procurement supply chain management (PSCM)","Module32"]
["HIV/TB","Prevention programs for MSM and TGs","Behavioral change as part of programs for MSM and TGs","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  Behavioral change as part of programs for MSM and TGs",null,null,null,null,null,null,"HIV/AIDS","HSS - Policy and governance","Module33"]
["HIV/TB","Prevention programs for MSM and TGs","Condoms as part of programs for MSM and TGs","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  Condoms as part of programs for MSM and TGs",null,null,null,null,null,null,"HIV/AIDS","HSS - Healthcare financing","Module34"]
["HIV/TB","Prevention programs for MSM and TGs","HIV testing and counseling as part of programs for MSM and TGs","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  HIV testing and counseling as part of programs for MSM and TGs",null,null,null,null,null,null,"HIV/AIDS","HSS - Financial management","Module35"]
["HIV/TB","Prevention programs for MSM and TGs","Diagnosis and treatment of STIs as part of programs for MSM and TGs","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  Diagnosis and treatment of STIs as part of programs for MSM and TGs",null,null,null,null,null,null,"Tuberculosis","Removing legal barriers to access","Module36"]
["HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners","Needle and Syringe programs as part of programs for PWID and their partners","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Needle and Syringe programs as part of programs for PWID and their partners",null,null,null,null,null,null,"Tuberculosis","HSS - Service delivery","Module37"]
["HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners","OST and other drug dependence treatment (PWIDs and their partners)","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  OST and other drug dependence treatment (PWIDs and their partners)",null,null,null,null,null,null,"Tuberculosis","HSS - Health and community workforce","Module38"]
["HIV/TB","Prevention programs for other vulnerable populations (please specify)","Condoms as part of programs for other vulnerable populations","HIV/AIDS; HIV/TB","Prevention programs for other vulnerable populations (please specify)  -  Condoms as part of programs for other vulnerable populations",null,null,null,null,null,null,"Tuberculosis","HSS - Health information systems and M&E","Module39"]
["HIV/TB","Prevention programs for other vulnerable populations (please specify)","Behavioral change as part of programs for other vulnerable populations","HIV/AIDS; HIV/TB","Prevention programs for other vulnerable populations (please specify)  -  Behavioral change as part of programs for other vulnerable populations",null,null,null,null,null,null,"Tuberculosis","Program management","Module40"]
["HIV/TB","Prevention programs for other vulnerable populations (please specify)","Diagnosis and treatment of STIs (other vulnerable populations)","HIV/AIDS; HIV/TB","Prevention programs for other vulnerable populations (please specify)  -  Diagnosis and treatment of STIs (other vulnerable populations)",null,null,null,null,null,null,"Tuberculosis","HSS - Procurement supply chain management (PSCM)","Module41"]
["HIV/TB","Prevention programs for other vulnerable populations (please specify)","Other interventions for other vulnerable populations - Please specify","HIV/AIDS; HIV/TB","Prevention programs for other vulnerable populations (please specify)  -  Other interventions for other vulnerable populations - Please specify",null,null,null,null,null,null,"Tuberculosis","HSS - Policy and governance","Module42"]
["HIV/TB","Prevention programs for adolescents and youth, in and out of school","Behavioral change as part of programs for adolescent and youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  Behavioral change as part of programs for adolescent and youth",null,null,null,null,null,null,"Tuberculosis","HSS - Healthcare financing","Module43"]
["HIV/TB","Prevention programs for adolescents and youth, in and out of school","Condoms part of programs for adolescent and youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  Condoms part of programs for adolescent and youth",null,null,null,null,null,null,"Tuberculosis","HSS - Financial management","Module44"]
["HIV/TB","Prevention programs for general population","Behavioral change as part of programs for general population","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Behavioral change as part of programs for general population",null,null,null,null,null,null,"Malaria","Removing legal barriers to access","Module45"]
["HIV/TB","Prevention programs for general population","Condoms as part of programs for general population","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Condoms as part of programs for general population",null,null,null,null,null,null,"Malaria","HSS - Service delivery","Module46"]
["HIV/TB","Prevention programs for general population","Male circumcision","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Male circumcision",null,null,null,null,null,null,"Malaria","HSS - Health and community workforce","Module47"]
["HIV/TB","Prevention programs for MSM and TGs","Diagnosis and treatment of viral hepatitis as part of programs for MSM and TGs","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  Diagnosis and treatment of viral hepatitis as part of programs for MSM and TGs",null,null,null,null,null,null,"Malaria","HSS - Health information systems and M&E","Module48"]
["HIV/TB","Prevention programs for MSM and TGs","Other interventions for MSM and TGs - Please specify","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  Other interventions for MSM and TGs - Please specify",null,null,null,null,null,null,"Malaria","Program management","Module49"]
["HIV/TB","Prevention programs for sex workers and their clients","Behavioral change as part of programs for sex workers and their clients","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  Behavioral change as part of programs for sex workers and their clients",null,null,null,null,null,null,"Malaria","HSS - Procurement supply chain management (PSCM)","Module50"]
["HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners","Diagnosis and treatment of viral hepatitis (PWIDs and their partners)","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Diagnosis and treatment of viral hepatitis (PWIDs and their partners)",null,null,null,null,null,null,"Malaria","HSS - Policy and governance","Module51"]
["HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners","Other interventions for IDUs and their partners - Please specify","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Other interventions for IDUs and their partners - Please specify",null,null,null,null,null,null,"Malaria","HSS - Healthcare financing","Module52"]
["HIV/TB","Prevention programs for other vulnerable populations (please specify)","HIV testing and counseling as part of programs for other vulnerable populations","HIV/AIDS; HIV/TB","Prevention programs for other vulnerable populations (please specify)  -  HIV testing and counseling as part of programs for other vulnerable populations",null,null,null,null,null,null,"Malaria","HSS - Financial management","Module53"]
["HIV/TB","Prevention programs for adolescents and youth, in and out of school","HIV testing and counseling as part of programs for adolescent and youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  HIV testing and counseling as part of programs for adolescent and youth",null,null,null,null,null,null,"Health Systems Strengthening","Removing legal barriers to access","Module54"]
["HIV/TB","Prevention programs for adolescents and youth, in and out of school","RMNCH linkages and GBV as part of programs for adolescent youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  RMNCH linkages and GBV as part of programs for adolescent youth",null,null,null,null,null,null,"Health Systems Strengthening","HSS - Service delivery","Module55"]
["HIV/TB","Prevention programs for adolescents and youth, in and out of school","Young Key Population interventions as part of programs for adolescent and youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  Young Key Population interventions as part of programs for adolescent and youth",null,null,null,null,null,null,"Health Systems Strengthening","HSS - Health and community workforce","Module56"]
["HIV/TB","Prevention programs for adolescents and youth, in and out of school","Other interventions for adolescent and youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  Other interventions for adolescent and youth",null,null,null,null,null,null,"Health Systems Strengthening","HSS - Health information systems and M&E","Module57"]
["HIV/TB","Prevention programs for general population","HIV testing and counseling as part of programs for general population","HIV/AIDS; HIV/TB","Prevention programs for general population  -  HIV testing and counseling as part of programs for general population",null,null,null,null,null,null,"Health Systems Strengthening","Program management","Module58"]
["HIV/TB","Prevention programs for sex workers and their clients","Condoms as part of programs for sex workers and their clients","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  Condoms as part of programs for sex workers and their clients",null,null,null,null,null,null,"Health Systems Strengthening","HSS - Procurement supply chain management (PSCM)","Module59"]
["HIV/TB","Prevention programs for sex workers and their clients","HIV testing and counseling as part of programs for sex workers and their clients","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  HIV testing and counseling as part of programs for sex workers and their clients",null,null,null,null,null,null,"Health Systems Strengthening","HSS - Policy and governance","Module60"]
["HIV/TB","Prevention programs for sex workers and their clients","Diagnosis and treatment of STIs (sex workers and their clients)","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  Diagnosis and treatment of STIs (sex workers and their clients)",null,null,null,null,null,null,"Health Systems Strengthening","HSS - Healthcare financing","Module61"]
["HIV/TB","Prevention programs for sex workers and their clients","Harm reduction as part of programs for sex workers and their clients","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  Harm reduction as part of programs for sex workers and their clients",null,null,null,null,null,null,"Health Systems Strengthening","HSS - Financial management","Module62"]
["HIV/TB","PMTCT","Prong 1: Primary prevention of HIV infection among women of childbearing age","HIV/AIDS; HIV/TB","PMTCT  -  Prong 1: Primary prevention of HIV infection among women of childbearing age",null,null,null,null,null,null,"HIV/TB","Removing legal barriers to access","Module63"]
["HIV/TB","PMTCT","Prong 2: Preventing unintended pregnancies among women living with HIV","HIV/AIDS; HIV/TB","PMTCT  -  Prong 2: Preventing unintended pregnancies among women living with HIV",null,null,null,null,null,null,"HIV/TB","HSS - Service delivery","Module64"]
["HIV/TB","PMTCT","Prong 3: Preventing vertical HIV transmission","HIV/AIDS; HIV/TB","PMTCT  -  Prong 3: Preventing vertical HIV transmission",null,null,null,null,null,null,"HIV/TB","HSS - Health and community workforce","Module65"]
["HIV/TB","PMTCT","Prong 4: Treatment, care & support to mothers living with HIV, their children &","HIV/AIDS; HIV/TB",{"$f":"CONCATENATE(B67,\"  -  \",C67)","v":"PMTCT  -  Prong 4: Treatment, care & support to mothers living with HIV, their children &"},null,null,null,null,null,null,"HIV/TB","HSS - Health information systems and M&E","Module66"]
["HIV/TB","PMTCT","Other interventions for PMTCT- Please specify","HIV/AIDS; HIV/TB","PMTCT  -  Other interventions for PMTCT- Please specify",null,null,null,null,null,null,"HIV/TB","Program management","Module67"]
["HIV/TB","Prevention programs for sex workers and their clients","Other interventions for sex workers and their clients - Please specify","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  Other interventions for sex workers and their clients - Please specify",null,null,null,null,null,null,"HIV/TB","HSS - Procurement supply chain management (PSCM)","Module68"]
["HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners","Behavioural change as part of programs for PWID and their partners","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Behavioural change as part of programs for PWID and their partners",null,null,null,null,null,null,"HIV/TB","HSS - Policy and governance","Module69"]
["HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners","Condoms as part of programs for PWID and their partners","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Condoms as part of programs for PWID and their partners",null,null,null,null,null,null,"HIV/TB","HSS - Healthcare financing","Module70"]
["HIV/TB","Treatment, care and support","Pre-ART care","HIV/AIDS; HIV/TB","Treatment, care and support  -  Pre-ART care",null,null,null,null,null,null,"HIV/TB","HSS - Financial management","Module71"]
["HIV/TB","Treatment, care and support","Antiretroviral Therapy (ART)","HIV/AIDS; HIV/TB","Treatment, care and support  -  Antiretroviral Therapy (ART)",null,null,null,null,null,null,"HIV/AIDS","Community systems strengthening","Module72"]
["HIV/TB","Treatment, care and support","Treatment monitoring","HIV/AIDS; HIV/TB","Treatment, care and support  -  Treatment monitoring",null,null,null,null,null,null,"HIV/AIDS","Results based Financing","Module73"]
["HIV/TB","Treatment, care and support","Treatment adherence","HIV/AIDS; HIV/TB","Treatment, care and support  -  Treatment adherence",null,null,null,null,null,null,"Tuberculosis","Community systems strengthening","Module74"]
["HIV/TB","Treatment, care and support","Prevention, diagnosis and treatment of opportunistic infections","HIV/AIDS; HIV/TB","Treatment, care and support  -  Prevention, diagnosis and treatment of opportunistic infections",null,null,null,null,null,null,"Tuberculosis","Results based Financing","Module75"]
["HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners","Diagnosis and treatment of STIs as part of programs for PWID and their partners","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Diagnosis and treatment of STIs as part of programs for PWID and their partners",null,null,null,null,null,null,"Malaria","Community systems strengthening","Module76"]
["HIV/TB","Treatment, care and support","Counseling and psycho-social support","HIV/AIDS; HIV/TB","Treatment, care and support  -  Counseling and psycho-social support",null,null,null,null,null,null,"Malaria","Results based Financing","Module77"]
["HIV/TB","Treatment, care and support","Out-patient care","HIV/AIDS; HIV/TB","Treatment, care and support  -  Out-patient care",null,null,null,null,null,null,"HIV/TB","Community systems strengthening","Module78"]
["HIV/TB","Treatment, care and support","In-patient care","HIV/AIDS; HIV/TB","Treatment, care and support  -  In-patient care",null,null,null,null,null,null,"HIV/TB","Results based Financing","Module79"]
["HIV/TB","Treatment, care and support","Other interventions for treatment - Please specify","HIV/AIDS; HIV/TB","Treatment, care and support  -  Other interventions for treatment - Please specify"]
["HIV/TB","Prevention programs for general population","Diagnosis and treatment of STIs as part of programs for general population","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Diagnosis and treatment of STIs as part of programs for general population"]
["HIV/TB","Prevention programs for general population","Blood safety","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Blood safety"]
["HIV/AIDS","Prevention programs for general population","Orphan and vulnerable children (OVC) package","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Orphan and vulnerable children (OVC) package"]
["HIV/AIDS","Prevention programs for general population","RMNCH linkages and gender-based violence (GBV)","HIV/AIDS; HIV/TB","Prevention programs for general population  -  RMNCH linkages and gender-based violence (GBV)"]
["HIV/AIDS","Prevention programs for general population","Other interventions for general population - Please specify","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Other interventions for general population - Please specify"]
["HIV/AIDS","Prevention programs for MSM and TGs","Behavioral change as part of programs for MSM and TGs","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  Behavioral change as part of programs for MSM and TGs"]
["HIV/AIDS","Prevention programs for MSM and TGs","Condoms as part of programs for MSM and TGs","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  Condoms as part of programs for MSM and TGs"]
["HIV/AIDS","Prevention programs for MSM and TGs","HIV testing and counseling as part of programs for MSM and TGs","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  HIV testing and counseling as part of programs for MSM and TGs"]
["HIV/AIDS","Prevention programs for MSM and TGs","Diagnosis and treatment of STIs as part of programs for MSM and TGs","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  Diagnosis and treatment of STIs as part of programs for MSM and TGs"]
["HIV/AIDS","Prevention programs for people who inject drugs (PWID) and their partners","Needle and Syringe programs as part of programs for PWID and their partners","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Needle and Syringe programs as part of programs for PWID and their partners"]
["HIV/AIDS","Prevention programs for people who inject drugs (PWID) and their partners","OST and other drug dependence treatment (PWIDs and their partners)","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  OST and other drug dependence treatment (PWIDs and their partners)"]
["HIV/AIDS","Prevention programs for other vulnerable populations (please specify)","Condoms as part of programs for other vulnerable populations","HIV/AIDS; HIV/TB","Prevention programs for other vulnerable populations (please specify)  -  Condoms as part of programs for other vulnerable populations"]
["HIV/AIDS","Prevention programs for other vulnerable populations (please specify)","Behavioral change as part of programs for other vulnerable populations","HIV/AIDS; HIV/TB","Prevention programs for other vulnerable populations (please specify)  -  Behavioral change as part of programs for other vulnerable populations"]
["HIV/AIDS","Prevention programs for other vulnerable populations (please specify)","Diagnosis and treatment of STIs (other vulnerable populations)","HIV/AIDS; HIV/TB","Prevention programs for other vulnerable populations (please specify)  -  Diagnosis and treatment of STIs (other vulnerable populations)"]
["HIV/AIDS","Prevention programs for other vulnerable populations (please specify)","Other interventions for other vulnerable populations - Please specify","HIV/AIDS; HIV/TB","Prevention programs for other vulnerable populations (please specify)  -  Other interventions for other vulnerable populations - Please specify"]
["HIV/AIDS","Prevention programs for adolescents and youth, in and out of school","Behavioral change as part of programs for adolescent and youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  Behavioral change as part of programs for adolescent and youth"]
["HIV/AIDS","Prevention programs for adolescents and youth, in and out of school","Condoms part of programs for adolescent and youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  Condoms part of programs for adolescent and youth"]
["HIV/AIDS","Prevention programs for general population","Behavioral change as part of programs for general population","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Behavioral change as part of programs for general population"]
["HIV/AIDS","Prevention programs for general population","Condoms as part of programs for general population","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Condoms as part of programs for general population"]
["HIV/AIDS","Prevention programs for general population","Male circumcision","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Male circumcision"]
["HIV/AIDS","Prevention programs for MSM and TGs","Diagnosis and treatment of viral hepatitis as part of programs for MSM and TGs","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  Diagnosis and treatment of viral hepatitis as part of programs for MSM and TGs"]
["HIV/AIDS","Prevention programs for MSM and TGs","Other interventions for MSM and TGs - Please specify","HIV/AIDS; HIV/TB","Prevention programs for MSM and TGs  -  Other interventions for MSM and TGs - Please specify"]
["HIV/AIDS","Prevention programs for sex workers and their clients","Behavioral change as part of programs for sex workers and their clients","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  Behavioral change as part of programs for sex workers and their clients"]
["HIV/AIDS","Prevention programs for people who inject drugs (PWID) and their partners","Diagnosis and treatment of viral hepatitis (PWIDs and their partners)","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Diagnosis and treatment of viral hepatitis (PWIDs and their partners)"]
["HIV/AIDS","Prevention programs for people who inject drugs (PWID) and their partners","Other interventions for IDUs and their partners - Please specify","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Other interventions for IDUs and their partners - Please specify"]
["HIV/AIDS","Prevention programs for other vulnerable populations (please specify)","HIV testing and counseling as part of programs for other vulnerable populations","HIV/AIDS; HIV/TB","Prevention programs for other vulnerable populations (please specify)  -  HIV testing and counseling as part of programs for other vulnerable populations"]
["HIV/AIDS","Prevention programs for adolescents and youth, in and out of school","HIV testing and counseling as part of programs for adolescent and youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  HIV testing and counseling as part of programs for adolescent and youth"]
["HIV/AIDS","Prevention programs for adolescents and youth, in and out of school","RMNCH linkages and GBV as part of programs for adolescent youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  RMNCH linkages and GBV as part of programs for adolescent youth"]
["HIV/AIDS","Prevention programs for adolescents and youth, in and out of school","Young Key Population interventions as part of programs for adolescent and youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  Young Key Population interventions as part of programs for adolescent and youth"]
["HIV/AIDS","Prevention programs for adolescents and youth, in and out of school","Other interventions for adolescent and youth","HIV/AIDS; HIV/TB","Prevention programs for adolescents and youth, in and out of school  -  Other interventions for adolescent and youth"]
["HIV/AIDS","Prevention programs for general population","HIV testing and counseling as part of programs for general population","HIV/AIDS; HIV/TB","Prevention programs for general population  -  HIV testing and counseling as part of programs for general population"]
["HIV/AIDS","Prevention programs for sex workers and their clients","Condoms as part of programs for sex workers and their clients","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  Condoms as part of programs for sex workers and their clients"]
["HIV/AIDS","Prevention programs for sex workers and their clients","HIV testing and counseling as part of programs for sex workers and their clients","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  HIV testing and counseling as part of programs for sex workers and their clients"]
["HIV/AIDS","Prevention programs for sex workers and their clients","Diagnosis and treatment of STIs (sex workers and their clients)","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  Diagnosis and treatment of STIs (sex workers and their clients)"]
["HIV/AIDS","Prevention programs for sex workers and their clients","Harm reduction as part of programs for sex workers and their clients","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  Harm reduction as part of programs for sex workers and their clients"]
["HIV/AIDS","PMTCT","Prong 1: Primary prevention of HIV infection among women of childbearing age","HIV/AIDS; HIV/TB","PMTCT  -  Prong 1: Primary prevention of HIV infection among women of childbearing age"]
["HIV/AIDS","PMTCT","Prong 2: Preventing unintended pregnancies among women living with HIV","HIV/AIDS; HIV/TB","PMTCT  -  Prong 2: Preventing unintended pregnancies among women living with HIV"]
["HIV/AIDS","PMTCT","Prong 3: Preventing vertical HIV transmission","HIV/AIDS; HIV/TB","PMTCT  -  Prong 3: Preventing vertical HIV transmission"]
["HIV/AIDS","PMTCT","Prong 4: Treatment, care & support to mothers living with HIV, their children &","HIV/AIDS; HIV/TB","PMTCT  -  Prong 4: Treatment, care & support to mothers living with HIV, their children &"]
["HIV/AIDS","PMTCT","Other interventions for PMTCT- Please specify","HIV/AIDS; HIV/TB","PMTCT  -  Other interventions for PMTCT- Please specify"]
["HIV/AIDS","Prevention programs for sex workers and their clients","Other interventions for sex workers and their clients - Please specify","HIV/AIDS; HIV/TB","Prevention programs for sex workers and their clients  -  Other interventions for sex workers and their clients - Please specify"]
["HIV/AIDS","Prevention programs for people who inject drugs (PWID) and their partners","Behavioural change as part of programs for PWID and their partners","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Behavioural change as part of programs for PWID and their partners"]
["HIV/AIDS","Prevention programs for people who inject drugs (PWID) and their partners","Condoms as part of programs for PWID and their partners","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Condoms as part of programs for PWID and their partners"]
["HIV/AIDS","Treatment, care and support","Pre-ART care","HIV/AIDS; HIV/TB","Treatment, care and support  -  Pre-ART care"]
["HIV/AIDS","Treatment, care and support","Antiretroviral Therapy (ART)","HIV/AIDS; HIV/TB","Treatment, care and support  -  Antiretroviral Therapy (ART)"]
["HIV/AIDS","Treatment, care and support","Treatment monitoring","HIV/AIDS; HIV/TB","Treatment, care and support  -  Treatment monitoring"]
["HIV/AIDS","Treatment, care and support","Treatment adherence","HIV/AIDS; HIV/TB","Treatment, care and support  -  Treatment adherence"]
["HIV/AIDS","Treatment, care and support","Prevention, diagnosis and treatment of opportunistic infections","HIV/AIDS; HIV/TB","Treatment, care and support  -  Prevention, diagnosis and treatment of opportunistic infections"]
["HIV/AIDS","Prevention programs for people who inject drugs (PWID) and their partners","Diagnosis and treatment of STIs as part of programs for PWID and their partners","HIV/AIDS; HIV/TB","Prevention programs for people who inject drugs (PWID) and their partners  -  Diagnosis and treatment of STIs as part of programs for PWID and their partners"]
["HIV/AIDS","Treatment, care and support","Counseling and psycho-social support","HIV/AIDS; HIV/TB",{"$f":"CONCATENATE(B131,\"  -  \",C131)","v":"Treatment, care and support  -  Counseling and psycho-social support"}]
["HIV/AIDS","Treatment, care and support","Out-patient care","HIV/AIDS; HIV/TB","Treatment, care and support  -  Out-patient care"]
["HIV/AIDS","Treatment, care and support","In-patient care","HIV/AIDS; HIV/TB","Treatment, care and support  -  In-patient care"]
["HIV/AIDS","Treatment, care and support","Other interventions for treatment - Please specify","HIV/AIDS; HIV/TB","Treatment, care and support  -  Other interventions for treatment - Please specify"]
["HIV/AIDS","Prevention programs for general population","Diagnosis and treatment of STIs as part of programs for general population","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Diagnosis and treatment of STIs as part of programs for general population"]
["HIV/AIDS","Prevention programs for general population","Blood safety","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Blood safety"]
["HIV/AIDS","Prevention programs for general population","Orphan and vulnerable children (OVC) package","HIV/AIDS; HIV/TB","Prevention programs for general population  -  Orphan and vulnerable children (OVC) package"]
["HIV/AIDS","TB/HIV","TB/HIV collaborative interventions","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  TB/HIV collaborative interventions"]
["HIV/AIDS","TB/HIV","Engaging all care providers","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Engaging all care providers"]
["HIV/AIDS","TB/HIV","Community TB care delivery","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Community TB care delivery"]
["HIV/AIDS","TB/HIV","Key Affected Populations","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Key Affected Populations"]
["HIV/AIDS","TB/HIV","Collaborative activities with other programs and sectors","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Collaborative activities with other programs and sectors"]
["Tuberculosis","TB/HIV","TB/HIV collaborative interventions","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  TB/HIV collaborative interventions"]
["Tuberculosis","TB/HIV","Engaging all care providers","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Engaging all care providers"]
["Tuberculosis","TB/HIV","Community TB care delivery","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Community TB care delivery"]
["Tuberculosis","TB/HIV","Key Affected Populations","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Key Affected Populations"]
["Tuberculosis","TB/HIV","Collaborative activities with other programs and sectors","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Collaborative activities with other programs and sectors"]
["HIV/TB","TB/HIV","TB/HIV collaborative interventions","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  TB/HIV collaborative interventions"]
["HIV/TB","TB/HIV","Engaging all care providers","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Engaging all care providers"]
["HIV/TB","TB/HIV","Community TB care delivery","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Community TB care delivery"]
["HIV/TB","TB/HIV","Key Affected Populations","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Key Affected Populations"]
["HIV/TB","TB/HIV","Collaborative activities with other programs and sectors","HIV/AIDS; Tuberculosis; HIV/TB","TB/HIV  -  Collaborative activities with other programs and sectors"]
["HIV/AIDS","Removing legal barriers to access","Training on rights for officials, health workers and police","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Training on rights for officials, health workers and police"]
["HIV/AIDS","HSS - Service delivery","Service organization and facility management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Service organization and facility management"]
["HIV/AIDS","HSS - Service delivery","Improving laboratory systems","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Improving laboratory systems"]
["HIV/AIDS","HSS - Service delivery","Improving service delivery infrastructure","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Improving service delivery infrastructure"]
["HIV/AIDS","HSS - Service delivery","Other","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Other"]
["HIV/AIDS","HSS - Health and community workforce","Health and community workers capacity building","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Health and community workers capacity building"]
["HIV/AIDS","HSS - Health information systems and M&E","Administrative and finance data sources","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Administrative and finance data sources"]
["HIV/AIDS","HSS - Health information systems and M&E","Vital registration system","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Vital registration system"]
["HIV/AIDS","HSS - Health information systems and M&E","Routine reporting","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Routine reporting"]
["HIV/AIDS","HSS - Health information systems and M&E","Analysis, review and transparency","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Analysis, review and transparency"]
["HIV/AIDS","HSS - Health information systems and M&E","Surveys","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Surveys"]
["HIV/AIDS","Program management","Policy, planning, coordination and management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Policy, planning, coordination and management"]
["HIV/AIDS","Program management","Grant management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Grant management"]
["HIV/AIDS","HSS - Health and community workforce","Scaling up health and community workers","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Scaling up health and community workers"]
["HIV/AIDS","HSS - Health and community workforce","Retention and distribution of health and community workers","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Retention and distribution of health and community workers"]
["HIV/AIDS","HSS - Procurement supply chain management (PSCM)","Operationalization of procurement and supply chain management system","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Procurement supply chain management (PSCM)  -  Operationalization of procurement and supply chain management system"]
["HIV/AIDS","HSS - Procurement supply chain management (PSCM)","PSM infrastructure and development of tools","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Procurement supply chain management (PSCM)  -  PSM infrastructure and development of tools"]
["HIV/AIDS","HSS - Policy and governance","Development and implementation of health legislation, strategies and policies","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Policy and governance  -  Development and implementation of health legislation, strategies and policies"]
["HIV/AIDS","Program management","Supporting procurement and supply management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Supporting procurement and supply management"]
["HIV/AIDS","HSS - Policy and governance","Monitoring and reporting implementation of laws and policies","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Policy and governance  -  Monitoring and reporting implementation of laws and policies"]
["HIV/AIDS","HSS - Healthcare financing","Financial sustainability","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Healthcare financing  -  Financial sustainability"]
["HIV/AIDS","HSS - Healthcare financing","Equity of healthcare financing","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Healthcare financing  -  Equity of healthcare financing"]
["HIV/AIDS","HSS - Financial management","Performance,transparency&accountability of financial management system in health","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Financial management  -  Performance,transparency&accountability of financial management system in health"]
["HIV/AIDS","Removing legal barriers to access","Legal and policy environment assessment and law reform","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Legal and policy environment assessment and law reform"]
["HIV/AIDS","Removing legal barriers to access","Legal aid services and legal literacy","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Legal aid services and legal literacy"]
["HIV/AIDS","Removing legal barriers to access","Community-based monitoring of legal rights","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Community-based monitoring of legal rights"]
["HIV/AIDS","Removing legal barriers to access","Policy advocacy on legal rights","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Policy advocacy on legal rights"]
["Tuberculosis","Removing legal barriers to access","Training on rights for officials, health workers and police","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Training on rights for officials, health workers and police"]
["Tuberculosis","HSS - Service delivery","Service organization and facility management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Service organization and facility management"]
["Tuberculosis","HSS - Service delivery","Improving laboratory systems","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Improving laboratory systems"]
["Tuberculosis","HSS - Service delivery","Improving service delivery infrastructure","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Improving service delivery infrastructure"]
["Tuberculosis","HSS - Service delivery","Other","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Other"]
["Tuberculosis","HSS - Health and community workforce","Health and community workers capacity building","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Health and community workers capacity building"]
["Tuberculosis","HSS - Health information systems and M&E","Administrative and finance data sources","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Administrative and finance data sources"]
["Tuberculosis","HSS - Health information systems and M&E","Vital registration system","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Vital registration system"]
["Tuberculosis","HSS - Health information systems and M&E","Routine reporting","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Routine reporting"]
["Tuberculosis","HSS - Health information systems and M&E","Analysis, review and transparency","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Analysis, review and transparency"]
["Tuberculosis","HSS - Health information systems and M&E","Surveys","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Surveys"]
["Tuberculosis","Program management","Policy, planning, coordination and management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Policy, planning, coordination and management"]
["Tuberculosis","Program management","Grant management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Grant management"]
["Tuberculosis","HSS - Health and community workforce","Scaling up health and community workers","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Scaling up health and community workers"]
["Tuberculosis","HSS - Health and community workforce","Retention and distribution of health and community workers","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Retention and distribution of health and community workers"]
["Tuberculosis","HSS - Procurement supply chain management (PSCM)","Operationalization of procurement and supply chain management system","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB",{"$f":"CONCATENATE(B195,\"  -  \",C195)","v":"HSS - Procurement supply chain management (PSCM)  -  Operationalization of procurement and supply chain management system"}]
["Tuberculosis","HSS - Procurement supply chain management (PSCM)","PSM infrastructure and development of tools","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Procurement supply chain management (PSCM)  -  PSM infrastructure and development of tools"]
["Tuberculosis","HSS - Policy and governance","Development and implementation of health legislation, strategies and policies","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Policy and governance  -  Development and implementation of health legislation, strategies and policies"]
["Tuberculosis","Program management","Supporting procurement and supply management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Supporting procurement and supply management"]
["Tuberculosis","HSS - Policy and governance","Monitoring and reporting implementation of laws and policies","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Policy and governance  -  Monitoring and reporting implementation of laws and policies"]
["Tuberculosis","HSS - Healthcare financing","Financial sustainability","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Healthcare financing  -  Financial sustainability"]
["Tuberculosis","HSS - Healthcare financing","Equity of healthcare financing","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Healthcare financing  -  Equity of healthcare financing"]
["Tuberculosis","HSS - Financial management","Performance,transparency&accountability of financial management system in health","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Financial management  -  Performance,transparency&accountability of financial management system in health"]
["Tuberculosis","Removing legal barriers to access","Legal and policy environment assessment and law reform","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Legal and policy environment assessment and law reform"]
["Tuberculosis","Removing legal barriers to access","Legal aid services and legal literacy","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Legal aid services and legal literacy"]
["Tuberculosis","Removing legal barriers to access","Community-based monitoring of legal rights","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Community-based monitoring of legal rights"]
["Tuberculosis","Removing legal barriers to access","Policy advocacy on legal rights","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Policy advocacy on legal rights"]
["Malaria","Removing legal barriers to access","Training on rights for officials, health workers and police","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Training on rights for officials, health workers and police"]
["Malaria","HSS - Service delivery","Service organization and facility management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Service organization and facility management"]
["Malaria","HSS - Service delivery","Improving laboratory systems","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Improving laboratory systems"]
["Malaria","HSS - Service delivery","Improving service delivery infrastructure","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Improving service delivery infrastructure"]
["Malaria","HSS - Service delivery","Other","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Other"]
["Malaria","HSS - Health and community workforce","Health and community workers capacity building","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Health and community workers capacity building"]
["Malaria","HSS - Health information systems and M&E","Administrative and finance data sources","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Administrative and finance data sources"]
["Malaria","HSS - Health information systems and M&E","Vital registration system","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Vital registration system"]
["Malaria","HSS - Health information systems and M&E","Routine reporting","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Routine reporting"]
["Malaria","HSS - Health information systems and M&E","Analysis, review and transparency","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Analysis, review and transparency"]
["Malaria","HSS - Health information systems and M&E","Surveys","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Surveys"]
["Malaria","Program management","Policy, planning, coordination and management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Policy, planning, coordination and management"]
["Malaria","Program management","Grant management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Grant management"]
["Malaria","HSS - Health and community workforce","Scaling up health and community workers","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Scaling up health and community workers"]
["Malaria","HSS - Health and community workforce","Retention and distribution of health and community workers","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Retention and distribution of health and community workers"]
["Malaria","HSS - Procurement supply chain management (PSCM)","Operationalization of procurement and supply chain management system","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Procurement supply chain management (PSCM)  -  Operationalization of procurement and supply chain management system"]
["Malaria","HSS - Procurement supply chain management (PSCM)","PSM infrastructure and development of tools","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Procurement supply chain management (PSCM)  -  PSM infrastructure and development of tools"]
["Malaria","HSS - Policy and governance","Development and implementation of health legislation, strategies and policies","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Policy and governance  -  Development and implementation of health legislation, strategies and policies"]
["Malaria","Program management","Supporting procurement and supply management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Supporting procurement and supply management"]
["Malaria","HSS - Policy and governance","Monitoring and reporting implementation of laws and policies","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Policy and governance  -  Monitoring and reporting implementation of laws and policies"]
["Malaria","HSS - Healthcare financing","Financial sustainability","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Healthcare financing  -  Financial sustainability"]
["Malaria","HSS - Healthcare financing","Equity of healthcare financing","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Healthcare financing  -  Equity of healthcare financing"]
["Malaria","HSS - Financial management","Performance,transparency&accountability of financial management system in health","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Financial management  -  Performance,transparency&accountability of financial management system in health"]
["Malaria","Removing legal barriers to access","Legal and policy environment assessment and law reform","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Legal and policy environment assessment and law reform"]
["Malaria","Removing legal barriers to access","Legal aid services and legal literacy","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Legal aid services and legal literacy"]
["Malaria","Removing legal barriers to access","Community-based monitoring of legal rights","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Community-based monitoring of legal rights"]
["Malaria","Removing legal barriers to access","Policy advocacy on legal rights","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Policy advocacy on legal rights"]
["Health Systems Strengthening","Removing legal barriers to access","Training on rights for officials, health workers and police","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Training on rights for officials, health workers and police"]
["Health Systems Strengthening","HSS - Service delivery","Service organization and facility management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Service organization and facility management"]
["Health Systems Strengthening","HSS - Service delivery","Improving laboratory systems","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Improving laboratory systems"]
["Health Systems Strengthening","HSS - Service delivery","Improving service delivery infrastructure","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Improving service delivery infrastructure"]
["Health Systems Strengthening","HSS - Service delivery","Other","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Other"]
["Health Systems Strengthening","HSS - Health and community workforce","Health and community workers capacity building","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Health and community workers capacity building"]
["Health Systems Strengthening","HSS - Health information systems and M&E","Administrative and finance data sources","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Administrative and finance data sources"]
["Health Systems Strengthening","HSS - Health information systems and M&E","Vital registration system","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Vital registration system"]
["Health Systems Strengthening","HSS - Health information systems and M&E","Routine reporting","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Routine reporting"]
["Health Systems Strengthening","HSS - Health information systems and M&E","Analysis, review and transparency","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Analysis, review and transparency"]
["Health Systems Strengthening","HSS - Health information systems and M&E","Surveys","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Surveys"]
["Health Systems Strengthening","Program management","Policy, planning, coordination and management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Policy, planning, coordination and management"]
["Health Systems Strengthening","Program management","Grant management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Grant management"]
["Health Systems Strengthening","HSS - Health and community workforce","Scaling up health and community workers","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Scaling up health and community workers"]
["Health Systems Strengthening","HSS - Health and community workforce","Retention and distribution of health and community workers","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Retention and distribution of health and community workers"]
["Health Systems Strengthening","HSS - Procurement supply chain management (PSCM)","Operationalization of procurement and supply chain management system","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Procurement supply chain management (PSCM)  -  Operationalization of procurement and supply chain management system"]
["Health Systems Strengthening","HSS - Procurement supply chain management (PSCM)","PSM infrastructure and development of tools","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Procurement supply chain management (PSCM)  -  PSM infrastructure and development of tools"]
["Health Systems Strengthening","HSS - Policy and governance","Development and implementation of health legislation, strategies and policies","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Policy and governance  -  Development and implementation of health legislation, strategies and policies"]
["Health Systems Strengthening","Program management","Supporting procurement and supply management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Supporting procurement and supply management"]
["Health Systems Strengthening","HSS - Policy and governance","Monitoring and reporting implementation of laws and policies","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Policy and governance  -  Monitoring and reporting implementation of laws and policies"]
["Health Systems Strengthening","HSS - Healthcare financing","Financial sustainability","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Healthcare financing  -  Financial sustainability"]
["Health Systems Strengthening","HSS - Healthcare financing","Equity of healthcare financing","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Healthcare financing  -  Equity of healthcare financing"]
["Health Systems Strengthening","HSS - Financial management","Performance,transparency&accountability of financial management system in health","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Financial management  -  Performance,transparency&accountability of financial management system in health"]
["Health Systems Strengthening","Removing legal barriers to access","Legal and policy environment assessment and law reform","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Legal and policy environment assessment and law reform"]
["Health Systems Strengthening","Removing legal barriers to access","Legal aid services and legal literacy","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Legal aid services and legal literacy"]
["Health Systems Strengthening","Removing legal barriers to access","Community-based monitoring of legal rights","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB",{"$f":"CONCATENATE(B259,\"  -  \",C259)","v":"Removing legal barriers to access  -  Community-based monitoring of legal rights"}]
["Health Systems Strengthening","Removing legal barriers to access","Policy advocacy on legal rights","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Policy advocacy on legal rights"]
["HIV/TB","Removing legal barriers to access","Training on rights for officials, health workers and police","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Training on rights for officials, health workers and police"]
["HIV/TB","HSS - Service delivery","Service organization and facility management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Service organization and facility management"]
["HIV/TB","HSS - Service delivery","Improving laboratory systems","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Improving laboratory systems"]
["HIV/TB","HSS - Service delivery","Improving service delivery infrastructure","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Improving service delivery infrastructure"]
["HIV/TB","HSS - Service delivery","Other","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Service delivery  -  Other"]
["HIV/TB","HSS - Health and community workforce","Health and community workers capacity building","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Health and community workers capacity building"]
["HIV/TB","HSS - Health information systems and M&E","Administrative and finance data sources","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Administrative and finance data sources"]
["HIV/TB","HSS - Health information systems and M&E","Vital registration system","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Vital registration system"]
["HIV/TB","HSS - Health information systems and M&E","Routine reporting","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Routine reporting"]
["HIV/TB","HSS - Health information systems and M&E","Analysis, review and transparency","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Analysis, review and transparency"]
["HIV/TB","HSS - Health information systems and M&E","Surveys","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health information systems and M&E  -  Surveys"]
["HIV/TB","Program management","Policy, planning, coordination and management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Policy, planning, coordination and management"]
["HIV/TB","Program management","Grant management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Grant management"]
["HIV/TB","HSS - Health and community workforce","Scaling up health and community workers","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Scaling up health and community workers"]
["HIV/TB","HSS - Health and community workforce","Retention and distribution of health and community workers","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Health and community workforce  -  Retention and distribution of health and community workers"]
["HIV/TB","HSS - Procurement supply chain management (PSCM)","Operationalization of procurement and supply chain management system","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Procurement supply chain management (PSCM)  -  Operationalization of procurement and supply chain management system"]
["HIV/TB","HSS - Procurement supply chain management (PSCM)","PSM infrastructure and development of tools","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Procurement supply chain management (PSCM)  -  PSM infrastructure and development of tools"]
["HIV/TB","HSS - Policy and governance","Development and implementation of health legislation, strategies and policies","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Policy and governance  -  Development and implementation of health legislation, strategies and policies"]
["HIV/TB","Program management","Supporting procurement and supply management","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Program management  -  Supporting procurement and supply management"]
["HIV/TB","HSS - Policy and governance","Monitoring and reporting implementation of laws and policies","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Policy and governance  -  Monitoring and reporting implementation of laws and policies"]
["HIV/TB","HSS - Healthcare financing","Financial sustainability","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Healthcare financing  -  Financial sustainability"]
["HIV/TB","HSS - Healthcare financing","Equity of healthcare financing","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Healthcare financing  -  Equity of healthcare financing"]
["HIV/TB","HSS - Financial management","Performance,transparency&accountability of financial management system in health","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","HSS - Financial management  -  Performance,transparency&accountability of financial management system in health"]
["HIV/TB","Removing legal barriers to access","Legal and policy environment assessment and law reform","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Legal and policy environment assessment and law reform"]
["HIV/TB","Removing legal barriers to access","Legal aid services and legal literacy","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Legal aid services and legal literacy"]
["HIV/TB","Removing legal barriers to access","Community-based monitoring of legal rights","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Community-based monitoring of legal rights"]
["HIV/TB","Removing legal barriers to access","Policy advocacy on legal rights","HIV/AIDS; Tuberculosis; Malaria; Health Systems Strengthening; HIV/TB","Removing legal barriers to access  -  Policy advocacy on legal rights"]
["HIV/AIDS","Community systems strengthening","Community-based monitoring for accountability","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Community-based monitoring for accountability"]
["HIV/AIDS","Community systems strengthening","Advocacy for social accountability","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Advocacy for social accountability"]
["HIV/AIDS","Community systems strengthening","Social mobilization, building community linkages, collaboration and coordination","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Social mobilization, building community linkages, collaboration and coordination"]
["HIV/AIDS","Community systems strengthening","Institutional capacity building, planning and leadership development","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Institutional capacity building, planning and leadership development"]
["HIV/AIDS","Results-based Financing","Results-based financing","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Results-based Financing  -  Results-based financing"]
["Tuberculosis","Community systems strengthening","Community-based monitoring for accountability","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Community-based monitoring for accountability"]
["Tuberculosis","Community systems strengthening","Advocacy for social accountability","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Advocacy for social accountability"]
["Tuberculosis","Community systems strengthening","Social mobilization, building community linkages, collaboration and coordination","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Social mobilization, building community linkages, collaboration and coordination"]
["Tuberculosis","Community systems strengthening","Institutional capacity building, planning and leadership development","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Institutional capacity building, planning and leadership development"]
["Tuberculosis","Results-based Financing","Results-based financing","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Results-based Financing  -  Results-based financing"]
["Malaria","Community systems strengthening","Community-based monitoring for accountability","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Community-based monitoring for accountability"]
["Malaria","Community systems strengthening","Advocacy for social accountability","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Advocacy for social accountability"]
["Malaria","Community systems strengthening","Social mobilization, building community linkages, collaboration and coordination","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Social mobilization, building community linkages, collaboration and coordination"]
["Malaria","Community systems strengthening","Institutional capacity building, planning and leadership development","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Institutional capacity building, planning and leadership development"]
["Malaria","Results-based Financing","Results-based financing","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Results-based Financing  -  Results-based financing"]
["HIV/TB","Community systems strengthening","Community-based monitoring for accountability","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Community-based monitoring for accountability"]
["HIV/TB","Community systems strengthening","Advocacy for social accountability","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Advocacy for social accountability"]
["HIV/TB","Community systems strengthening","Social mobilization, building community linkages, collaboration and coordination","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Social mobilization, building community linkages, collaboration and coordination"]
["HIV/TB","Community systems strengthening","Institutional capacity building, planning and leadership development","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Community systems strengthening  -  Institutional capacity building, planning and leadership development"]
["HIV/TB","Results-based Financing","Results-based financing","HIV/AIDS; Tuberculosis; Malaria; HIV/TB","Results-based Financing  -  Results-based financing"]

{"sheet":"Impact Outcome Indicators_1A","index":2,"n_rows":41,"n_cols":30,"rows_kept":41,"cut":false,"hidden":false,"merged":[[3,28,3,33],[32,29,32,33],[33,29,33,33],[34,29,34,33],[35,29,35,33],[36,29,36,33],[37,29,37,33],[38,29,38,33],[4,16,4,17],[4,18,5,18],[4,19,5,19],[4,20,5,20],[3,16,3,27],[37,23,37,27],[38,23,38,27],[4,21,5,21],[4,22,5,22],[4,23,5,27],[4,28,5,28],[4,29,5,33],[6,29,6,33],[7,29,7,33],[8,29,8,33],[9,29,9,33],[10,29,10,33],[11,29,11,33],[12,29,12,33],[40,29,40,33],[13,29,13,33],[14,29,14,33],[15,29,15,33],[16,29,16,33],[17,29,17,33],[18,29,18,33],[19,29,19,33],[20,29,20,33],[31,29,31,33],[39,29,39,33],[39,23,39,27],[40,23,40,27],[6,23,6,27],[32,23,32,27],[33,23,33,27],[34,23,34,27],[35,23,35,27],[36,23,36,27],[17,23,17,27],[18,23,18,27],[19,23,19,27],[20,23,20,27],[31,23,31,27],[12,23,12,27],[13,23,13,27],[14,23,14,27],[15,23,15,27],[16,23,16,27],[7,23,7,27],[8,23,8,27],[9,23,9,27],[10,23,10,27],[11,23,11,27],[3,14,3,15],[4,0,5,0],[4,1,5,5],[4,6,4,7],[4,8,5,8],[4,9,5,9],[4,10,5,10],[4,11,5,11],[4,12,5,12],[4,13,5,15],[6,13,6,15],[8,1,8,5],[8,13,8,15],[9,1,9,5],[9,13,9,15],[7,1,7,5],[7,13,7,15],[6,1,6,5],[10,1,10,5],[10,13,10,15],[11,1,11,5],[11,13,11,15],[12,1,12,5],[12,13,12,15],[13,1,13,5],[13,13,13,15],[14,1,14,5],[14,13,14,15],[15,1,15,5],[15,13,15,15],[16,1,16,5],[16,13,16,15],[17,1,17,5],[17,13,17,15],[18,1,18,5],[18,13,18,15],[19,1,19,5],[19,13,19,15],[20,1,20,5],[20,13,20,15],[31,1,31,5],[31,13,31,15],[40,1,40,5],[40,13,40,15],[36,1,36,5],[36,13,36,15],[37,1,37,5],[37,13,37,15],[38,1,38,5],[38,13,38,15],[32,1,32,5],[32,13,32,15],[33,1,33,5],[33,13,33,15],[34,1,34,5],[34,13,34,15],[35,1,35,5],[35,13,35,15],[39,1,39,5],[39,13,39,15],[21,1,21,5],[21,13,21,15],[21,23,21,27],[21,29,21,33],[22,1,22,5],[22,13,22,15],[22,23,22,27],[22,29,22,33],[23,1,23,5],[23,13,23,15],[23,23,23,27],[23,29,23,33],[24,1,24,5],[24,13,24,15],[24,23,24,27],[24,29,24,33],[25,1,25,5],[25,13,25,15],[25,23,25,27],[25,29,25,33],[26,1,26,5],[26,13,26,15],[26,23,26,27],[26,29,26,33],[30,1,30,5],[30,13,30,15],[30,23,30,27],[30,29,30,33],[27,1,27,5],[27,13,27,15],[27,23,27,27],[27,29,27,33],[28,1,28,5],[28,13,28,15],[28,23,28,27],[28,29,28,33],[29,1,29,5],[29,13,29,15],[29,23,29,27],[29,29,29,33]]}
["On-going Progress Update and Disbursement Request"]
["Section 1:  Programmatic Progress"]
["Note: The table below should contain those Impact/Outcome indicators that are (1) due for reporting during the current year of a grant and (2) those reporting on which is overdue from the previous periods."]
["A.  Impact / Outcome Indicators",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"For LFA Use Only",null,null,null,null,null,null,null,null,null,null,null,"For the Global Fund Use Only"]
["Impact / Outcome ","Indicator Description",null,null,null,null,"Baseline \n(if applicable)",null,"Year of Target","Intended Target","Report Due Date","Actual Result","Data Source of Results","Comments on results on Impact/Outcome indicators and data sources, and any other comments",null,null,"Baseline \n(if applicable)",null,"Year of Target","Intended Target","Report Due Date","Verification Method","Verified Result","LFA comments on (a) verified result, (b) source of information used by the PR to report results, including the status of completion of surveys and other methods to measure Impact/Outcome, as applicable,  ",null,null,null,null,"Validated Result","Country Team comments on validated results"]
[null,null,null,null,null,null,"Value","Year",null,null,null,null,null,null,null,null,"Value","Year"]
["Impact","TB mortality rate\nNumber of deaths attributable to TB (all forms) registered in a specified period per 100,000 populations",null,null,null,null,7,2014,"2016",6.3,"2017-02-15",3.9,"WHO Global TB Reports (Country Profiles)","The indicator significantly acceeded the intended target contributing to growing treatment success rate. ",null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,{"$f":"W7","v":0}]
["Outcome","Case notification rate per 100,000 population- all forms of TB i.e. bacteriologically confirmed + clinically diagnosed*\n*Case notification rate indicators include new and relapse cases",null,null,null,null,84,2015,"2016",82,"2017-02-15",79.8,"R&R TB system, yearly management report ","The overall number of TB cases has been steadily decreasing, although there are no access barriers to services and number of screened presumptive TB cases and contacts has not decreased.",null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,{"$f":"W8","v":0}]
["Outcome","Treatment success rate -  bacteriologically confirmed: Percentage of bacteriologically confirmed TB cases successfully treated (cured plus treatment completed)",null,null,null,null,77,2013,"2014",85,"2017-02-15",79.3,"R&R TB system, yearly management report ","The actual result demonstrates improvement as compared to baseline value.",null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Outcome","Treatment success rate- laboratory confirmed RR TB and/or MDR-TB:\nPercentage of bacteriologically-confirmed RR and/or MDR-TB cases successfully treated (cured plus completed treatment) among those enrolled on second-line anti-TB treatment during the year of assessment ",null,null,null,null,46,2012,"2013",75,"2017-02-15",40,"R&R TB system, yearly management report ","Poor treatment outcome among MDR patients is linked to high loss to follow up rate, that partially is explained by long-term (minimum 20 months) treatment recommended by the national guideline. Planned guideline update in line with the latest WHO recommendations will improve treatment outcome as in 2013 cohort, 14% of those identified as lost to follow up (22 patients) completed more than 13 months treatment and three or more consecutive cultures taken at least 30 days apart were negative after the intensive phase, thus met criteria of successful treatment.",null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Outcome","Case notification rate per 100,000 population- bacteriologically confirmed (new and relapse cases)",null,null,null,null,58,2015,"2016",57,"2017-02-15",56,"R&R TB system, quarterly reports","The overall number of TB cases has been steadily decreasing, although there are no access barriers to services and number of screened presumptive TB cases and contacts has not decreased.",null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,{"$f":"W22","v":0}]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,{"$f":"W23","v":0}]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]
["Select",null,null,null,null,null,"-","-","-","-","-","-","Select",null,null,null,"-","-","-","-","-","Select",null,null,null,null,null,null,0]

{"sheet":"Coverage Indicators_1B","index":3,"n_rows":67,"n_cols":45,"rows_kept":67,"cut":false,"hidden":false,"merged":[[16,35,16,39],[7,35,7,39],[8,35,8,39],[9,35,9,39],[10,35,10,39],[11,35,11,39],[12,35,12,39],[13,35,13,39],[14,35,14,39],[15,35,15,39],[53,2,53,5],[53,20,53,21],[55,2,55,5],[22,2,22,5],[17,35,17,39],[18,35,18,39],[19,35,19,39],[20,35,20,39],[57,35,57,39],[21,35,21,39],[22,35,22,39],[53,35,53,39],[55,35,55,39],[34,2,34,5],[34,20,34,21],[34,35,34,39],[37,2,37,5],[37,20,37,21],[37,35,37,39],[40,2,40,5],[40,20,40,21],[40,35,40,39],[43,2,43,5],[43,20,43,21],[0,0,0,8],[4,31,4,33],[4,35,5,39],[6,35,6,39],[4,20,5,21],[3,0,3,21],[4,0,5,0],[4,1,5,1],[4,2,5,5],[4,6,5,6],[4,7,5,7],[4,8,5,8],[6,2,6,5],[3,22,3,39],[4,16,4,18],[4,22,5,22],[4,23,5,23],[4,28,4,30],[4,9,4,12],[4,24,4,27],[4,34,5,34],[8,2,8,5],[8,20,8,21],[9,2,9,5],[9,20,9,21],[10,2,10,5],[10,20,10,21],[4,13,4,15],[6,20,6,21],[7,2,7,5],[7,20,7,21],[4,19,5,19],[15,2,15,5],[15,20,15,21],[16,2,16,5],[16,20,16,21],[11,2,11,5],[11,20,11,21],[12,2,12,5],[12,20,12,21],[13,2,13,5],[13,20,13,21],[14,20,14,21],[62,2,62,5],[55,20,55,21],[59,2,59,5],[59,20,59,21],[60,2,60,5],[60,20,60,21],[17,2,17,5],[17,20,17,21],[22,20,22,21],[62,20,62,21],[56,2,56,5],[56,20,56,21],[57,2,57,5],[57,20,57,21],[58,2,58,5],[58,20,58,21],[19,2,19,5],[19,20,19,21],[20,2,20,5],[20,20,20,21],[21,2,21,5],[21,20,21,21],[18,2,18,5],[18,20,18,21],[4,40,4,42],[3,40,3,48],[16,44,16,48],[17,44,17,48],[18,44,18,48],[19,44,19,48],[61,0,61,48],[4,44,5,48],[6,44,6,48],[7,44,7,48],[8,44,8,48],[9,44,9,48],[10,44,10,48],[11,44,11,48],[12,44,12,48],[13,44,13,48],[14,44,14,48],[15,44,15,48],[22,44,22,48],[53,44,53,48],[55,44,55,48],[20,44,20,48],[21,44,21,48],[14,2,14,5],[26,2,26,5],[26,20,26,21],[26,35,26,39],[26,44,26,48],[27,2,27,5],[27,20,27,21],[40,44,40,48],[41,2,41,5],[41,20,41,21],[41,35,41,39],[41,44,41,48],[37,44,37,48],[38,2,38,5],[38,20,38,21],[38,35,38,39],[38,44,38,48],[39,2,39,5],[39,20,39,21],[39,35,39,39],[39,44,39,48],[34,44,34,48],[35,2,35,5],[35,20,35,21],[35,35,35,39],[23,2,23,5],[23,20,23,21],[23,35,23,39],[23,44,23,48],[24,2,24,5],[24,20,24,21],[24,35,24,39],[24,44,24,48],[25,2,25,5],[25,20,25,21],[25,35,25,39],[25,44,25,48],[29,20,29,21],[29,35,29,39],[29,44,29,48],[43,35,43,39],[43,44,43,48],[44,2,44,5],[44,20,44,21],[44,35,44,39],[44,44,44,48],[42,2,42,5],[42,20,42,21],[42,35,42,39],[42,44,42,48],[35,44,35,48],[36,2,36,5],[36,20,36,21],[36,35,36,39],[36,44,36,48],[4,43,5,43],[33,2,33,5],[33,20,33,21],[33,35,33,39],[33,44,33,48],[30,2,30,5],[30,20,30,21],[30,35,30,39],[30,44,30,48],[31,2,31,5],[31,20,31,21],[31,35,31,39],[31,44,31,48],[32,2,32,5],[32,20,32,21],[32,35,32,39],[32,44,32,48],[27,35,27,39],[27,44,27,48],[28,2,28,5],[28,20,28,21],[28,35,28,39],[28,44,28,48],[29,2,29,5]]}
["On-going Progress Update and Disbursement Request"]
["Section 1:  Programmatic Progress"]
["Note: All programmatic indicators contained in the current Performance Framework should be listed, regardless of whether there are targets/results for the period covered by the Progress Update or whether the targets have been met in previous periods.  "]
["B.  Coverage Indicators",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"For LFA Use Only",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"For the Global Fund Use Only"]
["Objective\nNo.","* Indicator No.","Indicator Description",null,null,null,"Tied To","Targets cumulative?\n","Top 10 indicator?","Baseline",null,null,null,"Target",null,null,"Result",null,null,"Achievement Ratio","Reasons for programmatic deviation from intended target and deviations from the related workplan activities",null,"Targets cumulative?\n","Top 10 indicator?","Baseline",null,null,null,"Target",null,null,"Verified Result",null,null,"Achievement Ratio","LFA analysis on progress to date and any variance between targets and results, and any other comments\n(this should not be a “Copy and Paste” of the reasons provided by the PR)",null,null,null,null,"Validated Result",null,null,"Achievement Ratio","Country Team comments on validated results"]
[null,null,null,null,null,null,null,null,null,"Year","N#","D#","%","N#","D#","%","N#","D#","%",null,null,null,null,null,"Year","N#","D#","%","N#","D#","%","N#","D#","%",null,null,null,null,null,null,"N#","D#","%"]
[2,1,"Percentage of TB patients who had an HIV test result recorded in the TB register ",null,null,null,"Current grant","N-not cumulative","Yes - Top 10",2013,2535,4184,{"$f":"IFERROR(K7/L7,\"\")","v":0.60587954110898656},2100,2463,{"$f":"IFERROR(N7/O7,\"\")","v":0.85261875761266748},1438,1501,{"$f":"IFERROR(Q7/R7,\"\")","v":0.9580279813457695},{"$f":"IFERROR(IF(AND(N7<>\"\",O7=\"\",Q7<>\"\",R7=\"\"),IF((Q7/N7)>120%,120%,(Q7/N7)),IF((S7/P7)>120%,120%,(S7/P7))),\" \")","v":1.1236299609783953},"The indicator is overachieved. The numerator and denominator values are based on the TB Centre database for the said reporting period. The joint effort of PR/SR as well as the state TB program support resulted in the substantial scale-up of HIV testing",null,"Select","Select",null,null,null,{"$f":"IFERROR(Z7/AA7,\"\")","v":""},null,null,{"$f":"IFERROR(AC7/AD7,\"\")","v":""},null,null,{"$f":"IFERROR(AF7/AG7,\"\")","v":""},{"$f":"IFERROR(IF(AND(AC7<>\"\",AD7=\"\",AF7<>\"\",AG7=\"\"),IF((AF7/AC7)>120%,120%,(AF7/AC7)),IF((AH7/AE7)>120%,120%,(AH7/AE7))),\" \")","v":" "},null,null,null,null,null,{"$f":"AF7","v":0},{"$f":"AG7","v":0},{"$f":"IFERROR(AO7/AP7,\"\")","v":""},{"$f":"AI7","v":" "}]
[2,2,"Number of notified cases of bacteriologically confirmed TB, (new and relapse)",null,null,null,"Current grant","Y-cumulative annually","Yes - Top 10",2012,2464,null,{"$f":"IFERROR(K8/L8,\"\")","v":""},2839,2839,{"$f":"IFERROR(N8/O8,\"\")","v":1},2084,2839,{"$f":"IFERROR(Q8/R8,\"\")","v":0.73406128918633318},{"$f":"IFERROR(IF(AND(N8<>\"\",O8=\"\",Q8<>\"\",R8=\"\"),IF((Q8/N8)>120%,120%,(Q8/N8)),IF((S8/P8)>120%,120%,(S8/P8))),\" \")","v":0.73406128918633318},"The number comes from the TB Centre database for the said reporting period. Overall number of TB cases has a tendency to decrease. Still planned further roll-out of GeneXpert technology has the potential to increase the number of bacteriologically confirmed  cases.  ",null,"Select","Select",null,null,null,{"$f":"IFERROR(Z8/AA8,\"\")","v":""},null,null,{"$f":"IFERROR(AC8/AD8,\"\")","v":""},null,null,{"$f":"IFERROR(AF8/AG8,\"\")","v":""},{"$f":"IFERROR(IF(AND(AC8<>\"\",AD8=\"\",AF8<>\"\",AG8=\"\"),IF((AF8/AC8)>120%,120%,(AF8/AC8)),IF((AH8/AE8)>120%,120%,(AH8/AE8))),\" \")","v":" "},null,null,null,null,null,{"$f":"AF8","v":0},{"$f":"AG8","v":0},{"$f":"IFERROR(AO8/AP8,\"\")","v":""},{"$f":"AI8","v":" "}]
[3,1,"\nNumber of notified cases of all forms of TB - (i.e. bacteriologically confirmed +clinically diagnosed) (new and relapse)",null,null,null,"National Program","Y-cumulative annually","Yes - Top 10",2012,3939,null,{"$f":"IFERROR(K9/L9,\"\")","v":""},4056,4056,1,2969,4056,0.73200197238658782,0.73200197238658782,"The number comes from the TB Centre database for the said reporting period. Overall number of TB cases has a tendency to decrease. ",null,"Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,null,null,null,0,0,""," "]
[3,2,"Number of bacteriologically confirmed  TB cases in a specified period who subsequently were successfully treated (sum of WHO outcome categories \"cured” plus \"treatment completed”)",null,null,null,"National Program","Y-cumulative annually","Yes - Top 10",2011,1917,null,"",2249,2249,1,1764,2249,0.78434859937750112,0.78434859937750112,"The actual results falls behing the target value, however demonstrates improvement as compared to the previous year. \nTreatment success rate for this subgroup in prison is 78,8% (71 patients out of 90).",null,"Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,null,null,null,0,0,""," "]
[3,4,"\nLaboratory-confirmed X/MDR-TB patients enrolled on second line anti-TB treatment in the specified calendar year",null,null,null,"National Program","Y-cumulative annually","Yes - Top 10",2013,659,null,"",517,517,1,393,517,0.76015473887814311,0.76015473887814311,"The result is in line with the overall trend of decreasing TB cases in the country.",null,"Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,null,null,null,0,0,""," "]
[3,5,"Percentage of previously treated TB patients receiving DST\n",null,null,null,"National Program","Y-cumulative annually","Yes - Top 10",2012,569,632,0.90031645569620256,313,313,1,222,245,0.90612244897959182,0.90612244897959182,"The actual result falls behing the target value, however demonstrates improvement as compared to the previous year. Planned decentralization of lab service will further increase proportion of patients receiving DST   ",null,"Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,null,null,null,0,0,""," "]
[3,6,"Percentage of cases with drug resistant TB (RR-TB and/or MDR-TB) started on treatment for MDR-TB who were lost to follow up during the first six months of treatment",null,null,null,"National Program","N-not cumulative","Yes - Top 10",2013,31,253,0.1225296442687747,25,259,9.6525096525096526E-2,26,210,0.12380952380952381,1.2,"This is a reverse indicator. 12% of the cohort from January-June, 2016 were lost to follow-up during the first six months of treatment. The data is derived from the TB Centre Database. To address the issue PR supported adherence consultants and planned civil society engagement.   ",null,"Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,null,null,null,0,0,""," "]
[4,1,"Number of and percentage of TB patients on 1st line treatment receiving cash incentives for better adherence to treatment ",null,null,null,"Current grant","Y-cumulative annually","Yes - Top 10",2012,3217,4675,0.68812834224598929,3096,4409,0.70220004536176006,2822,3413,0.82683855845297394,1.1774971589855174,"The incidator is overachieved. The data are based on the eTB module.",null,"Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,null,null,null,0,0,""," "]
[4,2,"Number and percentage of M/XDR-TB patients on treatment receiving cash incentives for better adherence to treatment during out-patient phase",null,null,null,"Current grant","Y-cumulative annually","Yes - Top 10",2012,405,548,0.73905109489051091,390,517,0.75435203094777559,693,792,0.875,1.1599358974358975,"The incidator is overachieved.  The data are based on the eTB module.",null,"Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,null,null,null,0,0,""," "]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,null,null,null,0,0,""," "]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,null,null,null,0,0,""," "]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,null,null,null,0,0,""," "]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,null,null,null,0,0,""," "]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,null,null,null,0,0,""," "]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,null,null,null,0,0,""," "]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,null,null,null,0,0,""," "]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,null,null,null,0,0,""," "]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,{"$f":"IFERROR(K24/L24,\"\")","v":""},null,null,{"$f":"IFERROR(N24/O24,\"\")","v":""},null,null,{"$f":"IFERROR(Q24/R24,\"\")","v":""}," ",null,null,"Select","Select",null,null,null,{"$f":"IFERROR(Z24/AA24,\"\")","v":""},null,null,{"$f":"IFERROR(AC24/AD24,\"\")","v":""},null,null,{"$f":"IFERROR(AF24/AG24,\"\")","v":""}," ",null,null,null,null,null,{"$f":"AF24","v":0},{"$f":"AG24","v":0},{"$f":"IFERROR(AO24/AP24,\"\")","v":""}," "]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,null,null,null,0,0,""," "]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,null,null,null,0,0,""," "]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,null,null,null,0,0,""," "]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,null,null,null,0,0,""," "]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,null,null,null,0,0,""," "]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,null,null,null,0,0,""," "]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,null,null,null,0,0,""," "]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,null,null,null,0,0,""," "]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,null,null,null,0,0,""," "]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,null,null,null,0,0,""," "]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,{"$f":"IFERROR(K35/L35,\"\")","v":""},null,null,{"$f":"IFERROR(N35/O35,\"\")","v":""},null,null,{"$f":"IFERROR(Q35/R35,\"\")","v":""}," ",null,null,"Select","Select",null,null,null,{"$f":"IFERROR(Z35/AA35,\"\")","v":""},null,null,{"$f":"IFERROR(AC35/AD35,\"\")","v":""},null,null,{"$f":"IFERROR(AF35/AG35,\"\")","v":""}," ",null,null,null,null,null,{"$f":"AF35","v":0},{"$f":"AG35","v":0},{"$f":"IFERROR(AO35/AP35,\"\")","v":""}," "]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,null,null,null,0,0,""," "]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,null,null,null,0,0,""," "]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,null,null,null,0,0,""," "]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,null,null,null,0,0,""," "]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,null,null,null,0,0,""," "]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,null,null,null,0,0,""," "]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,null,null,null,0,0,""," "]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,null,null,null,0,0,""," "]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,null,null,null,0,0,""," "]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,null,null,null,0,0,""," "]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,null,null,null,0,0,""," "]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,null,null,null,0,0,""," "]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,null,null,null,0,0,""," "]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,null,null,null,0,0,""," "]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,null,null,null,0,0,""," "]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,null,null,null,0,0,""," "]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,null,null,null,0,0,""," "]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,null,null,null,0,0,""," "]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,null,null,null,0,0,""," "]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,null,null,null,0,0,""," "]
[null,null,null,null,null,null,"Select","Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,"Select","Select",null,null,null,"",null,null,"",null,null,""," ",null,null,null,null,null,0,0,""," "]
[null,null,null,null,null,null,"Select","Select","Select",null,"-","-",null,"-","-",null,null,null,null,null,null,null,"Select","Select",null,"-","-",null,"-","-",null,null,null,null,null,null,null,null,null,null,null,0]
[null,null,null,null,null,null,"Select","Select","Select",null,"-","-",null,"-","-",null,null,null,null,null,null,null,"Select","Select",null,"-","-",null,"-","-",null,null,null,null,null,null,null,null,null,null,null,0]
[null,null,null,null,null,null,"Select","Select","Select",null,"-","-",null,"-","-",null,null,null,null,null,null,null,"Select","Select",null,"-","-",null,"-","-",null,null,null,null,null,null,null,null,null,null,null,0]
[null,null,null,null,null,null,"Select","Select","Select",null,"-","-",null,"-","-",null,null,null,null,null,null,null,"Select","Select",null,"-","-",null,"-","-",null,null,null,null,null,null,null,null,null,null,null,0]
[null,null,null,null,null,null,"Select","Select","Select",null,"-","-",null,"-","-",null,null,null,null,null,null,null,"Select","Select",null,"-","-",null,"-","-",null,null,null,null,null,null,null,null,null,null,null,0]
[]
[null,null,null,null,null,null,"Select","Select","Select",null,"-","-",null,"-","-",null,null,null,null,null,null,null,"Select","Select",null,"-","-",null,"-","-"]
[null,null,null,null,null,null,"Select","Select","Select",null,"-","-",null,"-","-",null,null,null,null,null,null,null,"Select","Select",null,"-","-",null,"-","-"]
[null,null,null,null,null,null,"Select","Select","Select",null,"-","-",null,"-","-",null,null,null,null,null,null,null,"Select","Select",null,"-","-",null,"-","-"]
[null,null,null,null,null,null,"Select","Select","Select",null,"-","-",null,"-","-",null,null,null,null,null,null,null,"Select","Select",null,"-","-",null,"-","-"]
[null,null,null,null,null,null,"Select","Select","Select",null,"-","-",null,"-","-",null,null,null,null,null,null,null,"Select","Select",null,"-","-",null,"-","-"]

{"sheet":"ImpactOutcomeDisaggData","index":4,"n_rows":33,"n_cols":9,"rows_kept":33,"cut":false,"hidden":true,"merged":[[0,1,0,8]]}
[null,"Impact/outcome disaggregation Data "]
[]
[null,"HIV I-1: Percentage of young people aged 15–24 who are living with HIV","HIVI1","Sex",{"$f":"CONCATENATE(C3,D3)","v":"HIVI1Sex"},"Male","Female",null,"Impact"]
[null,"HIV I-2: HIV incidence among 15-49 age group","HIVI2","Sex",{"$f":"CONCATENATE(C4,D4)","v":"HIVI2Sex"},"Male","Female",null,"Impact"]
[null,"HIV I-2: HIV incidence among 15-49 age group","HIVI2","Age",{"$f":"CONCATENATE(C5,D5)","v":"HIVI2Age"},"15-24"]
[null,"HIV I-4: AIDS related mortality per 100,000 population","HIVI4","Sex","HIVI4Sex","Male","Female",null,"Impact"]
[null,"HIV I-4: AIDS related mortality per 100,000 population","HIVI4","Age","HIVI4Age","<15","15+","15-24","Impact"]
[null,"HIV I-9a: Percentage of men who have sex with men who are living with HIV","HIVI9a","Age","HIVI9aAge","<25","25+",null,"Impact"]
[null,"HIV I-9b: Percentage of transgender people who are living with HIV","HIVI9b","Age","HIVI9bAge","<25","25+",null,"Impact"]
[null,"Malaria I-1: Reported malaria cases - presumed and confirmed","MalariaI1","Sex","MalariaI1Sex","Male","Female",null,"Impact"]
[null,"Malaria I-1: Reported malaria cases - presumed and confirmed","MalariaI1","Age","MalariaI1Age","<5","5+",null,"Impact"]
[null,"Malaria I-2: Confirmed malaria cases (microscopy or RDT) per 1000 persons per year","MalariaI2","Sex","MalariaI2Sex","Male","Female",null,"Impact"]
[null,"Malaria I-2: Confirmed malaria cases (microscopy or RDT) per 1000 persons per year","MalariaI2","Age","MalariaI2Age","<5","5+",null,"Impact"]
[null,"Malaria I-2: Confirmed malaria cases (microscopy or RDT) per 1000 persons per year","MalariaI2","Species","MalariaI2Species","P. Vivax","P. Falciparum","Other - specify","Impact"]
[null,"Malaria I-3: Inpatient malaria deaths per 1000 persons per year","MalariaI3","Sex","MalariaI3Sex","Male","Female",null,"Impact"]
[null,"Malaria I-3: Inpatient malaria deaths per 1000 persons per year","MalariaI3","Age","MalariaI3Age","<5","5+",null,"Impact"]
[null,"Malaria I-4: Malaria test positivity rate","MalariaI4","Species","MalariaI4Species","P. Vivax","P. Falciparum","Other - specify","Impact"]
[null,"Malaria I-4: Malaria test positivity rate","MalariaI4","Type of testing",{"$f":"SUBSTITUTE(CONCATENATE(C18,D18),\" \",\"\")","v":"MalariaI4Typeoftesting"},"Microscopy","RDT",null,"Impact"]
[null,"Malaria I-5: Parasite prevalence: Proportion of children aged 6-59 months with malaria infection","MalariaI5","Sex","MalariaI5Sex","Male","Female",null,"Impact"]
[null,"Malaria I-5: Parasite prevalence: Proportion of children aged 6-59 months with malaria infection","MalariaI5","Species","MalariaI5Species","P. Vivax","P. Falciparum","Other - specify"]
[null,"Malaria I-6: All-cause under-5 mortality rate per 1000 live births","MalariaI6","Sex","MalariaI6Sex","Male","Female",null,"Impact"]
[null,"HIV O-1: Percentage of adults and children with HIV known to be on treatment 12 months after initiation of antiretroviral therapy","HIVO1","Sex","HIVO1Sex","Male","Female",null,"Outcome"]
[null,"HIV O-1: Percentage of adults and children with HIV known to be on treatment 12 months after initiation of antiretroviral therapy","HIVO1","Age","HIVO1Age","<15","15+",null,"Outcome"]
[null,"HIV O-1: Percentage of adults and children with HIV known to be on treatment 12 months after initiation of antiretroviral therapy","HIVO1","Duration of treatment",{"$f":"SUBSTITUTE(CONCATENATE(C24,D24),\" \",\"\")","v":"HIVO1Durationoftreatment"},"24 months","36 months",null,"Outcome"]
[null,"HIV O-2: Percentage of women and men aged 15-49 who have had sexual intercourse with more than one partner in the past 12 months","HIVO2","Sex","HIVO2Sex","Male","Female",null,"Outcome"]
[null,"HIV O-2: Percentage of women and men aged 15-49 who have had sexual intercourse with more than one partner in the past 12 months","HIVO2","Age","HIVO2Age","15-19","20-24",null,"Outcome"]
[null,"HIV O-3: Percentage of women and men aged 15-49 who had more than one partner in the past 12 months who used a condom during their last sexual intercourse","HIVO3","Sex","HIVO3Sex","Male","Female",null,"Outcome"]
[null,"HIV O-3: Percentage of women and men aged 15-49 who had more than one partner in the past 12 months who used a condom during their last sexual intercourse","HIVO3","Age","HIVO3Age","15-19","20-24",null,"Outcome"]
[null,"HIV O-5: Percentage of sex workers reporting the use of a condom with their most recent client","HIVO5","Sex","HIVO5Sex","Male","Female",null,"Outcome"]
[null,"HIV O-6: Percentage of people who inject drugs reporting the use of sterile injecting equipment the last time they injected","HIVO6","Sex","HIVO6Sex","Male","Female",null,"Outcome"]
[null,"HIV O-8: Current school attendance rate among orphans compared to non-orphans","HIVO8","Sex","HIVO8Sex","Male","Female",null,"Outcome"]
[null,"Malaria O-1a: Proportion of population that slept under an insecticide-treated net* the previous night","MalariaO1a","Sex","MalariaO1aSex","Male","Female",null,"Outcome"]
[null,"Malaria O-3: Proportion of population using an insecticide-treated net* among the population with access to an insecticide-treated net","MalariaO3","Sex","MalariaO3Sex","Male","Female",null,"Outcome"]

{"sheet":"Impactoutcome","index":5,"n_rows":28,"n_cols":11,"rows_kept":28,"cut":false,"hidden":true,"merged":[]}
[]
[null,"Type1","Type2","Type3","Type4","Type5","Type6","Type7","Type8","Type9","Type10"]
[null,"Malaria I-1: Reported malaria cases - presumed and confirmed","TB I-1: TB prevalence rate (per 100,000 population)","HIV I-1: Percentage of young people aged 15–24 who are living with HIV","HIV I-1: Percentage of young people aged 15–24 who are living with HIV","HSS I-1: Under 5 mortality rate per 1000 live births","Malaria O-1a: Proportion of population that slept under an insecticide-treated net* the previous night","TB O-1a: Case notification rate of all forms of TB per 100,000 population - bacteriologically confirmed plus clinically diagnosed, new and relapse cases","HIV O-1: Percentage of adults and children with HIV known to be on treatment 12 months after initiation of antiretroviral therapy","HIV O-1: Percentage of adults and children with HIV known to be on treatment 12 months after initiation of antiretroviral therapy","HSS O-1: Percentage of women attending antenatal care"]
[null,"Malaria I-2: Confirmed malaria cases (microscopy or RDT) per 1000 persons per year","TB I-2: TB incidence rate (per 100,000 population)","HIV I-2: HIV incidence among 15-49 age group","HIV I-2: HIV incidence among 15-49 age group","HSS I-2: Neonatal mortality rate, per 100,000 population","Malaria O-1b: Proportion of children under five years old who slept under an insecticide-treated net* the previous night","TB O-1b: Case notification rate per 100,000 population- bacteriologically-confirmed TB, new and relapse","HIV O-2: Percentage of women and men aged 15-49 who have had sexual intercourse with more than one partner in the past 12 months","HIV O-2: Percentage of women and men aged 15-49 who have had sexual intercourse with more than one partner in the past 12 months","HSS O-2: Percentage of births attended by skilled health professional"]
[null,"Malaria I-3: Inpatient malaria deaths per 1000 persons per year","TB I-3: TB mortality rate (per 100,000 population)","HIV I-3a: Percentage of antenatal care attendees who were positive for syphilis","HIV I-3a: Percentage of antenatal care attendees who were positive for syphilis","HSS I-3: Maternal mortality ratio, per 100,000 population","Malaria O-1c: Proportion of pregnant women who slept under an insecticide-treated net* the previous night","TB O-2a: Treatment success rate - all forms of TB","HIV O-3: Percentage of women and men aged 15-49 who had more than one partner in the past 12 months who used a condom during their last sexual intercourse","HIV O-3: Percentage of women and men aged 15-49 who had more than one partner in the past 12 months who used a condom during their last sexual intercourse","HSS O-3: Ratio of household out-of-pocket payments for health to total expenditure on health"]
[null,"Malaria I-4: Malaria test positivity rate","TB I-4: MDR-TB prevalence among new TB patients","HIV I-3b: Percentage of men who have sex with men with active syphilis","HIV I-3b: Percentage of men who have sex with men with active syphilis","Custom","Malaria O-2: Proportion of population with access to an ITN within their household","TB O-2b: Treatment success rate - bacteriologically confirmed TB cases","HIV O-4a: Percentage of men reporting the use of a condom the last time they had anal sex with a male partner","HIV O-4a: Percentage of men reporting the use of a condom the last time they had anal sex with a male partner","HSS O-4: General service readiness score for health facilities"]
[null,"Malaria I-5: Parasite prevalence: Proportion of children aged 6-59 months with malaria infection","TB I-5: Modelled lives saved based on latest epidemiological data","HIV I-3c: Percentage of sex workers with active syphilis","HIV I-3c: Percentage of sex workers with active syphilis",null,"Malaria O-3: Proportion of population using an insecticide-treated net* among the population with access to an insecticide-treated net","TB O-3: Notification of RR-TB and/or MDR-TB cases - Percentage of notified cases of bacteriologically confirmed, drug resistant RR-TB and/or MDR-TB? as a proportion of the estimated number of RR-TB and/or MDR-TB cases among notified TB cases","HIV O-4b: Percentage of transgender people who sell sex reporting the use of a condom with their most recent client","HIV O-4b: Percentage of transgender people who sell sex reporting the use of a condom with their most recent client","Custom"]
[null,"Malaria I-6: All-cause under-5 mortality rate per 1000 live births","TB I-6: Modelled infections averted based on latest epidemiological data","HIV I-4: AIDS related mortality per 100,000 population","HIV I-4: AIDS related mortality per 100,000 population",null,"Malaria O-4: Proportion of households with at least one insecticide-treated net for every two people and/or sprayed by IRS within the last 12 months","TB O-4: Treatment success rate of MDR-TB: Percentage of bacteriologically confirmed drug resistant TB cases (RR-TB and/or MDR-TB) successfully treated","HIV O-5: Percentage of sex workers reporting the use of a condom with their most recent client","HIV O-5: Percentage of sex workers reporting the use of a condom with their most recent client"]
[null,"Malaria I-7: Modelled lives saved (based on latest epidemiological data)","TB/HIV I-1: TB/HIV mortality rate, per 100,000 population","HIV I-5: New HIV infections among children","HIV I-5: New HIV infections among children",null,"Malaria O-6: Proportion of households with at least one insecticide-treated net* for every two people","HSS O-1: Percentage of women attending antenatal care","HIV O-6: Percentage of people who inject drugs reporting the use of sterile injecting equipment the last time they injected","HIV O-6: Percentage of people who inject drugs reporting the use of sterile injecting equipment the last time they injected"]
[null,"Malaria I-8: Modelled infections averted (based on latest epidemiological data)","HSS I-1: Under 5 mortality rate per 1000 live births","HIV I-6: Estimated percentage of child HIV infections from HIV-positive women delivering in the past 12 months","HIV I-6: Estimated percentage of child HIV infections from HIV-positive women delivering in the past 12 months",null,"HSS O-1: Percentage of women attending antenatal care","HSS O-2: Percentage of births attended by skilled health professional","HIV O-7: Percentage of other vulnerable populations who report the use of a condom at last sexual intercourse","HIV O-7: Percentage of other vulnerable populations who report the use of a condom at last sexual intercourse"]
[null,"HSS I-1: Under 5 mortality rate per 1000 live births","HSS I-2: Neonatal mortality rate, per 100,000 population","HIV I-7: Modelled lives saved based on latest epidemiological data","HIV I-7: Modelled lives saved based on latest epidemiological data",null,"Malaria O-5: Proportion of households with at least one insecticide-treated net","HSS O-3: Ratio of household out-of-pocket payments for health to total expenditure on health","HIV O-8: Current school attendance rate among orphans compared to non-orphans","HIV O-8: Current school attendance rate among orphans compared to non-orphans"]
[null,"HSS I-2: Neonatal mortality rate, per 100,000 population","HSS I-3: Maternal mortality ratio, per 100,000 population","HIV I-8: Modelled infections averted based on latest epidemiological data","HIV I-8: Modelled infections averted based on latest epidemiological data",null,"HSS O-2: Percentage of births attended by skilled health professional","HSS O-5: Specific services readiness score for health facilities","TB O-1a: Case notification rate of all forms of TB per 100,000 population - bacteriologically confirmed plus clinically diagnosed, new and relapse cases","TB O-1a: Case notification rate of all forms of TB per 100,000 population - bacteriologically confirmed plus clinically diagnosed, new and relapse cases"]
[null,"HSS I-3: Maternal mortality ratio, per 100,000 population","Custom","HIV I-9a: Percentage of men who have sex with men who are living with HIV","HIV I-9a: Percentage of men who have sex with men who are living with HIV",null,"HSS O-3: Ratio of household out-of-pocket payments for health to total expenditure on health","Custom","TB O-1b: Case notification rate per 100,000 population- bacteriologically-confirmed TB, new and relapse","TB O-1b: Case notification rate per 100,000 population- bacteriologically-confirmed TB, new and relapse"]
[null,"Custom",null,"HIV I-9b: Percentage of transgender people who are living with HIV","HIV I-9b: Percentage of transgender people who are living with HIV",null,"HSS O-5: Specific services readiness score for health facilities",null,"TB O-2a: Treatment success rate - all forms of TB","TB O-2a: Treatment success rate - all forms of TB"]
[null,null,null,"HIV I-10: Percentage of sex workers who are living with HIV","HIV I-10: Percentage of sex workers who are living with HIV",null,"Custom",null,"TB O-2b: Treatment success rate - bacteriologically confirmed TB cases","TB O-2b: Treatment success rate - bacteriologically confirmed TB cases"]
[null,null,null,"HIV I-11: Percentage of people who inject drugs who are living with HIV","HIV I-11: Percentage of people who inject drugs who are living with HIV",null,null,null,"TB O-3: Notification of RR-TB and/or MDR-TB cases - Percentage of notified cases of bacteriologically confirmed, drug resistant RR-TB and/or MDR-TB? as a proportion of the estimated number of RR-TB and/or MDR-TB cases among notified TB cases","TB O-3: Notification of RR-TB and/or MDR-TB cases - Percentage of notified cases of bacteriologically confirmed, drug resistant RR-TB and/or MDR-TB? as a proportion of the estimated number of RR-TB and/or MDR-TB cases among notified TB cases"]
[null,null,null,"HIV I-12: Percentage of other vulnerable populations (specify) who are living with HIV","HIV I-12: Percentage of other vulnerable populations (specify) who are living with HIV",null,null,null,"TB O-4: Treatment success rate of MDR-TB: Percentage of bacteriologically confirmed drug resistant TB cases (RR-TB and/or MDR-TB) successfully treated","TB O-4: Treatment success rate of MDR-TB: Percentage of bacteriologically confirmed drug resistant TB cases (RR-TB and/or MDR-TB) successfully treated"]
[null,null,null,"TB I-1: TB prevalence rate (per 100,000 population)","TB/HIV I-1: TB/HIV mortality rate, per 100,000 population",null,null,null,"HSS O-1: Percentage of women attending antenatal care","HSS O-1: Percentage of women attending antenatal care"]
[null,null,null,"TB I-2: TB incidence rate (per 100,000 population)","HSS I-1: Under 5 mortality rate per 1000 live births",null,null,null,"HSS O-2: Percentage of births attended by skilled health professional","HSS O-2: Percentage of births attended by skilled health professional"]
[null,null,null,"TB I-3: TB mortality rate (per 100,000 population)","HSS I-2: Neonatal mortality rate, per 100,000 population",null,null,null,"HSS O-3: Ratio of household out-of-pocket payments for health to total expenditure on health","HSS O-3: Ratio of household out-of-pocket payments for health to total expenditure on health"]
[null,null,null,"TB I-4: MDR-TB prevalence among new TB patients","HSS I-3: Maternal mortality ratio, per 100,000 population",null,null,null,"HSS O-5: Specific services readiness score for health facilities","HSS O-5: Specific services readiness score for health facilities"]
[null,null,null,"TB I-5: Modelled lives saved based on latest epidemiological data","Custom",null,null,null,"Custom","Custom"]
[null,null,null,"TB I-6: Modelled infections averted based on latest epidemiological data"]
[null,null,null,"TB/HIV I-1: TB/HIV mortality rate, per 100,000 population"]
[null,null,null,"HSS I-1: Under 5 mortality rate per 1000 live births"]
[null,null,null,"HSS I-2: Neonatal mortality rate, per 100,000 population"]
[null,null,null,"HSS I-3: Maternal mortality ratio, per 100,000 population"]
[null,null,null,"Custom"]

{"sheet":"Coverage Indicators","index":6,"n_rows":20,"n_cols":26,"rows_kept":20,"cut":false,"hidden":true,"merged":[]}
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"HIV/AIDS","HIV/AIDS","HIV/AIDS","HIV/AIDS","HIV/AIDS","HIV/AIDS","HIV/AIDS","HIV/AIDS"]
[null,null," ",null,null,null,null,null,null,null,null,null,null,null,null,"Tuberculosis","Tuberculosis","Tuberculosis","Tuberculosis","Tuberculosis","Tuberculosis","Tuberculosis","Tuberculosis","Tuberculosis","Tuberculosis","HIV/AIDS"]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,"HIV/AIDS","Malaria","Malaria","Malaria","Malaria","Malaria","Malaria","Malaria","Malaria","Malaria","HIV/AIDS","Tuberculosis"]
[null,null,null,null,null,"Tuberculosis","HIV/TB","HIV/TB","HIV/TB","HIV/TB","HIV/TB","HIV/TB","HIV/TB","HIV/TB","Tuberculosis","Health Systems Strengthening","Health Systems Strengthening","Health Systems Strengthening","Health Systems Strengthening","Health Systems Strengthening","Health Systems Strengthening","Health Systems Strengthening","Health Systems Strengthening","Health Systems Strengthening","HIV/TB","Malaria"]
[null,"Malaria","Malaria","Malaria","Tuberculosis","HIV/TB","HIV/AIDS","HIV/AIDS","HIV/AIDS","HIV/AIDS","HIV/AIDS","HIV/AIDS","HIV/AIDS","HIV/AIDS","HIV/TB","HIV/TB","HIV/TB","HIV/TB","HIV/TB","HIV/TB","HIV/TB","HIV/TB","HIV/TB","HIV/TB","Malaria","HIV/TB"]
[null,"Specific prevention interventions (SPI)","Vector control","Case management","TB care and prevention","MDR-TB","Prevention programs for general population","Prevention programs for MSM and TGs","Prevention programs for people who inject drugs (PWID) and their partners","Prevention programs for other vulnerable populations (please specify)","Prevention programs for adolescents and youth, in and out of school","Prevention programs for sex workers and their clients","PMTCT","HIV/AIDS","TB/HIV","Removing legal barriers to access","HSS - Service delivery","HSS - Health and community workforce","HSS - Health information systems and M&E","Program management","HSS - Procurement supply chain management (PSCM)","HSS - Policy and governance","HSS - Healthcare financing","HSS - Financial management","Community systems strengthening","Results based Financing"]
[null,"Module1","Module2","Module3","Module4","Module5","Module8","Module9","Module10","Module11","Module12","Module13","Module14","Module15","Module24","Module27","Module28","Module29","Module30","Module31","Module32","Module33","Module34","Module35","Module72","Module73"]
[null,"SPI-1: Proportion of pregnant women attending antenatal clinics who received three or more doses of intermittent preventive treatment (IPTp) for malaria","VC-1: Number of long-lasting insecticidal nets distributed to at-risk populations through mass campaigns","CM-1a: Proportion of suspected malaria cases that receive a parasitological test at public sector health facilities","DOTS-1a: Number of notified cases of all forms of TB - bacteriologically confirmed plus clinically diagnosed, new and relapses","MDR TB-1: Percentage of previously treated TB patients receiving DST (bacteriologically positive cases only)","GP-1: Number of women and men aged 15+ who received an HIV test and know their results","KP-1a: Percentage of MSM reached with HIV prevention programs - defined package of services","KP-1d: Percentage of PWID reached with HIV prevention programs - defined package of services","KP-1e: Percentage of other vulnerable populations reached with HIV prevention programs - defined package of services","YP-1: Percentage of young people aged 10?24 years reached by life skills?based HIV education in schools","KP-1c: Percentage of sex workers reached with HIV prevention programs - defined package of services","PMTCT-1: Percentage of pregnant women who know their HIV status","TCS-1: Percentage of adults and children currently receiving antiretroviral therapy among all adults and children living with HIV","TB/HIV-1: Percentage of TB patients who had an HIV test result recorded in the TB register","Custom ","SD-1: Number of health facilities per 10,000 population","HW-1: Number of health workers per 10,000 population (report on community health workers as applicable)","M&E-1: Percentage of HMIS or other routine reporting units submitting timely reports according to national guidelines","Custom","PSM-1: Percentage of health facilities reporting no stock-outs of essential drugs","Custom","HF-1: Government expenditure on health as percentage of general government expenditure","Custom","Custom","Custom"]
[null,"Custom","VC-2: Proportion of population at risk potentially covered by long lasting insecticidal nets distributed","CM-1b: Proportion of suspected malaria cases that receive a parasitological test in the community","DOTS-1b: Number of notified cases of bacteriologically confirmed TB, new and relapses","MDR TB-2: Number of bacteriologically confirmed, drug resistant TB cases (RR-TB and/or MDR-TB) notified","GP-2: Percentage of individuals from targeted population reached through community outreach with standardized HIV prevention interventions","KP-1b: Percentage of TG reached with HIV prevention programs - defined package of services","KP-2d: Percentage of PWID reached with HIV prevention programs - individual and/or smaller group level interventions","KP-2e: Percentage of other vulnerable populations reached with HIV prevention programs - individual and/or smaller group level interventions","Custom","KP-2c: Percentage of sex workers reached with HIV prevention programs - individual and/or smaller group level interventions","PMTCT-2: Percentage of HIV-positive pregnant women who received antiretrovirals to reduce the risk of mother-to-child transmission","TCS-2: Percentage of people living with HIV that initiated ART with CD4 count of <200 cells/mm³","TB/HIV-4: Percentage of new HIV-positive patients starting IPT during the reporting period",null,"SD-2: Number of outpatients visits per 10,000 population","HW-2: Distribution of health workers","M&E-2: Proportion of facility reports received over the reports expected during the reporting period",null,"Custom",null,"Custom"]
[null,null,"VC-3: Number of long-lasting insecticidal nets distributed to targeted risk groups through continuous distribution","CM-1c: Proportion of suspected malaria cases that receive a parasitological test at private sector sites","DOTS-2a: Percentage of TB cases, all forms, bacteriologically confirmed plus clinically diagnosed, successfully treated (cured plus treatment completed) among all TB cases registered for treatment during a specified period","MDR TB-3: Number of cases with drug resistant TB (RR-TB and/or MDR-TB) that began second-line treatment","GP-3: Proportion of new individuals who test positive for HIV, enrolled in care (pre-ART or ART) services","KP-2a: Percentage of MSM reached with HIV prevention programs - individual and/or smaller group level interventions","KP-3d: Percentage of PWID that have received an HIV test during the reporting period and know their results","KP-3e: Percentage of other vulnerable populations that have received an HIV test during the reporting period and know their results",null,"KP-3c: Percentage of sex workers that have received an HIV test during the reporting period and know their results","PMTCT-3: Percentage of infants born to HIV-positive women receiving a virological test for HIV within 2 months of birth","TCS-3: Percentage of adults and children that initiated ART, with an undetectable viral load at 12 months (<1000 copies/ml)","TB/HIV-3: Percentage of HIV-positive patients who were screened for TB in HIV care or treatment settings",null,"Custom","HW-3: Number of health workers newly recruited at primary health care facilities in the past 12 months, expressed as a percentage of planned recruitment targets","M&E-3: Percentage of deaths registered (as reported by civil or sample registration systems, hospitals, community-based reporting systems) among the total deaths for the same period and geographical region"]
[null,null,"VC-4: Proportion of targeted risk groups receiving long-lasting insecticidal-nets","CM-2a: Proportion of confirmed malaria cases that received first-line antimalarial treatment according to national policy at public sector health facilities","DOTS-2b: Percentage of bacteriologically confirmed TB cases successfully treated (cured plus completed treatment) among the bacteriologically confirmed TB cases registered during a specified period","MDR TB-4: Percentage of cases with drug resistant TB (RR-TB and/or MDR-TB) started on treatment for MDR-TB who were lost to follow up at six months","GP-4: Percentage of antenatal care attendees tested for syphilis","KP-2b: Percentage of TG reached with HIV prevention programs - individual and/or smaller group level interventions","KP-4: Number of needles and syringes distributed per person who injects drugs per year by needle and syringe programs","Custom",null,"Custom","Custom","TCS-4: Percentage of health facilities dispensing antiretroviral therapy that experienced a stock-out of at least one required antiretroviral drug in the last 12 month","TB/HIV-2: Percentage of HIV-positive registered TB patients given anti-retroviral therapy during TB treatment",null,null,"HW-4: Annual rate of retention of service providers at primary health care facilities","Custom"]
[null,null,"VC-5: Proportion of households in targeted areas that received Indoor Residual Spraying during the reporting period","CM-2b: Proportion of confirmed malaria cases that received first-line antimalarial treatment according to national policy in the community","DOTS-3: Percentage of laboratories showing adequate performance in external quality assurance for smear microscopy among the total number of laboratories that undertake smear microscopy during the reporting period","MDR TB-5: Percentage of DST laboratories showing adequate performance on External Quality Assurance","GP-5: Number of male circumcisions performed according to national standards","KP-3a: Percentage of MSM that have received an HIV test during the reporting period and know their results","KP-5: Percentage of individuals receiving Opioid Substitution Therapy who received treatment for at least 6 months",null,null,null,null,"TCS-5: Proportion of undernourished PLHIV that received therapeutic or supplementary food at any point during the reporting period","Custom",null,null,"Custom"]
[null,null,"VC-6: Proportion of population protected by Indoor Residual Spraying within the last 12 months","CM-2c: Proportion of confirmed malaria cases that received first-line antimalarial treatment according to national policy at private sector sites","DOTS-4: Percentage of reporting units reporting no stock-out of first-line anti-TB drugs on the last day of the quarter","Custom","GP-6: Percentage of orphaned and vulnerable children aged 0?17 years whose households received free basic external support in caring for the child according to national guidelines","KP-3b: Percentage of TG that have received an HIV test during the reporting period and know their results","Custom",null,null,null,null,"Custom"]
[null,null,"Custom","CM-3a: Proportion of estimated malaria cases (presumed and confirmed) that received first line antimalarial treatment at public sector health facilities","DOTS-5: Number of children <5 in contact with TB patients who began IPT",null,"Custom","Custom"]
[null,null,null,"CM-3b: Proportion of estimated malaria cases (presumed and confirmed) that received first line anti-malarial treatment in the community","DOTS-6: Number of TB cases (all forms) notified among key affected populations/high risk groups"]
[null,null,null,"CM-3c: Proportion of estimated malaria cases (presumed and confirmed) that received first line anti-malarial treatment at private sector sites","DOTS-7a: Percentage of notified TB cases, all forms, contributed by non-NTP providers - private/non-governmental facilities"]
[null,null,null,"CM-4: Proportion of health facilities without stock-outs of key commodities during the reporting period","DOTS-7b: Percentage of notified TB cases, all forms, contributed by non-NTP providers - public sector"]
[null,null,null,"CM-5: Percentage of confirmed cases fully investigated (malaria elimination phase)","DOTS-7c: Percentage of notified TB cases, all forms, contributed by non-NTP providers - community referrals"]
[null,null,null,"CM-6: Percentage of foci fully investigated (malaria elimination phase)","Custom"]
[null,null,null,"Custom"]

{"sheet":"CoverageDisaggregationData","index":7,"n_rows":37,"n_cols":10,"rows_kept":37,"cut":false,"hidden":true,"merged":[]}
[null,"Coverage disaggregation Data "]
[null,"Name of Indicator","ShortName","Disaggregation ","Concatenatedcode","Module","Categories"]
[null,"GP-1: Number of women and men aged 15+ who received an HIV test and know their results","GP1D","Sex",{"$f":"SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(CONCATENATE(C3,D3),\" \",\"\"),\"/\",\"\"),\"-\",\"\")","v":"GP1DSex"},"Prevention programs for general population","Male","Female"]
[null,"GP-1: Number of women and men aged 15+ who received an HIV test and know their results","GP1D","HIV status","GP1DHIVstatus","Prevention programs for general population","Positive","Negative"]
[null,"GP-1: Number of women and men aged 15+ who received an HIV test and know their results","GP1D","Age",{"$f":"SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(CONCATENATE(C5,D5),\" \",\"\"),\"/\",\"\"),\"-\",\"\")","v":"GP1DAge"},"Prevention programs for general population","15-24"]
[null,"PMTCT-1: Percentage of pregnant women who know their HIV status","PMTCT1","HIV status-pregnant women","PMTCT1HIVstatuspregnantwomen","PMTCT","Known positive HIV infection at ANC","Newly identified as HIV positive","Testing HIV negative"]
[null,"TCS-1: Percentage of adults and children currently receiving antiretroviral therapy among all adults and children living with HIV","TCS1a","Sex","TCS1aSex","Treatment, care and support","Male","Female"]
[null,"TCS-1: Percentage of adults and children currently receiving antiretroviral therapy among all adults and children living with HIV","TCS1a","Age","TCS1aAge","Treatment, care and support","<15","15+","15-24"]
[null,"TCS-2: Percentage of people living with HIV that initiated ART with CD4 count of <200 cells/mm³","TCS2a","Sex","TCS2aSex","Treatment, care and support","Male","Female"]
[null,"TCS-3: Percentage of adults and children that initiated ART, with an undetectable viral load at 12 months (<1000 copies/ml)","TCS3a","Sex","TCS3aSex","Treatment, care and support","Male","Female"]
[null,"TCS-3: Percentage of adults and children that initiated ART, with an undetectable viral load at 12 months (<1000 copies/ml)","TCS3a","Age","TCS3aAge","Treatment, care and support","15-24"]
[null,"DOTS-1a: Number of notified cases of all forms of TB - bacteriologically confirmed plus clinically diagnosed, new and relapses","DOTS1a","Sex","DOTS1aSex","TB care and prevention","Male","Female"]
[null,"DOTS-1a: Number of notified cases of all forms of TB - bacteriologically confirmed plus clinically diagnosed, new and relapses","DOTS1a","HIV test result","DOTS1aHIVtestresult","TB care and prevention","Positive","Negative","Not documented"]
[null,"DOTS-1a: Number of notified cases of all forms of TB - bacteriologically confirmed plus clinically diagnosed, new and relapses","DOTS1a","Age","DOTS1aAge","TB care and prevention","<15","15+"]
[null,"DOTS-2a: Percentage of TB cases, all forms, bacteriologically confirmed plus clinically diagnosed, successfully treated (cured plus treatment completed) among all TB cases registered for treatment during a specified period","DOTS2a","Sex","DOTS2aSex","TB care and prevention","Male","Female"]
[null,"DOTS-2a: Percentage of TB cases, all forms, bacteriologically confirmed plus clinically diagnosed, successfully treated (cured plus treatment completed) among all TB cases registered for treatment during a specified period","DOTS2a","Age","DOTS2aAge","TB care and prevention","<15","15+"]
[null,"DOTS-2a: Percentage of TB cases, all forms, bacteriologically confirmed plus clinically diagnosed, successfully treated (cured plus treatment completed) among all TB cases registered for treatment during a specified period","DOTS2a","HIV test result","DOTS2aHIVtestresult","TB care and prevention","Positive","Negative","Not documented"]
[null,"DOTS-6: Number of TB cases (all forms) notified among key affected populations/high risk groups","DOTS6","KAPs/high risk groups","DOTS6KAPshighriskgroups","TB care and prevention","Prisoners","Migrants/ Refugees/ IDPs","Others - specify"]
[null,"MDR TB-2: Number of bacteriologically confirmed, drug resistant TB cases (RR-TB and/or MDR-TB) notified","MDRTB2","Sex","MDRTB2Sex","MDR-TB","Male","Female"]
[null,"MDR TB-2: Number of bacteriologically confirmed, drug resistant TB cases (RR-TB and/or MDR-TB) notified","MDRTB2","Age","MDRTB2Age","MDR-TB","<15","15+"]
[null,"MDR TB-3: Number of cases with drug resistant TB (RR-TB and/or MDR-TB) that began second-line treatment","MDRTB3","Sex","MDRTB3Sex","MDR-TB","Male","Female"]
[null,"MDR TB-3: Number of cases with drug resistant TB (RR-TB and/or MDR-TB) that began second-line treatment","MDRTB3","Age","MDRTB3Age","MDR-TB","<15","15+"]
[null,"VC-3: Number of long-lasting insecticidal nets distributed to targeted risk groups through continuous distribution","VC3a","Targeted risk group","VC3aTargetedriskgroup","Vector control","Pregnant women","Children <5","Migrant workers/ refugees/ IDPs","Others - specify"]
[null,"VC-4: Proportion of targeted risk groups receiving long-lasting insecticidal-nets","VC4a","Targeted risk group","VC4aTargetedriskgroup","Vector control","Pregnant women","Children <5","Migrant workers/ refugees/ IDPs","Others - specify"]
[null,"CM-1a: Proportion of suspected malaria cases that receive a parasitological test at public sector health facilities","CM1a","Age","CM1aAge","Case management","<5","5+"]
[null,"CM-1a: Proportion of suspected malaria cases that receive a parasitological test at public sector health facilities","CM1a","Type of testing","CM1aTypeoftesting","Case management","Microscopy","RDTs"]
[null,"CM-1b: Proportion of suspected malaria cases that receive a parasitological test in the community","CM1b","Age","CM1bAge","Case management","<5","5+"]
[null,"CM-1b: Proportion of suspected malaria cases that receive a parasitological test in the community","CM1b","Type of testing","CM1bTypeoftesting","Case management","Microscopy","RDTs"]
[null,"CM-1c: Proportion of suspected malaria cases that receive a parasitological test at private sector sites","CM1c","Age","CM1cAge","Case management","<5","5+"]
[null,"CM-1c: Proportion of suspected malaria cases that receive a parasitological test at private sector sites","CM1c","Type of testing","CM1cTypeoftesting","Case management","Microscopy","RDTs"]
[null,"CM-2a: Proportion of confirmed malaria cases that received first-line antimalarial treatment according to national policy at public sector health facilities","CM2a","Age","CM2aAge","Case management","<5","5+"]
[null,"CM-2b: Proportion of confirmed malaria cases that received first-line antimalarial treatment according to national policy in the community","CM2b","Age","CM2bAge","Case management","<5","5+"]
[null,"CM-2c: Proportion of confirmed malaria cases that received first-line antimalarial treatment according to national policy at private sector sites","CM2c","Age","CM2cAge","Case management","<5","5+"]
[null,"CM-3a: Proportion of estimated malaria cases (presumed and confirmed) that received first line antimalarial treatment at public sector health facilities","CM3a","Age","CM3aAge","Case management","<5","5+"]
[null,"CM-3b: Proportion of estimated malaria cases (presumed and confirmed) that received first line anti-malarial treatment in the community","CM3b","Age","CM3bAge","Case management","<5","5+"]
[null,"CM-3c: Proportion of estimated malaria cases (presumed and confirmed) that received first line anti-malarial treatment at private sector sites","CM3c","Age","CM3cAge","Case management","<5","5+"]
[null,"HW-1: Number of health workers per 10,000 population (report on community health workers as applicable)","HW1a","Specialization","HW1aSpecialization","HSS - Health and community workforce","Doctors","Nurses","Lab technicians","Other - specify"]

{"sheet":"WPTM_1C","index":8,"n_rows":42,"n_cols":28,"rows_kept":42,"cut":false,"hidden":false,"merged":[[3,12,3,18],[3,20,3,21],[0,0,0,11],[3,0,3,11]]}
["Ongoing Progress Update and Disbursement Request"]
[null,null,null,"Section 1:  Programmatic Progress"]
[null,null,null,"Note: Enter only the Workplan Tracking Measures that are due for the reporting period "]
["C- Workplan Tracking Measures ",null,null,null,null,null,null,null,null,null,null,null,"LFA Use Only",null,null,null,null,null,null,null,"For the Global Fund Use Only"]
["Module",null,"Intervention","Activity","Activity details- milestones/ targets","Criterion for completion","Milestones/Target for the Current Period ","Country (relevant for multi-country grants)","Target","Progress Status","Score","Reasons for deviation from workplan activities and milestones","Activity details- milestones/ targets","Criterion for completion","Milestones/Target for the Current Period ","Country (relevant for multi-country grants)","Progress Status","Verified Score","LFA analysis of progress and any variance between targets and results, and any other comments\n(this should not be a “Copy and Paste” of the reasons provided by the PR)","Progress Status","Validated Score","Country Team Comments on Validated Score"]
[null,{"$f":"SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(A6,\" \",\"\"),\"-\",\"\"),\"&\",\"\"),\",\",\"\"),\"/\",\"\"),\")\",\"\"),\"(\",\"\")","v":""},null,null,null,null,null,null,"-",null,{"$f":"IFERROR(VLOOKUP(J6,$AA$8:$AB$11,2,FALSE),\"\")","v":""},null," "," ",null," ",null,{"$f":"IFERROR(VLOOKUP(Q6,$AA$8:$AB$11,2,FALSE),\"\")","v":""},null,null,{"$f":"IFERROR(VLOOKUP(T6,$AA$8:$AB$11,2,FALSE),\"\")","v":""}]
[null,{"$f":"SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(A7,\" \",\"\"),\"-\",\"\"),\"&\",\"\"),\",\",\"\"),\"/\",\"\"),\")\",\"\"),\"(\",\"\")","v":""},null,null,null,null,null,null,"-",null,{"$f":"IFERROR(VLOOKUP(J7,$AA$8:$AB$11,2,FALSE),\"\")","v":""},null,null,null,null,null,null,{"$f":"IFERROR(VLOOKUP(Q7,$AA$8:$AB$11,2,FALSE),\"\")","v":""},null,null,{"$f":"IFERROR(VLOOKUP(T7,$AA$8:$AB$11,2,FALSE),\"\")","v":""}]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,"",null,null,null,null,null,"Not Started",0]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,"",null,null,null,null,null,"Started",1]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,"",null,null,null,null,null,"Advancing",2]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,"",null,null,null,null,null,"Completed",3]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,{"$f":"SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(SUBSTITUTE(A19,\" \",\"\"),\"-\",\"\"),\"&\",\"\"),\",\",\"\"),\"/\",\"\"),\")\",\"\"),\"(\",\"\")","v":""},null,null,null,null,null,null,"-",null,{"$f":"IFERROR(VLOOKUP(J19,$AA$8:$AB$11,2,FALSE),\"\")","v":""},null,null,null,null,null,null,{"$f":"IFERROR(VLOOKUP(Q19,$AA$8:$AB$11,2,FALSE),\"\")","v":""},null,null,{"$f":"IFERROR(VLOOKUP(T19,$AA$8:$AB$11,2,FALSE),\"\")","v":""}]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]
[null,"",null,null,null,null,null,null,"-",null,"",null,null,null,null,null,null,"",null,null,""]

{"sheet":"Intervention By Modules old","index":9,"n_rows":20,"n_cols":80,"rows_kept":20,"cut":false,"hidden":true,"merged":[]}
[]
[null,null," "]
[]
[]
[]
[null,"Specific prevention interventions (SPI)","Vector control","Case management","TBcareandprevention","MDR-TB","TB care and prevention","MDR-TB","Prevention programs for general population","Prevention programs for MSM and TGs","Prevention programs for people who inject drugs (PWID) and their partners","Prevention programs for other vulnerable populations (please specify)","Prevention programs for adolescents and youth, in and out of school","Prevention programs for sex workers and their clients","PMTCT","Treatment, care and support","Prevention programs for general population","Prevention programs for MSM and TGs","Prevention programs for people who inject drugs (PWID) and their partners","Prevention programs for other vulnerable populations (please specify)","Prevention programs for adolescents and youth, in and out of school","Prevention programs for sex workers and their clients","PMTCT","Treatment, care and support","TB/HIV","TB/HIV","TB/HIV","Removing legal barriers to access","HSS - Service delivery","HSS - Health and community workforce","HSS - Health information systems and M&E","Program management","HSS - Procurement supply chain management (PSCM)","HSS - Policy and governance","HSS - Healthcare financing","HSS - Financial management","Removing legal barriers to access","HSS - Service delivery","HSS - Health and community workforce","HSS - Health information systems and M&E","Program management","HSS - Procurement supply chain management (PSCM)","HSS - Policy and governance","HSS - Healthcare financing","HSS - Financial management","Removing legal barriers to access","HSS - Service delivery","HSS - Health and community workforce","HSS - Health information systems and M&E","Program management","HSS - Procurement supply chain management (PSCM)","HSS - Policy and governance","HSS - Healthcare financing","HSS - Financial management","Removing legal barriers to access","HSS - Service delivery","HSS - Health and community workforce","HSS - Health information systems and M&E","Program management","HSS - Procurement supply chain management (PSCM)","HSS - Policy and governance","HSS - Healthcare financing","HSS - Financial management","Removing legal barriers to access","HSS - Service delivery","HSS - Health and community workforce","HSS - Health information systems and M&E","Program management","HSS - Procurement supply chain management (PSCM)","HSS - Policy and governance","HSS - Healthcare financing","HSS - Financial management","Community systems strengthening","Results-based Financing","Community systems strengthening","Results-based Financing","Community systems strengthening","Results-based Financing","Community systems strengthening","Results-based Financing"]
[null,"MalariaModule1","MalariaModule2","MalariaModule3","TuberculosisModule4","TuberculosisModule5","HIV/TBModule6","HIV/TBModule7","HIV/TBModule8","HIV/TBModule9","HIV/TBModule10","HIV/TBModule11","HIV/TBModule12","HIV/TBModule13","HIV/TBModule14","HIV/TBModule15","HIV/AIDSModule16","HIV/AIDSModule17","HIV/AIDSModule18","\nHIV/AIDSModule19","HIV/AIDSModule20","HIV/AIDSModule21","HIV/AIDSModule22","\nHIV/AIDSModule23","HIV/AIDSModule24","\nTuberculosisModule25","\nHIV/TBModule26","\nHIV/AIDSModule27","HIV/AIDSModule28","HIV/AIDSModule29","HIV/AIDSModule30","HIV/AIDSModule31","HIV/AIDSModule32","HIV/AIDSModule33","HIV/AIDSModule34","HIV/AIDSModule35","TuberculosisModule36","TuberculosisModule37","TuberculosisModule38","TuberculosisModule39","TuberculosisModule40","TuberculosisModule41","TuberculosisModule42","TuberculosisModule43","TuberculosisModule44","Module45","MalariaModule46","MalariaModule47","MalariaModule48","MalariaModule49","MalariaModule50","MalariaModule51","MalariaModule52","MalariaModule53","Health Systems StrengtheningModule54","Health Systems StrengtheningModule55","Health Systems StrengtheningModule56","Health Systems StrengtheningModule57","Health Systems StrengtheningModule58","Health Systems StrengtheningModule59","Health Systems StrengtheningModule60","Health Systems StrengtheningModule61","Health Systems StrengtheningModule62","HIV/TBModule63","HIV/TBModule64","HIV/TBModule65","HIV/TBModule66","HIV/TBModule67","HIV/TBModule68","HIV/TBModule69","HIV/TBModule70","HIV/TBModule71","HIV/AIDSModule72","HIV/AIDSModule73","TuberculosisModule74","TuberculosisModule75","MalariaModule76","MalariaModule77","HIV/TBModule78","HIV/TBModule79"]
[null,"Intermittent preventive treatment (IPT) - In pregnancy","Long-lasting insecticidal nets (LLIN) - Mass campaign","Facility-based treatment","Case detection and diagnosis","Case detection and diagnosis: MDR-TB","Case detection and diagnosis","Case detection and diagnosis: MDR-TB","RMNCH linkages and gender-based violence (GBV)","Behavioral change as part of programs for MSM and TGs","Needle and Syringe programs as part of programs for PWID and their partners","Condoms as part of programs for other vulnerable populations","Behavioral change as part of programs for adolescent and youth","Behavioral change as part of programs for sex workers and their clients","Prong 1: Primary prevention of HIV infection among women of childbearing age","Pre-ART care","RMNCH linkages and gender-based violence (GBV)","Behavioral change as part of programs for MSM and TGs","Needle and Syringe programs as part of programs for PWID and their partners","Condoms as part of programs for other vulnerable populations","Behavioral change as part of programs for adolescent and youth","Behavioral change as part of programs for sex workers and their clients","Prong 1: Primary prevention of HIV infection among women of childbearing age","Pre-ART care","TB/HIV collaborative interventions","TB/HIV collaborative interventions","TB/HIV collaborative interventions","Legal and policy environment assessment and law reform","Service organization and facility management","Health and community workers capacity building","Administrative and finance data sources","Policy, planning, coordination and management","Operationalization of procurement and supply chain management system","Development and implementation of health legislation, strategies and policies","Financial sustainability","Performance,transparency&accountability of financial management system in health","Legal and policy environment assessment and law reform","Service organization and facility management","Health and community workers capacity building","Administrative and finance data sources","Policy, planning, coordination and management","Operationalization of procurement and supply chain management system","Development and implementation of health legislation, strategies and policies","Financial sustainability","Performance,transparency&accountability of financial management system in health","Legal and policy environment assessment and law reform","Service organization and facility management","Health and community workers capacity building","Administrative and finance data sources","Policy, planning, coordination and management","Operationalization of procurement and supply chain management system","Development and implementation of health legislation, strategies and policies","Financial sustainability","Performance,transparency&accountability of financial management system in health","Legal and policy environment assessment and law reform","Service organization and facility management","Health and community workers capacity building","Administrative and finance data sources","Policy, planning, coordination and management","Operationalization of procurement and supply chain management system","Development and implementation of health legislation, strategies and policies","Financial sustainability","Performance,transparency&accountability of financial management system in health","Legal and policy environment assessment and law reform","Service organization and facility management","Health and community workers capacity building","Administrative and finance data sources","Policy, planning, coordination and management","Operationalization of procurement and supply chain management system","Development and implementation of health legislation, strategies and policies","Financial sustainability","Performance,transparency&accountability of financial management system in health","Community-based monitoring for accountability","Results-based financing","Community-based monitoring for accountability","Results-based financing","Community-based monitoring for accountability","Results-based financing","Community-based monitoring for accountability","Results-based financing"]
[null,"Intermittent preventive treatment (IPT) - In infancy","Long-lasting insecticidal nets (LLIN) - Continuous distribution","Epidemic preparedness and response","Treatment","Treatment: MDR-TB","Treatment","Treatment: MDR-TB","Other interventions for general population - Please specify","Condoms as part of programs for MSM and TGs","OST and other drug dependence treatment (PWIDs and their partners)","Behavioral change as part of programs for other vulnerable populations","Condoms part of programs for adolescent and youth","Condoms as part of programs for sex workers and their clients","Prong 2: Preventing unintended pregnancies among women living with HIV","Antiretroviral Therapy (ART)","Other interventions for general population - Please specify","Condoms as part of programs for MSM and TGs","OST and other drug dependence treatment (PWIDs and their partners)","Behavioral change as part of programs for other vulnerable populations","Condoms part of programs for adolescent and youth","Condoms as part of programs for sex workers and their clients","Prong 2: Preventing unintended pregnancies among women living with HIV","Antiretroviral Therapy (ART)","Engaging all care providers","Engaging all care providers","Engaging all care providers","Legal aid services and legal literacy","Improving laboratory systems","Scaling up health and community workers","Vital registration system","Grant management","PSM infrastructure and development of tools","Monitoring and reporting implementation of laws and policies","Equity of healthcare financing",null,"Legal aid services and legal literacy","Improving laboratory systems","Scaling up health and community workers","Vital registration system","Grant management","PSM infrastructure and development of tools","Monitoring and reporting implementation of laws and policies","Equity of healthcare financing",null,"Legal aid services and legal literacy","Improving laboratory systems","Scaling up health and community workers","Vital registration system","Grant management","PSM infrastructure and development of tools","Monitoring and reporting implementation of laws and policies","Equity of healthcare financing",null,"Legal aid services and legal literacy","Improving laboratory systems","Scaling up health and community workers","Vital registration system","Grant management","PSM infrastructure and development of tools","Monitoring and reporting implementation of laws and policies","Equity of healthcare financing",null,"Legal aid services and legal literacy","Improving laboratory systems","Scaling up health and community workers","Vital registration system","Grant management","PSM infrastructure and development of tools","Monitoring and reporting implementation of laws and policies","Equity of healthcare financing",null,"Advocacy for social accountability",null,"Advocacy for social accountability",null,"Advocacy for social accountability",null,"Advocacy for social accountability"]
[null,"Seasonal malaria chemoprevention","Indoor residual spraying (IRS)","Integrated community case management (ICCM)","Prevention","Prevention for MDR-TB","Prevention","Prevention for MDR-TB","Behavioral change as part of programs for general population","HIV testing and counseling as part of programs for MSM and TGs","Diagnosis and treatment of viral hepatitis (PWIDs and their partners)","Diagnosis and treatment of STIs (other vulnerable populations)","HIV testing and counseling as part of programs for adolescent and youth","HIV testing and counseling as part of programs for sex workers and their clients","Prong 3: Preventing vertical HIV transmission","Treatment monitoring","Behavioral change as part of programs for general population","HIV testing and counseling as part of programs for MSM and TGs","Diagnosis and treatment of viral hepatitis (PWIDs and their partners)","Diagnosis and treatment of STIs (other vulnerable populations)","HIV testing and counseling as part of programs for adolescent and youth","HIV testing and counseling as part of programs for sex workers and their clients","Prong 3: Preventing vertical HIV transmission","Treatment monitoring","Community TB care delivery","Community TB care delivery","Community TB care delivery","Community-based monitoring of legal rights","Improving service delivery infrastructure","Retention and distribution of health and community workers","Routine reporting","Supporting procurement and supply management",null,null,null,null,"Community-based monitoring of legal rights","Improving service delivery infrastructure","Retention and distribution of health and community workers","Routine reporting","Supporting procurement and supply management",null,null,null,null,"Community-based monitoring of legal rights","Improving service delivery infrastructure","Retention and distribution of health and community workers","Routine reporting","Supporting procurement and supply management",null,null,null,null,"Community-based monitoring of legal rights","Improving service delivery infrastructure","Retention and distribution of health and community workers","Routine reporting","Supporting procurement and supply management",null,null,null,null,"Community-based monitoring of legal rights","Improving service delivery infrastructure","Retention and distribution of health and community workers","Routine reporting","Supporting procurement and supply management",null,null,null,null,"Social mobilization, building community linkages, collaboration and coordination",null,"Social mobilization, building community linkages, collaboration and coordination",null,"Social mobilization, building community linkages, collaboration and coordination",null,"Social mobilization, building community linkages, collaboration and coordination"]
[null,"IEC/BCC","Other vector control measures","Active case detection and investigation (elimination phase)","Other","Other","Other","Other","Condoms as part of programs for general population","Diagnosis and treatment of STIs as part of programs for MSM and TGs","Other interventions for IDUs and their partners - Please specify","Other interventions for other vulnerable populations - Please specify","RMNCH linkages and GBV as part of programs for adolescent youth","Diagnosis and treatment of STIs (sex workers and their clients)","Prong 4: Treatment, care & support to mothers living with HIV, their children &","Treatment adherence","Condoms as part of programs for general population","Diagnosis and treatment of STIs as part of programs for MSM and TGs","Other interventions for IDUs and their partners - Please specify","Other interventions for other vulnerable populations - Please specify","RMNCH linkages and GBV as part of programs for adolescent youth","Diagnosis and treatment of STIs (sex workers and their clients)","Prong 4: Treatment, care & support to mothers living with HIV, their children &","Treatment adherence","Key Affected Populations","Key Affected Populations","Key Affected Populations","Policy advocacy on legal rights","Other",null,"Analysis, review and transparency",null,null,null,null,null,"Policy advocacy on legal rights","Other",null,"Analysis, review and transparency",null,null,null,null,null,"Policy advocacy on legal rights","Other",null,"Analysis, review and transparency",null,null,null,null,null,"Policy advocacy on legal rights","Other",null,"Analysis, review and transparency",null,null,null,null,null,"Policy advocacy on legal rights","Other",null,"Analysis, review and transparency",null,null,null,null,null,"Institutional capacity building, planning and leadership development",null,"Institutional capacity building, planning and leadership development",null,"Institutional capacity building, planning and leadership development",null,"Institutional capacity building, planning and leadership development"]
[null,"Other","Entomological monitoring","Therapeutic efficacy surveillance",null,null,null,null,"Male circumcision","Diagnosis and treatment of viral hepatitis as part of programs for MSM and TGs","Behavioural change as part of programs for PWID and their partners","HIV testing and counseling as part of programs for other vulnerable populations","Young Key Population interventions as part of programs for adolescent and youth","Harm reduction as part of programs for sex workers and their clients","Other interventions for PMTCT- Please specify","Prevention, diagnosis and treatment of opportunistic infections","Male circumcision","Diagnosis and treatment of viral hepatitis as part of programs for MSM and TGs","Behavioural change as part of programs for PWID and their partners","HIV testing and counseling as part of programs for other vulnerable populations","Young Key Population interventions as part of programs for adolescent and youth","Harm reduction as part of programs for sex workers and their clients","Other interventions for PMTCT- Please specify","Prevention, diagnosis and treatment of opportunistic infections","Collaborative activities with other programs and sectors","Collaborative activities with other programs and sectors","Collaborative activities with other programs and sectors","Training on rights for officials, health workers and police",null,null,"Surveys",null,null,null,null,null,"Training on rights for officials, health workers and police",null,null,"Surveys",null,null,null,null,null,"Training on rights for officials, health workers and police",null,null,"Surveys",null,null,null,null,null,"Training on rights for officials, health workers and police",null,null,"Surveys",null,null,null,null,null,"Training on rights for officials, health workers and police",null,null,"Surveys"]
[null,null,"Other  ","Severe malaria",null,null,null,null,"HIV testing and counseling as part of programs for general population","Other interventions for MSM and TGs - Please specify","Condoms as part of programs for PWID and their partners","Condoms as part of programs for other vulnerable populations","Other interventions for adolescent and youth","Other interventions for sex workers and their clients - Please specify",null,"Counseling and psycho-social support","HIV testing and counseling as part of programs for general population","Other interventions for MSM and TGs - Please specify","Condoms as part of programs for PWID and their partners","Condoms as part of programs for other vulnerable populations","Other interventions for adolescent and youth","Other interventions for sex workers and their clients - Please specify",null,"Counseling and psycho-social support"]
[null,null,null,"Private sector co-payment mechanism",null,null,null,null,"Diagnosis and treatment of STIs as part of programs for general population",null,"Diagnosis and treatment of STIs as part of programs for PWID and their partners","Behavioral change as part of programs for other vulnerable populations",null,null,null,"Out-patient care","Diagnosis and treatment of STIs as part of programs for general population",null,"Diagnosis and treatment of STIs as part of programs for PWID and their partners","Behavioral change as part of programs for other vulnerable populations",null,null,null,"Out-patient care"]
[null,null,null,"Private sector case management (other)",null,null,null,null,"Blood safety",null,"Needle and Syringe programs as part of programs for PWID and their partners","Diagnosis and treatment of STIs (other vulnerable populations)",null,null,null,"In-patient care","Blood safety",null,"Needle and Syringe programs as part of programs for PWID and their partners","Diagnosis and treatment of STIs (other vulnerable populations)",null,null,null,"In-patient care"]
[null,null,null,null,null,null,null,null,null,null,"OST and other drug dependence treatment (PWIDs and their partners)","Other interventions for other vulnerable populations - Please specify",null,null,null,"Other interventions for treatment - Please specify",null,null,"OST and other drug dependence treatment (PWIDs and their partners)","Other interventions for other vulnerable populations - Please specify",null,null,null,"Other interventions for treatment - Please specify"]
[null,null,null,null,null,null,null,null,null,null,"Diagnosis and treatment of viral hepatitis (PWIDs and their partners)","HIV testing and counseling as part of programs for other vulnerable populations",null,null,null,null,null,null,"Diagnosis and treatment of viral hepatitis (PWIDs and their partners)","HIV testing and counseling as part of programs for other vulnerable populations"]
[null,null,null,null,null,null,null,null,null,null,"Behavioural change as part of programs for PWID and their partners",null,null,null,null,null,null,null,"Behavioural change as part of programs for PWID and their partners"]
[null,null,null,null,null,null,null,null,null,null,"Condoms as part of programs for PWID and their partners",null,null,null,null,null,null,null,"Condoms as part of programs for PWID and their partners"]
[null,null,null,null,null,null,null,null,null,null,"Diagnosis and treatment of STIs as part of programs for PWID and their partners",null,null,null,null,null,null,null,"Diagnosis and treatment of STIs as part of programs for PWID and their partners"]

{"sheet":"Intervention By Modules","index":10,"n_rows":17,"n_cols":26,"rows_kept":17,"cut":false,"hidden":true,"merged":[]}
[]
[]
[null,"SpecificpreventioninterventionsSPI","Vectorcontrol","Casemanagement","TBcareandprevention","MDR-TB","Preventionprogramsforgeneralpopulation","PreventionprogramsforMSMandTGs","PreventionprogramsforpeoplewhoinjectdrugsPWIDandtheirpartners","Preventionprogramsforothervulnerablepopulationspleasespecify","Preventionprogramsforadolescentsandyouthinandoutofschool","Preventionprogramsforsexworkersandtheirclients","PMTCT","Treatmentcareandsupport","TBHIV","Removinglegalbarrierstoaccess","HSSServicedelivery","HSSHealthandcommunityworkforce","HSSHealthinformationsystemsandME","Programmanagement","HSSProcurementsupplychainmanagementPSCM","HSSPolicyandgovernance","HSS-Healthcarefinancing","HSSFinancialmanagement","Communitysystemsstrengthening","Results basedFinancing"]
[null,"Intermittent preventive treatment (IPT) - In pregnancy","Long-lasting insecticidal nets (LLIN) - Mass campaign","Facility-based treatment","Case detection and diagnosis","Case detection and diagnosis: MDR-TB","RMNCH linkages and gender-based violence (GBV)","Behavioral change as part of programs for MSM and TGs","Needle and Syringe programs as part of programs for PWID and their partners","Condoms as part of programs for other vulnerable populations","Behavioral change as part of programs for adolescent and youth","Behavioral change as part of programs for sex workers and their clients","Prong 1: Primary prevention of HIV infection among women of childbearing age","Pre-ART care","TB/HIV collaborative interventions","Legal and policy environment assessment and law reform","Service organization and facility management","Health and community workers capacity building","Administrative and finance data sources","Policy, planning, coordination and management","Operationalization of procurement and supply chain management system","Development and implementation of health legislation, strategies and policies","Financial sustainability","Performance,transparency&accountability of financial management system in health","Community-based monitoring for accountability","Results-based financing"]
[null,"Intermittent preventive treatment (IPT) - In infancy","Long-lasting insecticidal nets (LLIN) - Continuous distribution","Epidemic preparedness and response","Treatment","Treatment: MDR-TB","Other interventions for general population - Please specify","Condoms as part of programs for MSM and TGs","OST and other drug dependence treatment (PWIDs and their partners)","Behavioral change as part of programs for other vulnerable populations","Condoms part of programs for adolescent and youth","Condoms as part of programs for sex workers and their clients","Prong 2: Preventing unintended pregnancies among women living with HIV","Antiretroviral Therapy (ART)","Engaging all care providers","Legal aid services and legal literacy","Improving laboratory systems","Scaling up health and community workers","Vital registration system","Grant management","PSM infrastructure and development of tools","Monitoring and reporting implementation of laws and policies","Equity of healthcare financing",null,"Advocacy for social accountability"]
[null,"Seasonal malaria chemoprevention","Indoor residual spraying (IRS)","Integrated community case management (ICCM)","Prevention","Prevention for MDR-TB","Behavioral change as part of programs for general population","HIV testing and counseling as part of programs for MSM and TGs","Diagnosis and treatment of viral hepatitis (PWIDs and their partners)","Diagnosis and treatment of STIs (other vulnerable populations)","HIV testing and counseling as part of programs for adolescent and youth","HIV testing and counseling as part of programs for sex workers and their clients","Prong 3: Preventing vertical HIV transmission","Treatment monitoring","Community TB care delivery","Community-based monitoring of legal rights","Improving service delivery infrastructure","Retention and distribution of health and community workers","Routine reporting","Supporting procurement and supply management",null,null,null,null,"Social mobilization, building community linkages, collaboration and coordination"]
[null,"IEC/BCC","Other vector control measures","Active case detection and investigation (elimination phase)","Other","Other","Condoms as part of programs for general population","Diagnosis and treatment of STIs as part of programs for MSM and TGs","Other interventions for IDUs and their partners - Please specify","Other interventions for other vulnerable populations - Please specify","RMNCH linkages and GBV as part of programs for adolescent youth","Diagnosis and treatment of STIs (sex workers and their clients)","Prong 4: Treatment, care & support to mothers living with HIV, their children &","Treatment adherence","Key Affected Populations","Policy advocacy on legal rights","Other",null,"Analysis, review and transparency",null,null,null,null,null,"Institutional capacity building, planning and leadership development"]
[null,"Other","Entomological monitoring","Therapeutic efficacy surveillance",null,null,"Male circumcision","Diagnosis and treatment of viral hepatitis as part of programs for MSM and TGs","Behavioural change as part of programs for PWID and their partners","HIV testing and counseling as part of programs for other vulnerable populations","Young Key Population interventions as part of programs for adolescent and youth","Harm reduction as part of programs for sex workers and their clients","Other interventions for PMTCT- Please specify","Prevention, diagnosis and treatment of opportunistic infections","Collaborative activities with other programs and sectors","Training on rights for officials, health workers and police",null,null,"Surveys"]
[null,null,"Other  ","Severe malaria",null,null,"HIV testing and counseling as part of programs for general population","Other interventions for MSM and TGs - Please specify","Condoms as part of programs for PWID and their partners","Condoms as part of programs for other vulnerable populations","Other interventions for adolescent and youth","Other interventions for sex workers and their clients - Please specify",null,"Counseling and psycho-social support"]
[null,null,null,"Private sector co-payment mechanism",null,null,"Diagnosis and treatment of STIs as part of programs for general population",null,"Diagnosis and treatment of STIs as part of programs for PWID and their partners","Behavioral change as part of programs for other vulnerable populations",null,null,null,"Out-patient care"]
[null,null,null,"Private sector case management (other)",null,null,"Blood safety",null,"Needle and Syringe programs as part of programs for PWID and their partners","Diagnosis and treatment of STIs (other vulnerable populations)",null,null,null,"In-patient care"]
[null,null,null,null,null,null,null,null,"OST and other drug dependence treatment (PWIDs and their partners)","Other interventions for other vulnerable populations - Please specify",null,null,null,"Other interventions for treatment - Please specify"]
[null,null,null,null,null,null,null,null,"Diagnosis and treatment of viral hepatitis (PWIDs and their partners)","HIV testing and counseling as part of programs for other vulnerable populations"]
[null,null,null,null,null,null,null,null,"Other interventions for IDUs and their partners - Please specify"]
[null,null,null,null,null,null,null,null,"Behavioural change as part of programs for PWID and their partners"]
[null,null,null,null,null,null,null,null,"Condoms as part of programs for PWID and their partners"]
[null,null,null,null,null,null,null,null,"Diagnosis and treatment of STIs as part of programs for PWID and their partners"]

{"sheet":"PR Cash Reconciliation_2A,B,C","index":11,"n_rows":52,"n_cols":12,"rows_kept":52,"cut":false,"hidden":false,"merged":[[0,0,0,11],[27,1,27,11],[3,1,3,11],[38,5,38,8],[45,5,45,8],[44,1,44,11],[45,2,45,4],[45,9,45,11],[1,0,2,11],[4,2,4,4],[4,5,4,8],[4,9,4,11],[37,1,37,11],[38,1,39,1],[38,2,38,4],[38,9,38,11]]}
["Ongoing Progress Update and Disbursement Request "]
["Section 2: Financial Information"]
[]
[null,"A. Principal Recipient Cash Reconciliation Statement in Grant Currency"]
[null,null,"Principal Recipient",null,null,"For LFA Use Only ",null,null,null,"For the Global Fund Use Only"]
["Item No.","Description","Cumulative for Previous Periods","Current Reporting Period","Comments","Cumulative for Previous Periods as validated by Global Fund","LFA Adjustments on Current Reporting Period","As verified by LFA","Comments","CT Adjustments (incl. External Audit adjustments)","The Global Fund Validated Figures","Comments"]
[1.1000000000000001,"Cash Balance: Beginning of the Period",0,457181.30612556799,null,null,0,{"$f":"D7+G7","v":457181.30612556799},null,0,{"$f":"H7+J7","v":457181.30612556799}]
[null,"2. Grant Income"]
[null,"Add: "]
[2.1,"Disbursement made to the Principal Recipient ",2676216.6,{"$f":"1831227.48+56462.88+338566.95+238.62","v":2226495.9300000002},null,0,0,{"$f":"D10+G10","v":2226495.9300000002},null,0,{"$f":"H10+J10","v":2226495.9300000002}]
[2.2000000000000002,"Disbursement to third parties by the Global Fund on behalf of the Principal Recipient ",2521330.0699999998,{"$f":"736815.01-238.62","v":736576.39},null,0,0,{"$f":"D11+G11","v":736576.39},null,0,{"$f":"H11+J11","v":736576.39}]
[2.2999999999999998,"Interest received on bank accounts",0,0,null,0,0,{"$f":"D12+G12","v":0},null,0,0]
[2.4,"Revenue from income-generating activities (if applicable)",0,0,null,0,0,{"$f":"D13+G13","v":0},null,0,0]
[2.5,"Other income, if applicable (e.g. VAT/Other Tax returns, income from disposal of assets etc.)",37345.055296219114,{"$f":"41155.89+5698.24/2.7206+1481.81/2.513+9927.52/2.3934","v":47987.900256847366},"VAT refund (Corresponds to GEL 130,157.27)",0,0,{"$f":"D14+G14","v":47987.900256847366},null,0,47987.900256847366]
[2.6,"Total Grant Income",{"$f":"SUM(C10:C14)","v":5234891.7252962189},{"$f":"SUM(D10:D14)","v":3011060.2202568478},null,{"$f":"SUM(F10:F14)","v":0},{"$f":"SUM(G10:G14)","v":0},{"$f":"SUM(H10:H14)","v":3011060.2202568478},null,{"$f":"SUM(J10:J14)","v":0},{"$f":"SUM(K10:K14)","v":3011060.2202568478}]
[null,"3. Grant Cash Outflows"]
[null,"Less:"]
[3.1,"Principal Recipient Expenditure (including payments and other advance payments)",1646271.7876022039,1711675.0145514291,null,0,0,{"$f":"D18+G18","v":1711675.0145514291},null,0,{"$f":"H18+J18","v":1711675.0145514291}]
[3.2,"Disbursement to third parties by the Global Fund on behalf of the Principal Recipient ",{"$f":"C11","v":2521330.0699999998},{"$f":"D11","v":736576.39},null,{"$f":"F11","v":0},0,{"$f":"D19+G19","v":736576.39},null,{"$f":"J11","v":0},{"$f":"H19+J19","v":736576.39}]
[3.3,"Principal Recipient disbursement to sub-recipients",576674.72729495191,332703.63928937382,null,0,0,{"$f":"D20+G20","v":332703.63928937382},null,0,{"$f":"H20+J20","v":332703.63928937382}]
[3.4,"Bank charges on disbursements and payments",200,238.62,null,0,0,{"$f":"D21+G21","v":238.62},null,0,238.62]
[3.5,"Total Grant Cash Outflows",{"$f":"SUM(C18:C21)","v":4744476.5848971559},{"$f":"SUM(D18:D21)","v":2781193.6638408033},null,{"$f":"SUM(F18:F21)","v":0},{"$f":"SUM(G18:G21)","v":0},{"$f":"SUM(H18:H21)","v":2781193.6638408033},null,{"$f":"SUM(J18:J21)","v":0},{"$f":"SUM(K18:K21)","v":2781193.6638408033}]
[null,"4. Reconciling Adjustments"]
[4.0999999999999996,"Other reconciliation adjustments (including for prior periods)",0,0,null,0,0,{"$f":"D24+G24","v":0},null,0,{"$f":"H24+J24","v":0}]
[4.2,"Net exchange gains/losses on translation of balances",-33233.83,-48878.23,null,0,0,{"$f":"D25+G25","v":-48878.23},null,0,{"$f":"H25+J25","v":-48878.23}]
[4.3,"Ineligible transactions from previous periods for which justification was approved by the Global Fund",0,0,null,0,0,{"$f":"D26+G26","v":0},null,0,0]
[4.4000000000000004,"Reimbursement of ineligible transaction from previous periods",0,0,null,0,0,{"$f":"D27+G27","v":0},null,0,0]
[null,"5. Total Cash Balances: End of the reporting period"]
[5.0999999999999996,"Principal Recipient Cash Balance",0,{"$f":"(D7+D15-D22)+D24+D25+D27","v":638169.63254161226},null,null,{"$f":"(G15-G22)+G25+G24","v":0},{"$f":"(H7+H15-H22)+H24+H25-H26","v":638169.63254161226},null,{"$f":"J7+J15-J22+J25+J24","v":0},{"$f":"K7+K15-K22+K25+K24-K26","v":638169.63254161226}]
[5.2,"Sub-Recipient Cash Balance",0,{"$f":"'SR_Cash Reconciliation_2D'!H60","v":19257.433369280541},null,null,{"$f":"'SR_Cash Reconciliation_2D'!K60","v":0},{"$f":"'SR_Cash Reconciliation_2D'!L60","v":19257.433369280541},null,0,{"$f":"+H30+J30","v":19257.433369280541}]
[5.3,"Total Cash Balance",{"$f":"C29+C30","v":0},{"$f":"D29+D30","v":657427.06591089279},null,{"$f":"F29+F30","v":0},{"$f":"G29+G30","v":0},{"$f":"H29+H30","v":657427.06591089279},null,{"$f":"J29+J30","v":0},{"$f":"K29+K30","v":657427.06591089279}]
[null,"6. Commitments & Other Obligations"]
[6.1,"Unpaid invoices, accrued expenditure for severance pay, leave and other liabilities ",0,{"$f":"(103515.58+83947.54+32800+15614.2)/2.794","v":84422.806012884757},null,0,0,{"$f":"D33+G33","v":84422.806012884757},null,0,{"$f":"H33+J33","v":84422.806012884757}]
[6.2,"Open legal obligations (including signed contracts not yet invoiced) ",0,{"$f":"(71490+79747.45+285320.61+41988.28+4200+4500+3000)/2.794","v":175463.97279885467},null,0,0,{"$f":"D34+G34","v":175463.97279885467},null,0,{"$f":"H34+J34","v":175463.97279885467}]
[6.3,"Tenders and/or procurement contracts initiated but not yet signed as contracts",0,null,null,0,0,{"$f":"D35+G35","v":0},null,0,{"$f":"H35+J35","v":0}]
[6.4,"Total Commitments & Other Obligations",{"$f":"SUM(C33:C35)","v":0},{"$f":"SUM(D33:D35)","v":259886.77881173941},"Excluding commitment to NFM Grant int the amount of USD 428,004",{"$f":"SUM(F33:F35)","v":0},{"$f":"SUM(G33:G35)","v":0},{"$f":"SUM(H33:H35)","v":259886.77881173941},null,{"$f":"SUM(J33:J35)","v":0},{"$f":"SUM(K33:K35)","v":259886.77881173941}]
[]
[null,"B. Principal Recipient Bank Statement Balance & Cash In Transit in Grant Currency"]
[null,null,"Principal Recipient",null,null,"For LFA Use Only ",null,null,null,"For the Global Fund Use Only"]
[null,null,null,"As At End of Current Reporting Period","Comments",null,"LFA Adjustments on Current Reporting Period","As verified by LFA","Comments","CT Adjustments","The Global Fund Validated Figures","Comments"]
[7.1,"Principal Recipient Cash Balance as per bank statements (For Information Only):",null,{"$f":"(1206763.02/2.794)+206257.31","v":638169.62925554765},"EUR (The amount consists of GEL 1 206 763,02 and EUR 206 257,31)",null,0,{"$f":"D41+G41","v":638169.62925554765},null,0,{"$f":"H41+J41","v":638169.62925554765}]
[7.2,"Cash in Transit for the reporting period",null,0,null,null,0,{"$f":"D42+G42","v":0},null,0,{"$f":"H42+J42","v":0}]
[7.3,"Cash in Transit after the current reporting period",null,0,null,null,0,{"$f":"D43+G43","v":0},null,0,0]
[]
[null,"C. Principal Recipient Ineligible Transactions in Grant Currency "]
[null,null,"Principal Recipient",null,null,"For LFA Use Only ",null,null,null,"For the Global Fund Use Only"]
[null,null,"Cumulative for Previous Periods","Current Reporting Period","Comments","Cumulative for Previous Periods as validated by Global Fund","LFA Adjustments on Current Reporting Period","As verified by LFA","Comments","CT Adjustments","The Global Fund Validated Figures","Comments"]
[8.1,"Ineligible transactions validated for the reporting period",0,0,null,0,{"$f":"G31","v":0},{"$f":"D48+G48","v":0},null,0,{"$f":"H48+J48","v":0}]
[8.1999999999999993,"Ineligible transactions from previous periods for which justification was approved by the Global Fund",{"$f":"C26","v":0},{"$f":"D26","v":0},null,{"$f":"F26","v":0},{"$f":"G26","v":0},{"$f":"D49+G49","v":0},null,{"$f":"J26","v":0},{"$f":"H49+J49","v":0}]
[8.3000000000000007,"Reimbursement of ineligible transactions from previous periods",{"$f":"C27","v":0},{"$f":"D27","v":0},null,{"$f":"F27","v":0},{"$f":"G27","v":0},{"$f":"D50+G50","v":0},null,{"$f":"J27","v":0},0]
[8.4,"Cumulative ineligible transactions for the implementation period",0,{"$f":"D48+C51","v":0},null,0,{"$f":"H48","v":0},{"$f":"F51+G51","v":0},null,0,{"$f":"H51+J51","v":0}]
[8.5,"Open ineligible transactions to be justified and/or reimbursed",{"$f":"C51-C49-C50","v":0},{"$f":"C52+D48-D49-D50","v":0},null,0,null,{"$f":"H51-F49-F50-H49-H50","v":0},null,0,{"$f":"K51-J49-J50-K49-K50","v":0}]

{"sheet":"SR_Cash Reconciliation_2D","index":12,"n_rows":62,"n_cols":16,"rows_kept":62,"cut":false,"hidden":false,"merged":[[7,13,7,15],[2,0,3,11],[5,0,5,15],[7,0,7,9],[7,10,7,12]]}
["Ongoing Progress Update and Disbursement Request "]
[]
["Section 2: Financial Information"]
[]
[]
["D. Principal Recipient Reconciliation of funds provided to Sub-Recipients for the Current Implementation Period"]
[]
["Principal Recipient",null,null,null,null,null,null,null,null,null,"For Local Fund Agent Use Only ",null,null,"For the Global Fund Use Only"]
["(1) \nSub-Recipient Name","(2) \n Cumulative Sub-Recipient expenses for prior periods at Principal Recipient level","(3) \nSub-Recipient Open Advances at Principal Recipient Level","(4) \nDisbursements made by Principal Recipient during the Reporting Period","(5) \nOther Income* during the Reporting Period ","(6) \nExpenditure validated by Principal Recipient during the Reporting Period","(7) \nSub-Recipient Closing Balance at Principal Recipient Level","(8) \nActual Sub-Recipient Cash Balance (if applicable)"," (9)\nVariances on Sub-Recipient Balances","Comments","LFA Adjustments","As verified by LFA","Comments","Country Team Adjustments (incl. External Audit adjustments)","The Global Fund Validated Figures","Comments"]
["TB Centre",0,0,0,0,0,{"$f":"+C10+D10+E10-F10","v":0},{"$f":"50000/2.5964","v":19257.433369280541},{"$f":"+H10-G10","v":19257.433369280541},"Advance Payment",null,{"$f":"H10+K10","v":19257.433369280541},null,null,{"$f":"L10+N10","v":19257.433369280541}]
[null,0,0,0,0,0,{"$f":"+C11+D11+E11-F11","v":0},0,0,null,null,{"$f":"H11+K11","v":0},null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,{"$f":"+H24-G24","v":0},null,null,{"$f":"H24+K24","v":0},null,null,{"$f":"L24+N24","v":0}]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,{"$f":"+C31+D31+E31-F31","v":0},0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,{"$f":"+H44-G44","v":0},null,null,{"$f":"H44+K44","v":0},null,null,{"$f":"L44+N44","v":0}]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,{"$f":"+H57-G57","v":0},null,null,{"$f":"H57+K57","v":0},null,null,{"$f":"L57+N57","v":0}]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
[null,0,0,0,0,0,0,0,0,null,null,0,null,null,0]
["Total for the Reporting Period",{"$f":"SUM(B10:B59)","v":0},0,0,0,0,0,19257.433369280541,19257.433369280541,null,null,19257.433369280541,null,null,19257.433369280541]
[]
["* Includes interest income, income generating activites etc."]

{"sheet":"Budget Variance_2E","index":13,"n_rows":30,"n_cols":14,"rows_kept":30,"cut":false,"hidden":false,"merged":[[23,1,23,2],[22,1,22,2],[26,1,26,2],[27,1,27,2],[29,1,29,2],[28,1,28,2],[24,1,24,2],[6,1,6,2],[7,1,7,2],[6,7,6,8],[7,7,7,8],[1,0,1,13],[3,0,3,13],[8,1,8,2],[21,1,21,2],[9,1,9,2],[13,1,13,2],[14,1,14,2],[11,1,11,2],[18,0,18,11],[12,1,12,2],[26,7,26,8],[28,7,28,8],[29,7,29,8],[5,3,5,13],[20,3,20,13],[14,7,14,8],[21,7,21,8],[22,7,22,8],[23,7,23,8],[24,7,24,8],[8,7,8,8],[9,7,9,8],[11,7,11,8],[12,7,12,8],[13,7,13,8]]}
["Ongoing Progress Update and Disbursement Request"]
["Section 2: Financial Information"]
[]
["E. Total Principal Recipient Budget Variance and Funding Absorption Analysis"]
[]
[null,null,null,"Principal Recipient"]
[null,null,null,"Budget for Reporting Period","Actual Grant Cash Out-Flow - Cash Basis for Reporting Period","Budget Vs Actual Variances","Absorption Capacity","Reasons for Variance",null,"Cumulative Budget through period of Progress Update","Cumulative Actual Grant Cash-Outflow - Cash Basis through period of Progress Update","Cumulative Budget Vs Actuals Variances","Absorption Capacity","Reasons for Variance"]
[null,"1. Total Principal Recipient cash outflow vs. budget",null,{"$f":"SUM(D9:D10)","v":2324385.0368528347},{"$f":"SUM(E9:E10)","v":2781193.6638408033},{"$f":"IF(D8=\"\",IF(E8=\"\",\"\",D8-E8),D8-E8)","v":-456808.62698796857},{"$f":"E8/D8","v":1.1965288107371734},null,null,{"$f":"SUM(J9:J10)","v":11182991.918927178},{"$f":"SUM(K9:K10)","v":7525670.2487379592},{"$f":"IF(J8=\"\",IF(K8=\"\",\"\",J8-K8),J8-K8)","v":3657321.6701892186},{"$f":"K8/J8","v":0.67295678144958559}]
[null,"    1a. Principal Recipient's total expenditures (including any direct-disbursements to third-parties)",null,2101107.5592226866,{"$f":"'PR Cash Reconciliation_2A,B,C'!D18+'PR Cash Reconciliation_2A,B,C'!D19+'PR Cash Reconciliation_2A,B,C'!D21","v":2448490.0245514293},{"$f":"IF(D9=\"\",IF(E9=\"\",0,D9-E9),D9-E9)","v":-347382.46532874275},{"$f":"E9/D9","v":1.1653330234351535},"The net variance of EUR (-347,382) is derived from the following components:\nPositive Variance EUR 622,424 includes: \nEUR 1,171 - Actual unit price of fuel turned to be less than projected/budgeted. From the programmatic point of view, activities were performed as planned, though required quantity of fuel was less, despite the 6 months no cost extension period.\nEUR 533,221- Saving in procurement of SLD include: recalculation of needs; tendency of decreasing the prevalence of TB; BDQ Donation program provided the medicine free-of-charge; General tendency of decreasing cost of TB medicines through GDF; The saving was reallocated partly for no-cost extension and partly for different new activities initiated by PR in agreement with TGF.\nEUR 42,779 – Actual PSM costs related to SLD and procurement of GeneXperts was less than budgeted.\nEUR 45,252- Actual cost for Cash Incentives (Sensitive & MDR) was less than budgeted due to actual number of patients (slightly less than projected). Most importantly, budget was made assuming max (100%) compliance to treatment. Reimbursed period covers December 2015- November 2016. The savings were reduced due to no cost extension period.\nNegative Variance EUR 969,806 includes: \nEUR 459,253 – overspending in HPHE resulted due to the 6 months extension period PR procured additional lab supplies to cover TB centre needs and launched new activities in agreement with TGF. \nEUR 4,668 – Procurement of printing of statistical forms for TB Centre (reallocation request approved on 06/02/2015) \nEUR 6,106- HR costs for cash incentive administration was higher than budgeted due to 6 months no-cost extension.\nEUR 9,585 – Actual cost for GLC mission was greater than budgeted due to FX rate change.\nEUR 131,395 – Construction of prefabricated TB DOT center was not budgeted under IE and funds were reallocated from savings, in addition procurement of mobile phones for VOT.\nEUR 358,799 - Project management actual costs were higher than budgeted due to the following reasons: 6 months no cost extension, HR costs for HIV grant compensated under TB grant (1Q2Q2016); new activities implemented in agreement to TGF such as: transition plan (reallocation request approved on 09/02/16), attending ECHO training and Estonia Study tour (reallocation request approved on 23/08/16 and 02/03/2016) ; projects on country-wide advocacy, communication and social mobilization campaign using Georgian Orthodox Church and project aiming increasing the TB awareness in educational institutions (schools and universities) and seminars for media. (Reallocation request approved on 28/02/2016).\nCommitments to be reimbursed during the 6 months close-out period from the savings under TB SSF grant are following- Total EUR 635,296  includes:\nEUR 2,297– SRs fuel costs for December, payment transferred to January 2017.\nEUR 17,364 – Committed payment for Cash Incentives (Sensitive & MDR) for December 2016; \nEUR 88,148 – Commitments for:  PR fuel cost for December 2016, payable in January 2017;  cost for Transitions plan  payable in January 2017; Payments transferred  to the year 2017  for  ERP system development and procurement of infrastructure equipment, to accommodate ERP system development; \nEUR 698 – remaining Payment for the quality control of pharmaceuticals.\nEUR 106,307 – Commitment for the construction works of prefabricated  TB DOT Centre.\nEUR 15,028 – Contract signed for MGIT Test Systems upon request of TB Centre.\nEUR 405,455 – Commitment to the TB NFM Grant in the amount of USD 428,004  \n",null,{"$f":"(D9)+8042499.32321101","v":10143606.882433696},{"$f":"'PR Cash Reconciliation_2A,B,C'!D18+'PR Cash Reconciliation_2A,B,C'!D19+'PR Cash Reconciliation_2A,B,C'!D21+'PR Cash Reconciliation_2A,B,C'!C18+'PR Cash Reconciliation_2A,B,C'!C19+'PR Cash Reconciliation_2A,B,C'!C21","v":6616291.8821536331},{"$f":"IF(J9=\"\",IF(K9=\"\",0,J9-K9),J9-K9)","v":3527315.0002800627},{"$f":"K9/J9","v":0.65226225334219823},"The net variance of EUR 3,527,315 is derived from the following components:\nSavings – Total EUR 3,891,627 includes:  \nEUR 56,090 - Actual unit price of fuel turned to be less than projected/budgeted. From the programmatic point of view, activities were performed as planned, though required quantity of fuel was less; Fuel cost budgeted under line 4.7 (b) was cancelled due to the following factor: the adherence data is collected and monitored on a regular basis by regional coordinators with further submission to the TB Centre. Activity related to the on site monitoring of the cash incentive scheme was abolished, considering that it is being performed under the current set-up of the scheme. \nEUR 122,297 - Procurement of lab supplies and respirators (HPHE) caused saving, due to the following factors: 1. Local procurement with competitive bidding with preceding market assessment derived significantly cheaper unit costs compared to the budgeted amounts; 2. Available stock; 3. Re-calculation of average consumption rates; Resulted Savings were reduced by new activities implemented by PR in agreement with TGF and 6 months no cost extension.\nEUR 766,568- Actual cost of Cash incentives  (Sensitive & MDR) covered period June 2014 – November 2016 and was less than budgeted. The following are the reasons for saving:\nSensitive - budgeted amount was calculated for 1 year period covering 70% of all sensitive patients with 100% adherence (both installments). Actually patients enrolled in January - May, 2014 did not fit for being beneficiary of the scheme as approved scheme was enrolling patients starting June 1. \nMDR - budgeted amount was calculated for the entire treatment course (15 months) covering 75% of MDR patients from the 2012, 2013, 2014 cohorts, with100% adherence (all weeks on outpatient treatment).  Actually, 5 months were covered, payments started in August, there was no 100% compliance in many cases and number of patients was less than projected/budgeted. \nEUR 2,632,371– Net saving mainly derived from procurement of SLD, that include several reasons: recalculation of needs; tendency of decreasing prevalence of TB; BDQ Donation program provided the medicine free-of-charge; General tendency of decreasing cost of TB medicines through GDF; The latter saving was used to cover  new activities implemented by PR in agreement with TGF,  6 months no cost extension and commitment to TB NFM grant in the amount of USD 428,004. Also procurement of Side effect drugs resulted in savings due to lower unit cost and by State budget financing. \nEUR 268,492 - Actual PSM costs related to SLD and procurement of Genxperts was less than budgeted.\nEUR 45,809 – Saving in Project Management costs such as Audit cost, Fuel, supervisions occured less than budgeted, FX rate Change had also effect. \nOverspending – Total EUR 364,312 includes:  \nEUR 3,517 – Procurement of printing of statistical forms for TB Centre (reallocation request approved on 06/02/2015) ;\nEUR 131,109 – Construction of prefabricated TB DOT center was not budgeted under IE and funds were reallocated from savings, in addition procurement of mobile phones for VOT.\nEUR 17,708 – Actual cost for GLC mission was greater than budgeted due to FX rate change.\nEUR 1,830- HR costs for cash incentive administration was higher than budgeted due to 6 months no-cost extension.\nEUR 210,148 - Project management actual costs were higher than budgeted due to the following reasons: 6 months no cost extension, HR costs for HIV grant compensated under TB grant (1Q2Q2016); new activities implemented in agreement to TGF such as: transition plan (reallocation request approved on 09/02/16), attending ECHO training and Estonia Study tour (reallocation request approved on 23/08/16 and 02/03/2016) ; projects on country-wide advocacy, communication and social mobilization campaign using Georgian Orthodox Church and project aiming increasing the TB awareness in educational institutions (schools and universities) and seminars for media. (Reallocation request approved on 28/02/2016).\nCommitments to be reimbursed during the 6 months close-out period from the savings under TB SSF grant are following- Total EUR 635,296  includes:\nEUR 2,297– SRs fuel costs for December, payment transferred to January 2017.\nEUR 17,364 – Committed payment for Cash Incentives (Sensitive & MDR) for December 2016; \nEUR 88,148 – Commitments for:  PR fuel cost for December 2016, payable in January 2017;  cost for Transitions plan  payable in January 2017; Payments transferred  to the year 2017  for  ERP system development and procurement of infrastructure equipment, to accommodate ERP system development; \nEUR 698 – remaining Payment for the quality control of pharmaceuticals.\nEUR 106,307 – Commitment for the construction works of prefabricated  TB DOT Centre.\nEUR 15,028 – Contract signed for MGIT Test Systems upon request of TB Centre.\nEUR 405,455 – Commitment to the TB NFM Grant in the amount of USD 428,004  \n"]
[null,"    1b. Disbursements to sub-recipients",null,223277.47763014823,{"$f":"'PR Cash Reconciliation_2A,B,C'!D20","v":332703.63928937382},{"$f":"IF(D10=\"\",IF(E10=\"\",0,D10-E10),D10-E10)","v":-109426.16165922559},1.4900904597304991,"The reporting period relates to the activities performed by the TB center for January 2016 - December 2016, but according to the contract, SR received reimbursement for December 2015 -November 2016 services (EUR 313,447 ) and advance payment (EUR 19,257). The latter was deducted from the payment made by PR in January 2017 to cover services performed in December 2016.\nDue to 6 months no cost-extension period actual expenses were higher than budgeted resulting in Net Variance of (-109,426 EUR). \nCommitments EUR 30,046- December service cost, out of which EUR 19,257 advance payment was deducted and reimbursed in January 2017.\n",null,{"$f":"(D10)+816107.558863334","v":1039385.0364934823},{"$f":"'PR Cash Reconciliation_2A,B,C'!D20+'PR Cash Reconciliation_2A,B,C'!C20","v":909378.36658432567},{"$f":"IF(J10=\"\",IF(K10=\"\",0,J10-K10),J10-K10)","v":130006.66990915663},0.87491962521631716,"The Budget relates to the activities performed by the TB Center in April 2014-December 2016.  During the cumulative period SR received payment for April 2014-Novemebr 2016 services in the amount of EUR 890,121 and advance payment with remaining balance of EUR 19,257, The latter was deducted from the payment made by PR in January 2017 to cover services performed in December 2016.  SR performed all budgeted programatic activities and faced Savings. The Major part of savings was absorbed by 6 months no cost extension. \nThe Positive variance in the amount of EUR 130,007 related to TB Center performance includes: \nSaving EUR 106,851 - mainly unspent vehicle maintenance costs; less transportation incentives for patients; TA and ME costs were less than budgeted.\nCommitments EUR 30,046- December service cost, out of which EUR 19,257 advance payment was deducted and reimbursed in January 2017.\nNegative Variance EUR 6, 891 – Due to 6 months no cost-extension period actual expenses for HR and trainings were higher than budgeted.\n"]
[]
[null,"Procurement data for analytical purposes",null,"Budget for Reporting Period","Actual Grant Cash Out-Flow - Cash Basis for Reporting Period","Budget Vs Actual Variances","Absorption Capacity","Reasons for Variance",null,"Cumulative Budget through period of Progress Update","Cumulative Actual Grant Cash-Outflow - Cash Basis through period of Progress Update","Cumulative Budget Vs Actuals Variances","Absorption Capacity","Reasons for Variance"]
[null,"2. Total pharmaceutical & non-pharmaceutical incl. equipment expenditures vs.    budget",null,{"$f":"D14+D15","v":1598519.246008493},{"$f":"E14+E15","v":1524550.3451470421},{"$f":"IF(D13=\"\",IF(E13=\"\",\"\",D13-E13),D13-E13)","v":73968.900861450937},{"$f":"E13/D13","v":0.95372661227185629},null,null,{"$f":"J14+J15","v":7336969.8629017221},{"$f":"K14+K15","v":4582301.7097126599},{"$f":"IF(J13=\"\",IF(K13=\"\",\"\",J13-K13),J13-K13)","v":2754668.1531890621},{"$f":"K13/J13","v":0.62454961589557223}]
[null,"    2a.  Health Products- Pharmaceutical Products",null,1151470.3529311728,618248.93913535285,{"$f":"IF(D14=\"\",IF(E14=\"\",0,D14-E14),D14-E14)","v":533221.41379581997},{"$f":"E14/D14","v":0.53692128291583341},"The budget relates to pharmaceuticals procured locally as well as through the GDF.\nThe Positive variance EUR 533,221 is due to the following savings: \nEUR 509,594 - Saving in procurement of SLD include: recalculation of needs; tendency of decreasing prevalence of TB; BDQ Donation program provided the medicine free-of-charge; General tendency of decreasing cost of TB medicines through GDF; Commitment to NFM Grant in the amount of USD 428,004 will be financed from the saving. \nEUR 2,988 –The activity was canceled. Procurement (water for injectibles) was carried out by TB Centre.\nEUR 20,640 – Procurement of side effects drugs cancelled, as the activity was budgeted under  the state budget.\n",null,{"$f":"(D14)+4358024.97025976","v":5509495.3231909322},{"$f":"(E14)+2258875.44339463","v":2877124.3825299833},{"$f":"IF(J14=\"\",IF(K14=\"\",0,J14-K14),J14-K14)","v":2632370.9406609489},{"$f":"K14/J14","v":0.52221196566215444},"The budget relates to pharmaceuticals procured locally as well as through the GDF.\nThe Net positive variance EUR 2,632,371 is due to several reasons:\nEUR 2,548,769– Net saving in procurement of SLD include several reasons: recalculation of needs; tendency of decreasing prevalence of TB; BDQ Donation program provided the medicine free-of-charge; General tendency of decreasing cost of TB medicines through GDF; The total saving was used for the following activities in agreement with TGF: approved reallocation requests related to new projects such as VOT and procurement of mobile  ambulatories; construction of prefabricated TB DoT Centre, procurement of lab equipment for TB center and etc. Commitment to NFM Grant in the amount of USD 428,004 will also be financed from the saving. \nEUR 1,069 – Line 3.10 was cancelled (ref. PR letter to GF19/11/2014) as the pharmaceutical was included in the GDF Order (Act. 3.1.a)\nEUR 5,984 –The activity was canceled. Procurement (water for injectibles) was carried out by TB Centre.\nEUR 76,548 – Cost of Procurement side effects drugs was less than budgeted due to the decreasing number of patients and low prices derived through the local procurement (tender). In addition Procurement of side effects drugs in the year 2016 was cancelled, as the activity was included in the state budget.\n"]
[null,"    2b.  Health Products - Non-Pharmaceuticals & Equipment",null,447048.89307732024,906301.40601168922,{"$f":"IF(D15=\"\",IF(E15=\"\",0,D15-E15),D15-E15)","v":-459252.51293436898},2.0272981771032774,"The budget relates to internationally and locally procured lab supplies, consumables and equipment. Reasons for negative variance in the amount of EUR 459,253 are following: \nDue to the 6 months extension period PR procured additional lab supplies to cover TB centre needs,; Procurement of 19 GeneXpert machines and cartridges to meet the need for 2016-2017 years which was originally planned in the NFM but due to the change of the NFM launch date was moved within the extension period; in addition procurement of Laboratory equipment for TB center in agreement with TGF (reallocation request approved on 06/11/2015); Procurement of cold boxes and audiometers (reallocation request approved on 01/12/2015); Procurement of mobile ambulatories (reallocation request approved on 01/12/2015)\nCommitment EUR 15,028 – MGIT test procurement (signed contract) to be paid in the year 2017.\n",null,{"$f":"(D15)+1380425.64663347","v":1827474.5397107902},{"$f":"(E15)+798875.921170987","v":1705177.3271826762},{"$f":"IF(J15=\"\",IF(K15=\"\",0,J15-K15),J15-K15)","v":122297.21252811397},0.93307856833536607,"The budget relates to internationally and locally procured lab supplies, consumables and equipment. Reasons for Net positive variance ( EUR 122,297) are following: \nThe main Driver of savings from procurement of lab supplies and respirators are derived from 1. Local procurement with competitive bidding with preceding market assessment derived significantly cheaper unit costs compared to the budgeted amounts; 2. Available stocks; 3. Re-calculation of average consumption rates;\nDespite the above The total savings were reduced by the new activities budgeted under TB grant and 6 months no cost extension during the year 2016: PR procured additional lab supplies to cover TB centre needs for extension period; Procurement of 19 GeneXpert machines and cartridges to meet the need for 2016-2017 years which was originally planned in the NFM but due to the change of the NFM launch date was moved within the extension period; in addition procurement of Laboratory equipment for TB center in agreement with TGF (reallocation request approved on 06/11/2015); Procurement of cold boxes and audiometers (reallocation request approved on 01/12/2015); Procurement of mobile ambulatories (reallocation request approved on 01/12/2015).\nCommitment EUR 15,028 – MGIT test procurement (signed contract) to be paid in the year 2017.\n"]
[]
[]
["For LFA Use Only"]
["E. Total Principal Recipient Budget Variance and Absorption Analysis"]
[]
[null,null,null,"Local Fund Agent (LFA)"]
[null,null,null,"Budget for Reporting Period","Actual Grant Expenditure - Cash Basis for Reporting Period","Budget Vs Actual Variances","Absorption Capacity","LFA comments on thePrincipal Recipient's explanation of variances ",null,"Cumulative Budget through period of Progress Update","Cumulative Actual Grant Expenditure - Cash Basis through period of Progress Update","Cumulative Budget Vs Actuals Variances","Absorption Capacity","LFA comments on the Principal Recipient's explanation of variances "]
[null,"1. Total Principal Recipient cash outflow vs. budget",null,{"$f":"SUM(D24:D25)","v":0},{"$f":"SUM(E24:E25)","v":2781193.6638408033},{"$f":"IF(D23=\"\",IF(E23=\"\",\"\",D23-E23),D23-E23)","v":-2781193.6638408033},{"$f":"E23/D23","v":{"$error":"#DIV/0!"}},null,null,{"$f":"SUM(J24:J25)","v":0},2781193.6638408033,{"$f":"IF(J23=\"\",IF(K23=\"\",\"\",J23-K23),J23-K23)","v":-2781193.6638408033},{"$f":"K23/J23","v":{"$error":"#DIV/0!"}}]
[null,"    1a. Principal Recipient's total expenditures (including any direct-disbursements to third-parties)",null,0,{"$f":"'PR Cash Reconciliation_2A,B,C'!H18+'PR Cash Reconciliation_2A,B,C'!H19+'PR Cash Reconciliation_2A,B,C'!H21","v":2448490.0245514293},{"$f":"IF(D24=\"\",IF(E24=\"\",0,D24-E24),D24-E24)","v":-2448490.0245514293},{"$error":"#DIV/0!"},null,null,0,{"$f":"'PR Cash Reconciliation_2A,B,C'!F18+'PR Cash Reconciliation_2A,B,C'!F19+'PR Cash Reconciliation_2A,B,C'!F21+E24","v":2448490.0245514293},{"$f":"IF(J24=\"\",IF(K24=\"\",0,J24-K24),J24-K24)","v":-2448490.0245514293},{"$f":"K24/J24","v":{"$error":"#DIV/0!"}}]
[null,"    1b. Disbursements to sub-recipients",null,0,{"$f":"'PR Cash Reconciliation_2A,B,C'!H20","v":332703.63928937382},{"$f":"IF(D25=\"\",IF(E25=\"\",0,D25-E25),D25-E25)","v":-332703.63928937382},{"$error":"#DIV/0!"},null,null,0,{"$f":"'PR Cash Reconciliation_2A,B,C'!F20+E25","v":332703.63928937382},{"$f":"IF(J25=\"\",IF(K25=\"\",0,J25-K25),J25-K25)","v":-332703.63928937382},{"$error":"#DIV/0!"}]
[]
[null,"Procurement data for analytical purposes",null,"Budget for Reporting Period","Actual Grant Expenditure - Cash Basis for Reporting Period","Budget Vs Actual Variances","Absorption Capacity","LFA comments on the Principal Recipient's explanation of variances ",null,"Cumulative Budget through period of Progress Update","Cumulative Actual Grant Expenditure - Cash Basis through period of Progress Update","Cumulative Budget Vs Actuals Variances","Absorption Capacity","LFA comments on the Principal Recipient's explanation of variances "]
[null,"2. Total pharmaceutical & non-pharmaceutical incl. equipment expenditures vs. budget",null,{"$f":"D29+D30","v":0},{"$f":"E29+E30","v":0},{"$f":"IF(D28=\"\",IF(E28=\"\",\"\",D28-E28),D28-E28)","v":0},{"$f":"E28/D28","v":{"$error":"#DIV/0!"}},null,null,{"$f":"J29+J30","v":0},{"$f":"K29+K30","v":0},{"$f":"IF(J28=\"\",IF(K28=\"\",\"\",J28-K28),J28-K28)","v":0},{"$f":"K28/J28","v":{"$error":"#DIV/0!"}}]
[null,"    2a.  Health Products- Pharmaceutical Products",null,0,0,{"$f":"IF(D29=\"\",IF(E29=\"\",0,D29-E29),D29-E29)","v":0},{"$error":"#DIV/0!"},null,null,0,0,{"$f":"IF(J29=\"\",IF(K29=\"\",0,J29-K29),J29-K29)","v":0},{"$f":"K29/J29","v":{"$error":"#DIV/0!"}}]
[null,"    2b.  Health Products - Non-Pharmaceuticals & Equipment",null,0,0,{"$f":"IF(D30=\"\",IF(E30=\"\",0,D30-E30),D30-E30)","v":0},{"$error":"#DIV/0!"},null,null,0,0,{"$f":"IF(J30=\"\",IF(K30=\"\",0,J30-K30),J30-K30)","v":0},{"$error":"#DIV/0!"}]

{"sheet":"Procurement_3","index":14,"n_rows":55,"n_cols":23,"rows_kept":55,"cut":false,"hidden":false,"merged":[[54,12,54,22],[55,12,55,22],[48,12,48,13],[48,16,48,22],[49,12,49,13],[50,12,50,13],[51,12,51,13],[51,16,51,22],[49,16,49,22],[50,16,50,22],[45,12,45,13],[45,16,45,22],[46,12,46,13],[46,16,46,22],[47,12,47,13],[47,16,47,22],[42,12,42,22],[43,12,43,13],[43,16,43,22],[44,12,44,13],[44,16,44,22],[37,12,37,13],[37,17,37,18],[39,12,39,13],[39,17,39,18],[40,12,40,13],[40,17,40,18],[38,12,38,13],[38,17,38,18],[34,12,34,13],[34,17,34,18],[35,12,35,13],[35,17,35,18],[36,12,36,13],[36,17,36,18],[30,12,30,22],[31,12,31,13],[32,12,32,13],[32,17,32,18],[33,12,33,13],[33,17,33,18],[17,12,17,22],[18,12,18,22],[23,12,23,22],[26,16,26,22],[27,16,27,22],[27,12,27,13],[15,12,15,13],[15,16,15,22],[16,12,16,13],[16,16,16,17],[14,16,14,22],[12,12,12,13],[12,16,12,22],[13,12,13,13],[13,16,13,22],[14,12,14,13],[9,12,9,13],[9,16,9,22],[10,12,10,13],[10,16,10,22],[11,12,11,13],[11,16,11,22],[7,12,7,13],[7,16,7,22],[4,12,4,16],[8,12,8,13],[8,16,8,22],[0,12,0,22],[1,12,1,21],[3,18,3,22],[4,18,4,22],[6,12,6,22]]}
[null,null,null,null,null,null,null,null,null,null,null,null,"Ongoing Progress Review and Disbursement Request"]
[null,null,null,null,null,null,null,null,null,null,null,null,"Section 3A:  PR - Procurement and Supply Management"]
[]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"Comments"]
[null,null,null,null,null,null,null,null,null,null,null,null,"1.  Have you updated the Price Quality Reporting (PQR) with the required information on the pharmaceuticals and health products received during the period covered by this PU/DR’ (if applicable)?  If health products procurement information has not been entered into the PQR, please explain why.\n\n!  For further guidance on PQR data entry, please refer to the guidelines.",null,null,null,null,"Select","All the info on applicable health products procurement within this reporting period was entered into the  PQR system.  \nFollowing items were processed and submitted accordingly:                   \n1. Second line anti -TB drugs procured through GDF/IDA.\na. PO#GF-T/SSP/G-56;inv GEO/DP/14/4376-GS14441:                                                   \n1. Bedaquiline-100 mg 188  tabs 34 packs                                                                         \n2. Moxifloxacin 400 mg tabs 332 packs, \n3. Clofazimine 100mg-94 packs,  \n4. Cycloserine 250mg Caps ,4972 packs; \n5. Linezolide 600mg tab ,1900 packs,\n6. Capreomycin 1g powder for inj -30964 packs ;\n7. Imipenem+Cilastatin inj. 1g (500mg+500mg) powder for inj-  16598 packs   \n\nb. PO GF-T/SSP/G-235 /2; GEO/DP/15/5350-15000931 SO:\n1. Kanamycin 1g/4 ml inj 10 amps- 480 packs   \n2. Amoxicillin+Clavulanate - FDC 500mg/125mg tab- 205 packs \n3. TB testing consumables/test kits: PO#GF- T/ET/G-299 \na) BACTEC MGIT 960 Supplement Kit 100s [245124] – 36 packs\nb) BD Biosciences TB testing consumables/test kits BACTEC MGIT 960 SIRE Kit 40s [245123] -25 packs\nc) BD Biosciences TB testing consumables/test kits BBL MGIT 7 ml Tube (100 tests) [245122] -60 packs\n3.     TB testing consumables/test: PO #GF-T/ET/G-334                                                                      \n  SD BIOLINE TB Ag MPT64 Rapid [08FK50]    25 tests, 197 packs \n4.   TB molecular diagnostics:\na. PO# GF –H/ET/G-366:\n1. Geno Lyse V1  [51610],96 tests 10 packs; Hain Lifescience GmbH  \n2. GenoType MTBDRsl  Version 2.0 [ 31796A] 96 tests- 10 packs. Hain Lifescience GmbH  \nb.  PO # GF-T/ET/G-262: GenoType MTBDRs 12s ,96 s[ 317,31796]  96 tests , 10 packs. Hain Lifescience GmbH  \n5. HIV RDT and EIA/test kits – PO# GF-H-T/ET/G-282: Advanced Quality HIV rapid Test [ITP02121-TC40]  InTec  Products Inc. (Xiamen, PR China) , -2010 tests. \n6. TB testing consumables/test kits- – PO# GF-H-T/ET/G-299:\n1. BACTEC MGIT 960 Supplement Kit 100s [245124] \n2. BD Biosciences TB testing consumables/test kits BACTEC MGIT 960 SIRE Kit 40s [245123] \n3. BD Biosciences TB testing consumables/test kits BBL MGIT 7 ml Tube (100 tests) [245122] \n"]
[]
[null,null,null,null,null,null,null,null,null,null,null,null," 2. Based on the most up-to-date stock situation, are there any risks of stock-outs or expiries for the key pharmaceuticals & health products, listed below, at the central level in the next period of implementation?  If yes, please comment."]
[null,null,null,null,null,null,null,null,null,null,null,null,"Key Pharmaceuticals & Health Products",null,"Risk of Stock-Out","Risk of Expiry","Comment (if yes, please provide information on the specific items that are at risk of stock-out or expiry and the mitigation measures in place or to be implemented)"]
[null,null,null,null,null,null,null,null,null,null,null,null,"1. Anti-malaria medicines",null,"Select","Select"]
[null,null,null,null,null,null,null,null,null,null,null,null,"2. Bed nets",null,"Select","Select"]
[null,null,null,null,null,null,null,null,null,null,null,null,"3. In-Vitro Diagnostic Products",null,"Select","Select"]
[null,null,null,null,null,null,null,null,null,null,null,null,"4. Condoms",null,"Select","Select"]
[null,null,null,null,null,null,null,null,null,null,null,null,"5. Anti-retrovirals",null,"Select","Select"]
[null,null,null,null,null,null,null,null,null,null,null,null,"6. Anti-TB medicines",null,"No","Yes","About 47,000 sachets of PAS is expected to expire in coming 12 months. The issue was anticipated and communicated to GDF and the GF"]
[null,null,null,null,null,null,null,null,null,null,null,null,"7. Lab supplies (e.g. CD4, Viral Load, Cartridges…)",null,"Select","Select"]
[null,null,null,null,null,null,null,null,null,null,null,null,"8. Other (Please specify in the \"Comment\" column)",null,"Select","Select"]
[]
[null,null,null,null,null,null,null,null,null,null,null,null,"3.  Comment on additional issues related to the procurement and supply management of pharmaceuticals and health products."]
[null,null,null,null,null,null,null,null,null,null,null,null,"\"Global Test\" was  contracted for quality check of  5  Anti - TB drugs using the competitive selection (e-tender). Sampling was made in Tbilisi , Batumi  and Zugdidi TB facilities. \nFollowing products were tested:                                          \n1. Capreomycin for Injection . Powder, 1g , Vianex S.A. Greece \n2. PAS , 5.52 g -Olainfarm, Latvia \n3. Levofloxacin tabs, 250 mg -  Micro Labs Limited,  India\n4. Pyrazinamide tabs, 400 mg, 24x28   ”Macleods Pharmaceuticals Ltd” India  \n5. Rifampicin 150mg/ Isoniazid 75 mg/ Pirazinamid 400 mg/ Ethambutol Hidrochlorid 275 mg, 24/28 –Lupin Ltd ,India\nNo batches with out-of -specification results observed.\nPeriod of reporting: 1 November 2015 - 1 January 2017         "]
[]
[null,null,null,null,null,null,null,null,null,null,null,null,"For LFA Use Only"]
[]
[]
[null,null,null,null,null,null,null,null,null,null,null,null,"Section 3B: LFA-Verified Procurement and Supply Management Information"]
[]
[]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,"PR's response","LFA's response","LFA Comments/Analysis "]
[null,null,null,null,null,null,null,null,null,null,null,null,"1a.  Has the PR updated the Price Quality Reporting (PQR) with the required information on the pharmaceuticals and health products received during the period covered by this PU/DR’ (if applicable)?  (If health products procurement information has not been entered into the PQR, please explain why in comments box)    ",null,{"$f":"R5","v":"Select"},"Select"]
[]
[null,null,null,null,null,null,null,null,null,null,null,null,"1b.  Value of Pharmaceuticals and Health Products in the PQR "]
[null,null,null,null,null,null,null,null,null,null,null,null,"(!) This table is included in the PU/DR form with the aim to improve completeness of information in the PQR system and not for comparing PQR amounts vis-à-vis expenditure per se. NB: PQR and expenditure amounts on health products may not be equal due to a timelag between payments and delivery of pharmaceuticals/health products.\n(!)  For further guidance on PQR data entry, please refer to the guidelines."]
[null,null,null,null,null,null,null,null,null,null,null,null,"Reporting Currency"]
[null,null,null,null,null,null,null,null,null,null,null,null,"PQR Product Categories",null,"Value of  products received during reporting period","Value of products entered by the PR and verified as correct by the LFA in the PQR during reporting period","Variance","Reason for Variance",null,"Cumulative value of  products received since the start of the grant","Cumulative value of products verified as correct by the LFA in the PQR since the start of the grant","Variance","Reason for Variance"]
[null,null,null,null,null,null,null,null,null,null,null,null,"1. Anti-malaria medicines",null,null,null,{"$f":"IF(O34=\"\",IF(P34=\"\",\"\",O34-P34),O34-P34)","v":""},null,null,null,null,{"$f":"IF(T34=\"\",IF(U34=\"\",\"\",T34-U34),T34-U34)","v":""}]
[null,null,null,null,null,null,null,null,null,null,null,null,"2. Bed nets",null,null,null,"",null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,"3. In-Vitro Diagnostic Products",null,null,null,"",null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,"4. Condoms",null,null,null,"",null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,"5. Anti-retrovirals",null,null,null,"",null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,"6. Anti-TB medicines"]
[null,null,null,null,null,null,null,null,null,null,null,null,"7. Indoor Residual Spraying (IRS)",null,null,null,"",null,null,null,null,""]
[null,null,null,null,null,null,null,null,null,null,null,null,"Total",null,{"$f":"SUM(O34:O40)","v":0},{"$f":"SUM(P34:P40)","v":0},{"$f":"SUM(Q34:Q40)","v":0},null,null,{"$f":"SUM(T34:T40)","v":0},{"$f":"SUM(U34:U40)","v":0},{"$f":"SUM(V34:V40)","v":0}]
[]
[null,null,null,null,null,null,null,null,null,null,null,null," 2. Based on best information available to the LFA, are there any risks of drug stock-out or expiries at the central level in the next period of implementation?  (If yes, please explain in comments box)\n! This section should be completed by the LFA based on best information on stock at the central level available to the LFA and should not require dedicated visits for on-site checks of stocks."]
[null,null,null,null,null,null,null,null,null,null,null,null,"Key Pharmaceuticals & Health Products",null,"Risk of Stock-Out","Risk of Expiry","Comment (if yes, please provide information on the specific items that are at risk of stock-out or expiry and the mitigation measures in place or to be implemented)"]
[null,null,null,null,null,null,null,null,null,null,null,null,"1. Anti-malaria medicines",null,"Select","Select"]
[null,null,null,null,null,null,null,null,null,null,null,null,"2. Bed nets",null,"Select","Select"]
[null,null,null,null,null,null,null,null,null,null,null,null,"3. In-Vitro Diagnostic Products",null,"Select","Select"]
[null,null,null,null,null,null,null,null,null,null,null,null,"4. Condoms",null,"Select","Select"]
[null,null,null,null,null,null,null,null,null,null,null,null,"5. Anti-retrovirals",null,"Select","Select"]
[null,null,null,null,null,null,null,null,null,null,null,null,"6. Anti-TB medicines",null,"Select","Select"]
[null,null,null,null,null,null,null,null,null,null,null,null,"7. Lab supplies (e.g. CD4, Viral Load, Cartridges…)",null,"Select","Select"]
[null,null,null,null,null,null,null,null,null,null,null,null,"8. Other (Please specify in the \"Comment\" column)",null,"Select","Select"]
[]
[]
[null,null,null,null,null,null,null,null,null,null,null,null,"3. LFA analysis of issues related to the procurement and supply management of pharmaceuticals and health products"]

{"sheet":"Grant Management_4","index":15,"n_rows":98,"n_cols":29,"rows_kept":98,"cut":false,"hidden":false,"merged":[[97,15,97,18],[60,24,60,32],[61,24,61,32],[62,24,62,32],[63,24,63,32],[64,24,64,32],[65,24,65,32],[82,24,82,32],[95,24,95,27],[82,14,82,22],[84,14,84,22],[85,14,85,22],[86,14,86,22],[87,14,87,22],[88,14,88,22],[96,15,96,18],[94,13,94,22],[95,13,95,14],[97,13,97,14],[63,14,63,22],[64,14,64,22],[65,14,65,22],[95,19,95,22],[96,19,96,22],[55,24,55,32],[56,24,56,32],[57,24,57,32],[58,24,58,32],[59,24,59,32],[96,24,96,27],[97,24,97,27],[94,23,94,32],[95,28,95,32],[96,28,96,32],[97,28,97,32],[66,24,66,32],[68,24,68,32],[5,23,5,32],[6,24,6,32],[7,24,7,32],[8,24,8,32],[9,24,9,32],[10,24,10,32],[11,24,11,32],[12,24,12,32],[13,24,13,32],[97,1,97,4],[96,1,96,4],[95,1,95,4],[89,5,89,13],[95,7,95,12],[96,7,96,12],[97,7,97,12],[14,24,14,32],[15,24,15,32],[16,24,16,32],[17,24,17,32],[18,24,18,32],[19,24,19,32],[20,24,20,32],[37,24,37,32],[50,23,50,32],[21,24,21,32],[22,24,22,32],[23,24,23,32],[24,24,24,32],[51,24,51,32],[52,24,52,32],[53,24,53,32],[44,7,44,13],[92,1,92,13],[46,1,46,5],[48,1,48,13],[53,1,53,5],[89,1,89,4],[46,7,46,13],[88,1,88,4],[88,5,88,13],[87,1,87,4],[87,5,87,13],[83,1,83,4],[83,5,83,13],[57,7,57,12],[85,1,85,4],[85,5,85,13],[61,7,61,12],[56,1,56,5],[66,1,66,5],[66,7,66,12],[71,1,71,5],[71,7,71,12],[74,1,74,5],[67,1,67,5],[84,1,84,4],[84,5,84,13],[89,14,89,22],[83,14,83,22],[95,15,95,18],[96,13,96,14],[6,7,6,12],[7,7,7,12],[9,7,9,12],[18,7,18,12],[19,7,19,12],[20,7,20,12],[37,7,37,12],[16,14,16,22],[45,14,45,20],[17,1,17,5],[17,7,17,12],[38,7,38,13],[21,1,21,5],[21,7,21,12],[21,14,21,22],[22,1,22,5],[22,7,22,12],[45,1,45,5],[22,14,22,22],[5,1,5,12],[5,13,5,22],[10,1,10,5],[10,7,10,12],[10,14,10,22],[14,1,14,5],[17,14,17,22],[15,14,15,22],[8,14,8,22],[11,1,11,5],[11,7,11,12],[11,14,11,22],[12,14,12,22],[13,1,13,5],[13,7,13,12],[13,14,13,22],[12,1,12,5],[15,1,15,5],[12,7,12,12],[15,7,15,12],[14,7,14,12],[14,14,14,22],[16,1,16,5],[16,7,16,12],[0,1,0,19],[3,1,3,13],[97,19,97,22],[49,1,49,22],[6,14,6,22],[7,14,7,22],[9,14,9,22],[18,14,18,22],[20,14,20,22],[19,14,19,22],[37,14,37,22],[43,1,43,22],[7,1,7,5],[18,1,18,5],[19,1,19,5],[9,1,9,5],[38,1,38,5],[39,1,39,5],[6,1,6,5],[8,1,8,5],[8,7,8,12],[4,1,4,13],[20,1,20,5],[37,1,37,5],[23,1,23,5],[23,7,23,12],[23,14,23,22],[24,1,24,5],[24,7,24,12],[24,14,24,22],[82,1,82,5],[51,7,51,12],[52,7,52,12],[53,7,53,12],[55,7,55,12],[62,7,62,12],[63,7,63,12],[64,7,64,12],[65,7,65,12],[82,7,82,12],[54,1,54,5],[54,7,54,12],[59,1,59,5],[59,7,59,12],[60,1,60,5],[60,7,60,12],[61,1,61,5],[25,1,25,5],[25,7,25,12],[25,14,25,22],[25,24,25,32],[26,1,26,5],[26,7,26,12],[26,14,26,22],[26,24,26,32],[27,1,27,5],[27,7,27,12],[27,14,27,22],[27,24,27,32],[28,1,28,5],[28,7,28,12],[28,14,28,22],[28,24,28,32],[29,1,29,5],[29,7,29,12],[29,14,29,22],[29,24,29,32],[30,1,30,5],[30,7,30,12],[30,14,30,22],[30,24,30,32],[31,1,31,5],[31,7,31,12],[31,14,31,22],[31,24,31,32],[32,1,32,5],[32,7,32,12],[32,14,32,22],[32,24,32,32],[33,1,33,5],[33,7,33,12],[33,14,33,22],[33,24,33,32],[34,1,34,5],[34,7,34,12],[34,14,34,22],[34,24,34,32],[35,1,35,5],[35,7,35,12],[35,14,35,22],[35,24,35,32],[36,1,36,5],[36,7,36,12],[36,14,36,22],[36,24,36,32],[67,7,67,12],[67,14,67,22],[67,24,67,32],[41,7,41,13],[42,1,42,5],[45,7,45,13],[42,7,42,13],[44,1,44,5],[46,14,46,20],[51,14,51,22],[52,14,52,22],[53,14,53,22],[55,14,55,22],[41,14,41,20],[42,14,42,20],[41,1,41,5],[62,1,62,5],[63,1,63,5],[64,1,64,5],[65,1,65,5],[51,1,51,5],[52,1,52,5],[62,14,62,22],[54,24,54,32],[38,14,38,20],[58,14,58,22],[56,7,56,12],[57,1,57,5],[55,1,55,5],[39,14,39,20],[44,14,44,20],[68,1,68,5],[68,7,68,12],[68,14,68,22],[66,14,66,22],[39,7,39,13],[40,1,40,5],[40,14,40,20],[40,7,40,13],[50,13,50,22],[54,14,54,22],[59,14,59,22],[60,14,60,22],[61,14,61,22],[56,14,56,22],[57,14,57,22],[58,1,58,5],[58,7,58,12],[69,1,69,5],[69,7,69,12],[69,14,69,22],[69,24,69,32],[70,1,70,5],[70,7,70,12],[70,14,70,22],[70,24,70,32],[71,14,71,22],[71,24,71,32],[72,1,72,5],[72,7,72,12],[72,14,72,22],[72,24,72,32],[73,1,73,5],[73,7,73,12],[73,14,73,22],[73,24,73,32],[74,7,74,12],[74,14,74,22],[74,24,74,32],[75,1,75,5],[75,7,75,12],[75,14,75,22],[75,24,75,32],[76,1,76,5],[76,7,76,12],[76,14,76,22],[76,24,76,32],[80,1,80,5],[80,7,80,12],[80,14,80,22],[80,24,80,32],[81,1,81,5],[81,7,81,12],[81,14,81,22],[81,24,81,32],[77,1,77,5],[77,7,77,12],[77,14,77,22],[77,24,77,32],[78,1,78,5],[78,7,78,12],[78,14,78,22],[78,24,78,32],[79,1,79,5],[79,7,79,12],[79,14,79,22],[79,24,79,32]]}
[null,"On-going Progress Update and Disbursement Request"]
[null,"Section 4:  Grant Management"]
[]
[null,"A.  PR and LFA Comments on the Fulfilment of Conditions Precedent and/or Special Conditions Under the Grant Agreement"]
[]
[null,"! Please include in this table the Condition Precedent number as per Grant Agreement and full text of Conditions Precedent and/or other special conditions due for fulfilment during this period or outstanding from previous periods. \n! Some Special Conditions may apply to more than one period of grant implementation.  Their fulfilment during one period does not automatically imply fulfilment in subsequent periods.  The LFA should verify that the status of such conditions is reported by the PR during each period concerned.",null,null,null,null,null,null,null,null,null,null,null,"For LFA Use Only",null,null,null,null,null,null,null,null,null,"For the Global Fund Use Only"]
[null,"Conditions Precedent and/or other special conditions\n",null,null,null,null,"Status","PR Comments on Progress of Implementation",null,null,null,null,null,"Status","LFA Analysis\n(this should not be a \"Copy and Paste\" of the comments provided by the PR)",null,null,null,null,null,null,null,null,"Validate Status","Country Team Comments"]
[null,"CP1 Condition Precedent to Use of Funds for procurement of Second-Line\nAnti-Tuberculosis Drugs\n\nPrior to the use of Grant funds by the Principal Recipient to finance the procurement of\nsecond-line anti-tuberculosis drugs, the Principal Recipient shall deliver to the Global Fund the following items, each in form and substance satisfactory to the Global Fund:\n\na. A current detailed MDR-TB expansion plan (including the number of MDR-TB\npatients to be treated and the list and quantifications of the medicines to be procured\nfor the MDR-TB program reflecting the Principal Recipient’s finalized forecast for the\nGrant implementation period covered by this Agreement); and\n\nb. The national guidelines for programmatic management of MDR-TB, both of which\nhave been developed in collaboration with a technical partner acceptable to the\nGlobal Fund.",null,null,null,null,"Met","\nThe condition was met for procurement of the SLDs in 2016 (Orders to GDF as per approved quantifications by TGF, no. SLD GEO/DP/16/5877, GEO/DP/16/5878, GEO/DP/16/5927 and GEO/DP/16/5976) \nThe Order reflects forecast for the years of 2017 -2018 with quantifications approved by TGF and WHO Euro. The next Order is scheduled to take place in April, 2017\nBedaquiline Implementation Plan was developed and approved by the Global Fund on 2 April 2015.\nThe updated National Guideline for Programmatic  Management  of MDR-TB was approved on 6 August, 2015 by the MoLHSA Guideline Board.  ",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,{"$f":"N8","v":"Select"}]
[null,"SC1.\nNo later than 31 December 2016 the CCM shall, or the Principal Recipient shall cause\nthe CCM to submit a Budgeted Sustainability Plan for governmental take-over of financing for the first line TB medicines during the second year of the implementation, and gradual take-over of financing for the NTP by the end of the second implementation period, which at a minimum shall include the financing of second-line anti-tuberculosis medicines and patient support.",null,null,null,null,"Met","The calculations implying gradual handover of the financial responsibilities to the government in 2016-2019 were drafted and  integrated in the respective MTEF, as well as are stipulated under the National TB Strategy/Action Plan 2016-2020;\nThe state budget law, 2017 integrates governmental commitments at 1 387 500 GEL. The amount covers funding for cash incentives for 300 beneficiaries (including the income tax), procurement of FLDs (fully), SLDs (up to 25% of total cost) and co-funding of laboratory tests (bacterioscopy and solid media investigations) and supplies (masks/respirators). \nProcurement of FLDs was carried out in November, 2016 using the GDF mechanism and fully financed via the state budget with the total value of 165 053.04 USD.",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,{"$f":"N9","v":"Select"}]
[null,"SC2.\nNo later than 30 days prior to a scheduled cash transfer that includes funds for the\nprocurement of MDR-TB medicines, the Principal Recipient shall deliver to the Global Fund a pro forma invoice issued by the designated Procurement Agent of the Global Drug Facility, as delegated by the Green Light Committee Initiative.",null,null,null,null,"Met","The condition was met for procurement of the medicines for the\nMDR-TB treatment for year 2016 (orders to GDF as per approved quantifications by the Global Fund,  SLD GEO/DP/16/5877, GEO/DP/16/5878, GEO/DP/16/5927 and GEO/DP/16/5976 ).\n\nBi-laterally signed invoices #16200750 SQ, 16200752 SQ, 16200754 SQ and 16200829 SQ related to the SLD procurement were submitted to GDF on November 11, 2016",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,"SC3.\nThe Principal Recipient shall cooperate with the Green Light Committee (the “GLC”)\nin GLC’s efforts to provide technical support and assistance to the Principal Recipient with respect to monitoring and the scaling-up of MDR-TB-related services provided in Georgia. Accordingly, the Principal Recipient shall budget and authorize the Global Fund to disburse up to a maximum of US$ 50,000, or such lower amount as may be agreed between the GLC and the Global Fund, each year to pay for the GLC services.",null,null,null,null,"Met","The GLC fees were reflected in the GEO-T-NCDC Budget. GLC mission to Georgia took place on June  06-10, 2016 (rGLC EUROPE/Europe consultant Dr. Elmira Gurbanova)",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,"SC4.\nNo later than 31 December 2016, the Government of Georgia shall, or the Principal\nRecipient shall cause the Government of Georgia to, prepare and provide a formal document describing the tuberculosis program coordination mechanisms, with clear segregation of the roles and responsibilities among the implementing entities in Georgia.In addition, the Principal Recipient shall confirm (as verified by the LFA) that each Sub-recipient contract complies with Articles 14, 18 (d) and 20 (a) of the Standard Terms and Conditions of this Agreement.",null,null,"Select",null,"Met","The National TB Strategy/Action Plan Post-2016 integrates proposed model of TB governance with costed operational strategies implying all necessary components of TB service delivery, including coordination mechanisms, with clear segregation of the roles and responsibilities among the implementing entities in Georgia, etc. The document represents an integral part of the NFM application package and was approved by CCM and later by the Cabinet of Ministers.\n",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,{"$f":"N22","v":"Select"}]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,"Select",null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select"]
[]
[null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select"]
[]
[null,"B.  PR & LFA Review of Progress on Implementation of Outstanding Management Actions from Previous Disbursements"]
[null,"! Please list all issues raised in the last Performance Letter from the Global Fund or outstanding from previous Performance Letters, and comment on the progress. Please include the date of the Performance Letter and the item number."]
[null,null,null,null,null,null,null,null,null,null,null,null,null,"For LFA Use Only",null,null,null,null,null,null,null,null,null,"For the Global Fund Use Only"]
[null,"Global Fund Management Actions",null,null,null,null,"Status","PR Comments on Progress of Implementation",null,null,null,null,null,"Status","LFA Review of PR Progress on Global Fund Management Actions",null,null,null,null,null,null,null,null,"Validate Status","Country Team Comments of PR Progress on Global Fund Management Actions"]
[null,"M&E Issue 1: Reporting results for the indicator 3•4  \"Laboratory-confirmed  X/MDR-TB\npatients enrolled on second line anti-TB treatment in the specified calendar year\"\n\nRequired action:\n\nThe PR is requested  to ensure that the reporting for the indicator 3-4 is based on the actual number of the XDR/MDR-TB patients' as registered in the admissions forms and these results are included in the next progress updates.\n\nTimeline: ongoing\n ",null,null,null,null,"Met","PR worked with SR to ensure that the reporting on the said indicators is based on the actual number of the XDR/MDR-TB patients' as registered in the admissions forms. These results are included in the present progress update.\n",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,{"$f":"N53","v":"Select"}]
[null,"M&E Issue 2: Management of the patients' registry in the Health Management System\n\nRequired action:\n\nThe Global Fund notes with concern this data quality issue and requests the PR to follow up with the SR to ensure that the patients' registry is completed and all required  information  is entered into the system.\n\nTimeline: ongoing.The PR is requested  to update on the implementation of this management action with the next progress update by no later than 14 August 2015.",null,null,null,null,"Met","PR is working with SR to support improving data-entry processes, including communicating the issue with management, articulating the issue at the meetings with SR staff, as well as by using official correspondence. As a part of his weekly routine M&E officer checks the progress on data entry. It should be emphasized that the process had significantly been improved since initiation of the current grant, though the compliance will further improved as the TB module is fully operationalized.",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,{"$f":"N54","v":"Select"}]
[null,"M&E Issue 3: Reporting on  the Impact and Outcome Indicators; Revision of Performance\nFramework\n\nRequired action:\n\na)   The PR is requested to submit revised Performance Framework for the approval of the Global Fund which includes the targets set according to the latest methodology developed by the WHO.\nb)  The PR is requested to submit revised Performance Framework to update the definitions of the\nreporting for cohorts according to the WH0 guidelines.\nc)  The PR is requested to submit revised Performance Framework and exclude the line (3) \"other\nretreatment cases\" from the comments section of the indicator 3.1.\n\nTimeline: 15July 2015",null,null,null,null,"Met","All required changes were reflected in the PF and submitted to the TGF for approval on July 15. The approval was obtained with the Implementation Letter 2 on August 12.",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,"FM&S Issue 1: Recommendations to be addressed from the Audit of fiscal year 2014\nRequired Action:\n\nDuring the preparation for the Audit review of the financial statements for fiscal year 2015 we recommend the PR:\na)   To bring to the Secretariat's attention any specific regulations applied to the PR reporting and\npreparation of the financial statements, well in advance. The PR is requested to disclose these\nrequirements already  at the  stage  of review and  approval  of the  TORs for the  Audit of\nFinancial Statements for fiscal year 2015.\nb)  To further develop and refine the process of preparing the financial statements.\nc)   To ensure that the procedures  and related deadlines for all staff involved in preparation of\nthe financial statements are developed in advance and formally documented.\n\nTimeline: The PR should submit to the Secretariat  the TORs for the Audit review of the financial statements for fiscal year 2015 addressing the actions outlined by no later than 31July 2015.",null,null,null,null,"Met","The required actions were taken/recommendations are considered and followed precisely. ToR was submitted to the TGF for review per indicated deadline. The actual service is procured and the Audit process has undergone by BDO.",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,"FM&S Issue 2: Recording the expenditures in existing bookkeeping system\n\nRequired Action:\n\na) The PR is expected to follow up on the integration of the new financial software  in existing accounting systems. While this activity should have been implemented during the last reporting period and was postponed, the PR is requested  to ensure that the transition  is completed  before the end of fiscal year 2015. Additionally, the Secretariat  recommends the PR and SRs to produce semi-annual and  monthly  reports  while  reconciling  between  the  financial  reports and  other accounting data, using MS Excel.\n\nb) The PR is requested to ensure that further automation process is taking place, to better facilitate the  process  of  gathering   information   for  the  preparation  of  the  grant   program   financial statements.\n\nAdditionally, the PR should explore options to incorporate the accounting of PP and HPHE in the new financial software during its integration with the existing accounting systems by the end of fiscal year 2015.\n\nTimeline: The  PR is requested  to report  on the progress  made concerning  the  management actions outlined  above with the submission of the next progress  update by no later than 14\nAugust 2015.",null,null,null,null,"Met","PR and SR’s have  integrated budget categories and lines in their existing accounting software and reports are reconciled with the accounting data on regular basis.   \nPR has successfully initiated development of ERP system. Procurement of Microsoft Dynamics AX licenses was carried out under the Agreement between Government of Georgia and Microsoft. The service agreement on the development of ERP system is implemented by the “UGT Intelligent Software Solutions”, the winner identified through tender. The development process is in progress: Business process review, analyses and ToR was defined in the phase 1; Different Module configuration and customizations are carried out, alongside with PR staff trainings; Test and real-time environment is prepared; Testing on data/processes, preparing data for migration from current system to ERP, as well as integration with State treasury is in progress. The ERP system will go live by the end of May, 2017.  \n\nNCDC started using of the Software for logistic PP and HPHE from 2015. Information regarding GF PIU assets was provided to the LIMS software managers two times during the last year - as of January 1st positions and of Jane 1st positions. However, during the roll out period some technical issues raised by NCDC logistic staff regarding the system, which is now under review (DITRA GH2 project in collaboration with  USAD HSSP proved support to NCDC). PR made a decision to develop independent system from NCDC LIMS as a part of the ERP system. Meantime the excel based system is implied. ",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,"HIMS Issue 3: Health Management System Module and reporting on cash incentive scheme\nAction required:\n\nThe PR is invited to explore the options which will allow to enhance the HMIS module and the data recording mechanism currently being used, in order to facilitate the reporting on the indicators and to be able to generate  the updates  on the implementation of the cash incentive scheme. The PR is requested  to report  on the available options  and on possible solutions  which could enhance  the module.\n\nTimeline: with submission of the next progress update by no later than 14 August 2015.",null,null,null,null,"Met","The required action was taken: issue was communicated with USAID/HSSP and the respective changes were made to the software, enabling it to generate the reports  on  the  number  of patients who had received cash incentives at given period of time",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,"OSDV 2015 Issue 1 (moderate)\nThe contracts of most of TB treatment units being under management of private entities will expire next year and those private health institutions will not be obliged anymore to provide TB treatment services. As a result there is a risk that in 2016 the mentioned health institutions can change their profile and stop providing TB treatment services to their patients.\nTimeline: end of 2015\nRecommendation: PR should investigate this issue with the Ministry of Health and try to find a sustainable solution.",null,null,null,null,"Met","The issue goes far beyond the control of PIU. The rights of the private entities are regulated through the respective legislation. The MoLHSA is well aware with the topic and closely following processes using available legal mechanisms to address the issue.  Though we found minor inconsistency – as the agreements with private providers were signed back in  2011-2012 (double-checked). The providers committed to keep TB service points for the coming 7 years, i.e. minimum 2018. Though it was non-standard case of one TB service delivery point in Tbilisi located at the private institution. The management of the facility requested the TB point to move. The MoLHSA reacted immediately and the alternative venue (state-owned) for the TB service point was provided.\nIn-line with the NSP post-2016 over the next program period, a number of measures are planned under the NFM to facilitate the provision of TB services by private providers. To uphold universal access to essential TB care in all areas of the country, the tasks and responsibilities of private providers will be formalized in annual service contracts with MoLHSA / SSA. These agreements will stipulate in detail the scope and volume of services to be provided. The payment conditions will be clearly articulated in the contracts, according to the payments methods (see above under financing and allocation). Additionally, the modes of cooperation, related to referrals and other processes, between private medical centers and public institutions (NCDCPH territorial units and laboratories, public hospitals) will be elaborated.  \n",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,"OSDV 2015 Issue 2 (minor)\nIn the drug inventory documents checked, the batch numbers and expiry dates for TB drugs were not specified (for both FLDs and SLDs).  Furthermore, the pharmacy of NCTBLD doesn't indicate the batch numbers and corresponding expiry dates in \"handling over documents/acts\" that accompany drugs when they are supplied to the regional facilities and SDPs.\n\nTimeline: 31 December, 2015\nRecommendation: All inventory documents should consistently carry the batch numbers and corresponding expiry dates for all TB drugs (both FLDs and SLDs) all along the distribution chain at all levels.",null,null,null,null,"Met","\nPR worked closely with SR to follow with the issue on the batch numbers. For all medicines procured through the GEO-T-NCDC – numbers were incorporated within the warehouse el. registry (starting date January 2015). So, the NCTBLD pharmacy indicates/marks the batch numbers and corresponding drug expiry dates in the handover documents/acts accompanying drugs. \nAs for the drugs delivered before the launch of the current Grant, SR is not able to incorporate it into the registry due to technical issues –the system does not allow entering data retrospectively. It was agreed with SR that the batch numbers will be entered manually into the handover documents/acts accompanying drugs at all levels - from central to regional and from regional to district/village level. ",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,"OSDV 2015 Issue 3 (minor)\n\nThere is no mechanism to allow for the redistribution of short-dated medicines.  This results in a wastage of significant amount of drugs.\nTimeline: 31 December, 2015\nRecommendation: \n1.       The PR should ensure that they routinely receive information on the shelf-life and stock-levels of TB medicines.\n2.       The PR should work with relevant stakeholders to develop a mechanism that enables either more frequent distribution with less stock-holding at SDPs or the redistribution of short-dated medicines in an effort to decrease wastage.   ",null,null,null,null,"Met","PR has worked to identify the best mechanism to address this problem, such as short shelf-life drugs are ordered for shorter periods with zero buffer stock and with several shipments; monthly reports on stock at hand are obtained from SR including the information on expiration date; drugs are distributed on monthly basis, compared to the previously adopted quarterly based distribution. ",null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,{"$f":"N67","v":"Select"}]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[null,null,null,null,null,null,"Select",null,null,null,null,null,null,"Select",null,null,null,null,null,null,null,null,null,"Select"]
[]
[]
[]
[]
[]
[]
[]
[]
[]
[null,"C.  Comments on Annual Grant Reporting Requirements"]
[]
[null,"! Please indicate a date for the report due for submission.  If a report is overdue, indicate the original due date and explain the reason for delay.",null,null,null,null,null,null,null,null,null,null,null,"For LFA Use Only",null,null,null,null,null,null,null,null,null,"For the Global Fund Use Only"]
[null,"Required Documentation",null,null,null,"Due date \n(dd-mmm-yy)","Status","Comments",null,null,null,null,null,"Due date\n(dd-mmm-yy)",null,"Status",null,null,null,"Comments",null,null,null,"Due date\n(dd-mmm-yy)","Validate Status",null,null,null,"Country Team Comments"]
[null,"PR Audit Report",null,null,null,"2017-03-31","Preparation on track","New deadline agreed with TGF is May 1, 2017 as a result of  development of new reporting formats by TGF "]
[null,"Annual Financial Report (AFR) / Enhanced Financial Report (EFR)",null,null,null,"2017-03-01","Submitted to GF","New deadline agreed with TGF is April 5, 2017 as a result of  development of new reporting formats by TGF "]

{"sheet":"PR-LFA Evaluation_5","index":16,"n_rows":49,"n_cols":8,"rows_kept":49,"cut":false,"hidden":false,"merged":[[56,0,56,10],[40,0,45,14],[39,0,39,14],[49,0,54,14],[27,15,27,29],[32,0,37,14],[27,0,27,14],[28,0,28,10],[18,0,18,14],[5,0,9,14],[0,0,0,15],[12,0,16,14],[19,0,23,14],[4,0,4,10],[11,0,11,14]]}
["Ongoing Progress Update and Disbursement Request"]
["Section 5: PR and LFA Evaluation of Overall Performance"]
[]
["A.  PR's Overall Self-Evaluation of Grant Performance (including a summary of how financial performance is linked to programmatic achievements)"]
["!  The self-evaluation should be undertaken by taking into account programmatic achievements, financial performance and program issues in various functional areas (M&E, Finance, Procurement, and Program Management, including management of Sub-Recipients).  See Guidelines for more detailed guidance."]
["Absolute numbers of notified TB cases in Georgia continued to show the trend of decrease in 2016. It is worth mentioning that the trend of decrease is maintained also in re-treated cases that indicates the fact that program is on the right track.\n\nProgram implementation went in-line with planned objectives, activities and timelines. The latter is well reflected in the overall grant performance - the top 10 indicators, whereas the results are either overachieved or are close to planned targets, several relatively low indicators are in line with the overall trend of decreasing TB cases in the country. Uninterrupted supply of treatment and diagnostic services to TB patients, as well as supervision and monitoring processes were well-maintained. All activities under the GEO-T-NCDC grant, including activities under the extension period (July-December 2016) is either completed or will be finalized during the grant closure period (before June 2017). all management actions raised within the MA EECA/TS/147-07/06/2016 were taken into account as articulated in the respective section of the PU/DR (Grant Management 4).\n\nImportant projects and initiatives that were started during previous years were carried on further in 2016 i.e.: \nNational TB center continued to implement mobile consilium project and carried out the initial and follow-up monitoring visits throughout the country, including penitentiary sector, whereas the decision on the enrollment the targeted patients based on the analysis of their clinical/diagnostic characteristics and risk assessment are carried out on-the-spot. \n\nEnrollment of patients on the new TB treatment continued in 2016. The routine programmatic implementation of Bedaquiline along with Delamanid is steadily progressing in Georgia. Based on the drug susceptibility data and the patient eligibility criteria it is estimated that on average around 8-10 patients should be enrolled on new TB drugs on monthly basis. Overall, as of December 2016, total of 311 patients were enrolled on new treatment regimens: \n• 246 patients were enrolled on Bedaquiline, out of which 20 were through compassionate use (CU) \n• 65 patients were enrolled on Delamanid, out of which 12 were through CU \n• 227 are still on treatment\n\nWithin frames of USAID/SIAPS technical assistance Georgia has established an adequate pharmacovigilance system for TB in accordance with the latest Active Drug Safety Monitoring Guidelines. As a result of the effective collaboration between the National Center for Tuberculosis and Lung Diseases, USAID/SIAPS, MSF, NCDC and Ministry of Health a comprehensive mechanism for the mandatory reporting of the Serious Adverse Events has been created and approved by the Ministerial decree issued on May 18, 2016. Per the decree, the recording and reporting of all Serious Adverse Events (SAEs) occurring among all drug-resistant TB patients being on treatment has become the mandatory component of programmatic management of Drug Resistant TB (PMDT). Total of 275 TB doctors and PMDT staff have received the active PV training throughout the 16 training sessions of 3 days duration each covering the 100% of need. As of December 31, 2016 total number of 73 SAE terms have been reported to the NCTLD that have encountered to 48 (15%) out of 311 patients enrolled on new TB drugs by then.\nThe year of 2016 also brought some innovative projects and groundbreaking initiatives:\nThe pilot project for using GX machines in the general healthcare facilities to improve TB detection was included in the TB State Program and respective funds were allocated. Order was placed to Cepheid for procurement of additional 19 GX machines through the GF program. Delivery is expected in March 2017.\n\nVideo Observed Therapy (VOT) project was launched in June. Patients are taking TB drugs with the direct supervision of nurse during the video call in Skype. 53 mobile phones were procured within the project and as of January 2017, 18 MDR-TB patients are on VOT treatment, with no single missed drug dose documented so far.\n\nMobile Ambulatory project was initiated at the end of the year. 3 vans equipped with all necessary tools were procured and handed over to the national TB center.\n\nExtension for Community Healthcare Outcomes (ECHO) is another innovative project started in 2016, it is a collaborative model of medical education and care management that provides healthcare professionals with the knowledge and support their need to manage patients with TB. Using teleconference technology, it incorporates case review, consultation, and didactics for clinicians working with TB. Georgia team including PIU and participants from TB center attended the training course at the University of New Mexico. The implementation of TB ECHO project in Georgia is planned in 2017. The project will include TB facilities in regions and the national TB center will serve as an ECHO central clinic in the country.\nTwo projects that aimed strengthening the involvement of the civil society organizations in TB related issues were implemented in 2016: 1. “Country-wide advocacy, communication and social mobilization campaign using Georgian Orthodox Church”; 2. “Increase the TB awareness in educational institutions (schools and universities) and seminars for media”\nFinancial management: To accomplish set objectives two components can be outlined a) external to Georgia - communication with the donor (GFATM), and b) internal to Georgia – communication and reporting with the Ministries of Health and Finance, with NCDC, state statistics department, tax authorities, state revenue service, suppliers, service providers, etc. The former is smooth and efficient, which helps the stable and robust operations. PR has met all of the donor’s requests on the provision of financial and/or operational data. The PR has successfully procured audit service for the year 2016 through tender and contract is signed with BDO. The Audit of Consolidated financial statements is ongoing and as agreed audit report will be submitted in the beginning of May, 2017.\n\nPR has successfully initiated development of ERP system. Procurement of Microsoft Dynamics AX licenses was carried out under the Agreement between Government of Georgia and Microsoft. The service agreement on the development of ERP system is implemented by the “UGT Intelligent Software Solutions”, the winner identified through tender. The development process is in progress: Business process review, analyses and ToR was defined in the phase 1; Different Module configuration and customizations are carried out, alongside with PR staff trainings; Test and real-time environment is prepared; Testing on data/processes, preparing data for migration from current system to ERP, as well as integration with State treasury is in progress. The ERP system will go live by the end of May, 2017.  \n\nDuring the current reporting period under SSF Grant the following disbursements were carried out by TGF:  PR received EUR 2,226 K worth of three transfer and vendors through direct payment received EUR 737 K. In addition, in December 2016, PR received USD 444 K for the implementation of TB NFM Grant (starting from January 1, 2017).\nPR paid total of EUR 2,044 K to the vendors/providers/patients during the current reporting period.\n\nPR manages VAT smoothly. The total refunded amount during the year 2016 comprise EUR 47,988. The surplus of refundable VAT on the State Revenue Service system amounts EUR 37,975 as of 31/12/2016 and additional EUR 38,5 K is submitted as surplus in the first quarter of the year 2017.\n\nPR effectively manages TB Cash Incentive Scheme. Total cash incentives paid in the current reporting period is EUR 187 K (in addition EUR 156K was financed through the state budget- income tax and monthly 225 MDR patients) and covered period through December 2015- November 2016, for both MDR and sensitive TB patients.\n"]
[]
[]
[]
[]
[]
["B.  Planned Changes in the Program, if any"]
[]
[]
[]
[]
[]
[]
["C.  External factors beyond the control of the Principal Recipient that have impacted or may impact the Program"]
[]
[]
[]
[]
[]
[]
["For LFA Use Only"]
[]
["A. LFA  Overall Evaluation and Rating of Grant Performance (including a summary of how financial performance is linked to programmatic achievements)"]
["!  The evaluation should be undertaken by taking into account programmatic achievements, financial performance and program issues in various functional areas (M&E, Finance, Procurement, and Program Management, including management of sub-recipients).  See Guidelines for more detailed guidance on the completion of this section."]
[]
["Indicator rating","Select",null,"Any major management issues resulting in downgrade?","Select",null,"Overall Grant Rating","Select"]
[]
[]
[]
[]
[]
[]
[]
[]
["B.  LFA comments on PR planned changes in the program, if any"]
[]
[]
[]
[]
[]
[]
[]
[]
["C.  LFA Comments on External Factors Beyond Control of the Principal Recipients that have impacted or may impact program"]

{"sheet":"LFA_Findings&Recommendations_6","index":17,"n_rows":33,"n_cols":10,"rows_kept":33,"cut":false,"hidden":false,"merged":[[12,0,12,1],[13,0,13,1],[14,0,14,1],[15,5,15,8],[16,5,16,8],[13,2,13,4],[14,2,14,4],[15,2,15,4],[16,2,16,4],[11,0,11,1],[8,0,8,1],[9,0,9,1],[20,2,20,4],[20,5,20,8],[19,2,19,4],[19,5,19,8],[17,5,17,8],[18,5,18,8],[17,2,17,4],[18,2,18,4],[15,0,15,1],[16,0,16,1],[12,2,12,4],[13,5,13,8],[14,5,14,8],[8,2,8,4],[8,5,8,8],[7,0,7,1],[10,2,10,4],[6,2,6,4],[10,0,10,1],[0,0,0,9],[20,0,20,1],[18,0,18,1],[7,2,7,4],[19,0,19,1],[11,2,11,4],[17,0,17,1],[9,2,9,4],[9,5,9,8],[12,5,12,8],[10,5,10,8],[4,0,4,9],[6,5,6,8],[11,5,11,8],[6,0,6,1],[7,5,7,8]]}
[" Ongoing Progress Review and Disbursement Request"]
["For LFA Use Only"]
["Section 6: LFA Findings & Recommendations  "]
[]
["! Based on the information provided in the previous sections and your understanding of the grant, please summarise any important management issues, proposing a recommendation for each.\nNB: an issue is considered as 'important' if it impacts or is likely to impact program implementation and results.                                                                                                                                                                                                          ! Instead of repeating detailed descriptions of issues covered in other sections, it is acceptable to state the issue and reference the section containing the details."]
[]
["Functional Areas",null,"Description of Identified Issues \n(in order of importance)",null,null,"LFA Recommendations \n(in order of importance)",null,null,null,"Country Team Comments"]
["Select"]
["Select"]
["Select"]
["Select"]
["Select"]
["Select"]
["Select"]
["Select"]
["Select"]
["Select"]
["Select"]
["Select"]
["Select"]
["Select"]
[]
[]
["Select"]
["Yes"]
["No"]
[]
["Select"]
["Program management (including SR management)"]
["Financial management and systems"]
["Monitoring and evaluation"]
["Pharmaceutical & health product management"]
["Other management issues, including: PR capacity to develop quality programmatic and financial reports"]

{"sheet":"PR EFR_7A","index":18,"n_rows":206,"n_cols":12,"rows_kept":206,"cut":false,"hidden":false,"merged":[[187,4,187,10],[169,0,169,11],[204,4,204,10],[176,4,176,11],[177,4,177,10],[178,4,178,10],[201,4,201,10],[202,4,202,10],[203,4,203,10],[188,4,188,10],[189,4,189,10],[200,4,200,10],[179,4,179,10],[180,4,180,10],[181,4,181,10],[182,4,182,10],[186,4,186,10],[111,0,113,4],[115,4,115,7],[115,8,115,11],[161,0,163,4],[168,0,168,11],[183,4,183,10],[184,4,184,10],[185,4,185,10],[170,0,174,11],[29,1,29,3],[30,0,30,2],[33,4,33,7],[33,8,33,11],[110,0,110,3],[28,1,28,3],[17,1,17,3],[18,1,18,3],[19,1,19,3],[20,1,20,3],[21,1,21,3],[22,1,22,3],[23,1,23,3],[24,1,24,3],[25,1,25,3],[26,1,26,3],[27,1,27,3],[8,4,9,4],[8,8,9,8],[12,4,14,7],[15,4,15,7],[15,8,15,11],[16,1,16,2],[5,0,5,1],[5,2,5,3],[6,0,6,1],[6,2,6,3],[7,0,7,1],[8,0,8,1],[7,2,7,3],[0,0,0,5],[3,0,3,1],[3,2,3,3],[3,5,4,7],[4,0,4,1],[4,2,4,3],[2,0,2,5],[1,0,1,5],[190,4,190,10],[191,4,191,10],[192,4,192,10],[193,4,193,10],[194,4,194,10],[195,4,195,10],[196,4,196,10],[197,4,197,10],[198,4,198,10],[199,4,199,10]]}
["Ongoing Progress Update and Disbursement Request"]
["Section 7A: PR - Enhanced Financial Reporting"]
[]
["Country",null,{"$f":"CoverSheet!D5","v":"Georgia"},null,null,"PLEASE REFER TO THE \"GUIDANCE FOR COMPLETION OF THE ENHANCED FINANCIAL REPORTING TEMPLATE\" DOCUMENT TO ASSIST YOU IN COMPLETING THE TEMPLATE"]
["Grant No.",null,{"$f":"CoverSheet!D7","v":"GEO-T-NCDC"}]
["PR",null,{"$f":"CoverSheet!D8","v":"NCDC"},null,null,"TO BE COMPLETED ONLY ONCE A YEAR "]
["Currency",null,{"$f":"CoverSheet!D11","v":"EUR"}]
["Disease(Component)",null,{"$f":"CoverSheet!D6","v":"Tuberculosis"},null,null,null,"dd-mm-yyyy",null,null,null,"dd-mm-yyyy"]
[null,null,null,null,"Current Reporting Period","Start Date:",{"$f":"CoverSheet!J7","v":"2016-01-01"},null,"Cumulative Reporting Period","Start Date:","2014-04-01"]
[null,null,null,null,null,"End Date:",{"$f":"CoverSheet!L7","v":"2016-12-31"},null,null,"End Date:",{"$f":"CoverSheet!L10","v":"2016-12-31"}]
[null,null,null,null,null,null,null,"The end date for the current reporting period and cumulative reporting period must be the same"]
[null,null,{"$f":"CONCATENATE(\"EFR\",SUBSTITUTE(SUBSTITUTE(C8,\"/\",\"\"),\" \",\"\"))","v":"EFRTuberculosis"}]
[null,null,{"$f":"CONCATENATE(\"SDA\",SUBSTITUTE(SUBSTITUTE(C8,\"/\",\"\"),\" \",\"\"))","v":"SDATuberculosis"},null,"The \"TOTAL\" rows in Table A, B and C will have a RED background if the amounts in each table do not agree. If the Totals for each Table agrees, these rows will have a YELLOW background. "]
[]
[]
["A- BREAKDOWN* BY  EXPENDITURE CATEGORY",null,null,null,"Current Reporting Period",null,null,null,"Cumulative Reporting Period"]
["#","Category",null,null," \nBudget","\nExpenditures","Variance","Reason for Variance","Cumulative Budget","Cumulative Expenditure","Variance","Reason for Variance"]
[1,"Human Resources",null,null,135454.14007096039,336623.29575276905,{"$f":"E18-F18","v":-201169.15568180865},"PR Overspending of EUR (-152,767) – During HIV Grant Extension period, HR costs was covered from TB Grant, and also there was TB grant Extension HR had impact on overspending. \nSR Overspending of EUR (-48,402) – On one hand there was no need for recruiting additional staff (nurses at penitentiaries), also on HIV screening there were less patients than budgeted. It had saving impact. But on the other hand, there was additional 6 month no cost extension and HR costs exceeded the approved budget. Also, FX rate change had impact. \nCommitment EUR 10,142 – HR costs for December, 2016. Payment was made in January 2017.\n",{"$f":"(E18)+509565.69807758","v":645019.83814854035},759616.02393814118,{"$f":"I18-J18","v":-114596.18578960083},"PR Overspending of EUR (-123,198) – During HIV Grant Extension period, HR costs were covered from TB Grant, and also HR component under the TB grant Extension had impact on overspending. \nSR Saving of EUR 8,602 – Actual costs were less than budgeted, despite the no-cost extension period: this was resulted due to the fact that there was no need for recruiting additional staff (nurses at penitentiaries), and less patients needed HIV screening than budgeted. \nCommitment EUR 10,142 – HR costs for December, 2016. Payment was made in January 2017.\n"]
[2,"Technical Assistance",null,null,13420,134674.38309510172,{"$f":"E19-F19","v":-121254.38309510172},"PR Overspending of EUR (-123,630) – due to 6 months no cost extension period   and Project management costs attributed to HIV Grant during Extension period  covered from TB grant.  New activities, in agreement with TGF, were added: TB support and TB education projects, Transition plan. \nCommitment – EUR 23,290 – cost for Transitions plan payable in January 2017\nSR Saving of EUR 2,376 – Actual TA costs were lee than budgeted. From the programmatic point of view, activities were performed as planned\nCommitment EUR 862 - TA costs for December, 2016. Payment was made in January 2017\n",{"$f":"(E19)+173648","v":187068},204103.71106171937,{"$f":"I19-J19","v":-17035.711061719368},"PR Overspending of EUR (-48,058) – due to 6 months no cost extension period   and Project management costs attributed to HIV Grant during Extension period  covered from TB grant.  New activities, in agreement with TGF, were added: TB projects involving NGOs and Transition plan. \nCommitment – EUR 23,290 – cost for Transitions plan was paid in January 2017\nSR Saving of EUR 31,022 – Actual TA costs were less than budgeted. From the programmatic point of view, activities were performed as planned\nCommitment EUR 862 - TA costs for December, 2016. Payment was made in January 2017\n"]
[3,"Training",null,null,3000,40894.170165158233,-37894.170165158233,"PR overspending of EUR (- 31,062) - Due to 6 months no cost extension period   and Project management costs attributed to HIV Grant during Extension period  covered from TB grant.  New activities, in agreement with TGF, were added: attending ECHO training and Estonia Study tour.\nSR overspending of EUR (-6,832) – Actual costs were higher than budgeted due to 6 months no cost extension period   \n",{"$f":"(E20)+57800","v":60800},87800.913040565443,-27000.913040565443,"PR overspending of EUR (- 21,764) - Due to 6 months no cost extension period   and Project management costs attributed to HIV Grant during Extension period  covered from TB grant.  New activities, in agreement with TGF, were added: attending ECHO training and Estonia Study tour.\nSR overspending of EUR (- 5,237)– Due to 6 months no cost extension period actual costs were higher than budgeted and attending ECHO project was financed.\n"]
[4,"Health Products and Health Equipment",null,null,447048.89307732024,906301.40601168922,-459252.51293436898,"The budget relates to internationally and locally procured lab supplies, consumables and equipment. Reasons for negative variance in the amount of EUR 459,253 are following: \nDue to the 6 months extension period PR procured additional lab supplies to cover TB centre needs,; Procurement of 19 GeneXpert machines and cartridges to meet the need for 2016-2017 years which was originally planned in the NFM but due to the change of the NFM launch date was moved within the extension period; in addition procurement of Laboratory equipment for TB center in agreement with TGF (reallocation request approved on 06/11/2015); Procurement of cold boxes and audiometers (reallocation request approved on 01/12/2015); Procurement of mobile ambulatories (reallocation request approved on 01/12/2015)\nCommitment EUR 15,028 – MGIT test procurement (signed contract) to be paid in the year 2017.\n",{"$f":"(E21)+1380425.64663347","v":1827474.5397107902},1705177.3271826766,122297.21252811351,"The budget relates to internationally and locally procured lab supplies, consumables and equipment. Reasons for Net positive variance ( EUR 122,297) are following: \nThe main Driver of savings from procurement of lab supplies and respirators are derived from 1. Local procurement with competitive bidding with preceding market assessment derived significantly cheaper unit costs compared to the budgeted amounts; 2. Available stocks; 3. Re-calculation of average consumption rates;\nDespite the above The total savings were reduced by the new activities budgeted under TB grant and 6 months no cost extension during the year 2016: PR procured additional lab supplies to cover TB centre needs for extension period; Procurement of 19 GeneXpert machines and cartridges to meet the need for 2016-2017 years which was originally planned in the NFM but due to the change of the NFM launch date was moved within the extension period; in addition procurement of Laboratory equipment for TB center in agreement with TGF (reallocation request approved on 06/11/2015); Procurement of cold boxes and audiometers (reallocation request approved on 01/12/2015); Procurement of mobile ambulatories (reallocation request approved on 01/12/2015).\nCommitment EUR 15,028 – MGIT test procurement (signed contract) to be paid in the year 2017.\n"]
[5,"Medicines and Pharmaceutical Products",null,null,1151470.3529311728,618248.93913535285,533221.41379581997,"The budget relates to pharmaceuticals procured locally as well as through the GDF.\nThe Positive variance EUR 533,221 is due to the following savings: \nEUR 509,594 - Saving in procurement of SLD include: recalculation of needs; tendency of decreasing prevalence of TB; BDQ Donation program provided the medicine free-of-charge; General tendency of decreasing cost of TB medicines through GDF; Commitment to NFM Grant in the amount of USD 428,004 will be financed from the saving. \nEUR 2,988 –The activity was canceled. Procurement (water for injectibles) was carried out by TB Centre.\nEUR 20,640 – Procurement of side effects drugs cancelled, as the activity was budgeted under  the state budget.\n",{"$f":"(E22)+4358024.97025976","v":5509495.3231909322},2877124.3825299796,2632370.9406609526,"The budget relates to pharmaceuticals procured locally as well as through the GDF.\nThe Net positive variance EUR 2,632,371 is due to several reasons:\nEUR 2,548,769– Net saving in procurement of SLD include several reasons: recalculation of needs; tendency of decreasing prevalence of TB; BDQ Donation program provided the medicine free-of-charge; General tendency of decreasing cost of TB medicines through GDF; The total saving was used for the following activities in agreement with TGF: approved reallocation requests related to new projects such as VOT and procurement of mobile  ambulatories; construction of prefabricated TB DoT Centre, procurement of lab equipment for TB center and etc. Commitment to NFM Grant in the amount of USD 428,004 will also be financed from the saving. \nEUR 1,069 – Line 3.10 was cancelled (ref. PR letter to GF19/11/2014) as the pharmaceutical was included in the GDF Order (Act. 3.1.a)\nEUR 5,984 –The activity was canceled. Procurement (water for injectibles) was carried out by TB Centre.\nEUR 76,548 – Cost of Procurement side effects drugs was less than budgeted due to the decreasing number of patients and low prices derived through the local procurement (tender). In addition Procurement of side effects drugs in the year 2016 was cancelled, as the activity was included in the state budget.\n"]
[6,"Procurement and Supply Management Costs",null,null,126085.14813311728,83306.395973095248,42778.752160022035,"PR -Saving of EUR 42,779 – Actual PSM cost was less than budgeted. Saving mainly was occurred due to the savings in MPP categories. \nCommitment: EUR 698 – remaining Payment for the quality control of pharmaceuticals.\n",{"$f":"(E23)+480438.77937708","v":606523.92751019727},338031.51176316733,268492.41574702994,"PR -Saving of EUR 268,492 – Actual PSM cost was less than budgeted. Saving mainly was occurred due to the savings in MPP and HPHE categories. \nCommitment: EUR 698 – remaining Payment for the quality control of pharmaceuticals.\n\n"]
[7,"Infrastructure and Other Equipment",null,null,7864.1829071233315,191331.93945546373,-183467.7565483404,"PR Overspending of EUR (-183,431) – Costs exceeded the budgeted amount due to the construction of new prefabricated TB DOT Center, procurement of mobile phones to implement VOT project and ERP system development costs. Saving from MPP category was reallocated. \nCommitment: EUR 64,548 Payments transferred to the year 2017 for ERP system development and procurement of infrastructure equipment, to accommodate ERP system development; EUR 106,307 – Commitment for the construction works of prefabricated TB DOT Centre.\nSR – Overspending of EUR (-37) – Actual vehicle maintenance costs were higher than budgeted due to 6 months no cost extension period   \n",{"$f":"(E24)+80128.9025399315","v":87993.085447054837},232435.49889583417,-144442.41344877932,"PR Overspending of EUR (-150,067) – Costs exceeded the budgeted amount due to the construction of new prefabricated TB DOT Center, procurement of mobile phones to implement VOT project and ERP system development costs. Saving from MPP category was reallocated. \nCommitment: EUR 64,548 Payments transferred to the year 2017 for ERP system development and procurement of infrastructure equipment, to accommodate ERP system development; EUR 106,307 – Commitment for the construction works of prefabricated TB DOT Centre.\nSR – Saving of EUR 5,624 – Actual vehicle maintenance costs were less than budgeted \n"]
[8,"Communication Materials",null,null,0,0,0,"N/A",{"$f":"(E25)+0","v":0},0,0,"N/A"]
[9,"Monitoring & Evaluation",null,null,43629.711687670308,68099.668239627354,-24469.956551957046,"PR saving of EUR 5,008 – Activities performed in accordance with the workplan, but actual costs were less than budgeted, also Actual fuel cost budgeted under ME for TB center was less than budgeted. \nCommitment – EUR 368 fuel cost provided to SR for December, 2016. Payment was made in January 2017\nSR – Overspending of EUR (-29,478) – Actual costs were higher than budgeted due to 6 months no cost extension period and covering Mobile consilium , that was not initially budgeted ( reallocation request approved on 16/06/2015).\nCommitment – EUR 3,312 - ME costs for December, 2016. Payment was made in January 2017.\n",{"$f":"(E26)+184789.516849844","v":228419.22853751428},182426.91432972593,45992.314207788353,"PR saving of EUR 32,266 – Activities performed in accordance with the workplan, but actual costs were less than budgeted, also Actual fuel cost budgeted under ME for TB center was less than budgeted. \nCommitment – EUR 368 fuel cost provided to SR for December, 2016. Payment was made in January 2017\nSR – saving of EUR 13,726 – Actual costs were less than budgeted, though all planned activities were carried out.\nCommitment – EUR 3,312 - ME costs for December, 2016. Payment was made in January 2017.\n"]
[10,"Living Support to Clients/Target Populations",null,null,338856.12,334025.07212382997,4831.0478761700215,"PR   Saving of EUR 43,570 -   Actual cost for Cash Incentives (Sensitive & MDR) was less than budgeted due to actual number of patients (slightly less than projected). Most importantly, budget was made assuming max (100%) compliance to treatment. Reimbursed period covers December 2015- November 2016. The actual savings were reduced due to no cost extension period. Also Actual fuel costs budgeted under LS for TB center was less than budgeted. \nCommitment:  EUR 17,363 – Committed payment for Cash Incentives (Sensitive & MDR) for December 2016; EUR 1,929 fuel cost provided to SR for December, 2016. Payment was made in January 2017\nSR – Overspending of EUR (-38,739) – Actual costs for LS was less than budgeted due to less patients required transportation allowence, less DOT nurses were recruited; but due to 6 months no-cost extension period costs exceeded budget. \nCommitment EUR 3,985 – LS costs for December, 2016. Payment was made in January 2017.\n",{"$f":"(E27)+1493843.22","v":1832699.3399999999},949633.69127010426,883065.64872989559,"PR   Saving of EUR 802,057 -   Actual cost of Cash incentives (Sensitive & MDR) covered period June 2014 – November 2016 and was less than budgeted. The following are the reasons for saving: Sensitive - budgeted amount was calculated for 1 year period covering 70% of all sensitive patients with 100% adherence (both installments). Actually patients enrolled in January - May, 2014 did not fit for being beneficiary of the scheme as approved scheme was enrolling patients starting June 1. MDR - budgeted amount was calculated for the entire treatment course (15 months) covering 75% of MDR patients from the 2012, 2013, 2014 cohorts, with100% adherence (all weeks on outpatient treatment).  Actually, 5 months were covered, payments started in August, there was no 100% compliance in many cases and number of patients was less than projected/budgeted. \nCommitment:  EUR 17,363 – Committed payment for Cash Incentives (Sensitive & MDR) for December 2016; EUR 1,929 fuel cost provided to SR for December, 2016. Payment was made in January 2017\nSR – Saving EUR 81,009 – Actual costs for LS was less than budgeted due to less patients required transportation allowence, less DOT nurses were recruited; \nCommitment EUR 3,985 – LS costs for December, 2016. Payment was made in January 2017.\n"]
[11,"Planning and Administration",null,null,53317.403837406266,74082.557869228986,-20765.15403182272,"PR Overspending of EUR (- 21,545) - PA costs attributed to HIV Grant during Extension period, was covered from TB grant such as Audit costs. Actual cost for GLC mission was greater than budgeted due to FX rate change and Procurement of printing of statistical forms for TB Centre (reallocation request approved on 06/02/2015) \nSR Saving of EUR 780 – Actual PA costs were less than budgeted. \n",{"$f":"(E28)+124951.359987523","v":178268.76382492925},172398.78350961616,5869.9803153130924,"PR Overspending of EUR (- 21,225) - PA costs attributed to HIV Grant during Extension period, was covered from TB grant such as Audit costs. Actual cost for GLC mission was greater than budgeted due to FX rate change and Procurement of printing of statistical forms for TB Centre (reallocation request approved on 06/02/2015); \nSaving EUR 24,756 – Actual Project management PA costs like audit service was less than budgeted.\nSR Saving of EUR 2,339 – Actual PA costs were less than budgeted. \n"]
[12,"Overheads",null,null,4239.0842080638377,4511.3446318040151,-272.26042374017743,"PR Overspending of EUR (-272) – Actual costs were less than budgeted but due to 6 months no cost extension period costs slightly exceeded budget.\nCommitment EUR 310 –fuel cost for December, 2016. Payment was made in January 2017\n",{"$f":"(E29)+14990.7883491529","v":19229.872557216739},9842.5764921895807,9387.296065027158,"PR Saving EUR 9,387– Actual costs were less than budgeted \nCommitment EUR 310 –fuel cost for December, 2016. Payment was made in January 2017\n"]
[13,"Other",null,null,0,7.3832481543831818E-3,-7.3832481543831818E-3,"N/A",{"$f":"(E30)+0","v":0},1.0484355212156515E-2,-1.0484355212156515E-2,"N/A"]
[null,null,null,"TOTAL",{"$f":"E18+E19+E20+E21+E22+E23+E24+E25+E27+E26+E28+E29+E30","v":2324385.0368528338},{"$f":"F18+F19+F21+F20+F22+F23+F24+F25+F26+F27+F28+F29+F30","v":2792099.1798363691},{"$f":"SUM(G18:G30)","v":-467714.14298353402},null,{"$f":"SUM(I18:I30)","v":11182991.918927176},{"$f":"SUM(J18:J30)","v":7518591.3444980755},{"$f":"SUM(K18:K30)","v":3664400.5744291008}]
[]
[]
["B- BREAKDOWN* BY PROGRAM ACTIVITY",null,null,null,"Current Reporting Period",null,null,null,"Cumulative Reporting Period"]
["#","Macro-category","Objectives","Service Delivery Area"," \nBudget","\nExpenditures","Variance","Reason for Variance","Cumulative Budget","Cumulative Expenditure","Variance","Reason for Variance"]
[1,"Supportive Environment","To strengthen the National TB Control Program management, coordination, monitoring and evaluation","Program Management, M&E, Capacity Building",118010.8887810669,175168.73426270066,{"$f":"E36-F36","v":-57157.845481633762},"Overspending of EUR (-57,158) - Activities performed in-line with approved work plan Additional costs occurred due to the 6 months no-cost extension period.  \nCommitments: PR – EUR 368 - fuel cost provided to SR for December, 2016. SR – EUR 11,934 M&E costs for December, 2016. Payments were made in January 2017.\n",{"$f":"(E36)+424324.897891549","v":542335.78667261591},503605.37026304239,{"$f":"I36-J36","v":38730.416409573518},"Saving EUR 38,730 - Activities performed in-line with approved work plan and actual costs were less than budgeted. Mainly fuel cost unit price was less through consolidated state procurement.\nCommitments: PR – EUR 368 - fuel cost provided to SR for December, 2016. SR – EUR 11,934 M&E costs for December, 2016. Payments were made in January 2017.\n"]
[2,"TB Detection","To improve diagnosis of TB including M/XDR-TB","Improving diagnosis",404547.20808656118,910287.66522790666,{"$f":"E37-F37","v":-505740.45714134548},"Overspending of EUR (-505,740) – All activities were performed as planned. Actual Savings, occurred due to lower procurement costs of lab supplies, available stocks and average consumption rates at SR level, was reduced by new activities implemented during the year 2016 in agreement with TGF.  The latter relates to: construction of new prefabricated TB DOT Center, Procurement of 19 GeneXpert machines and cartridges to meet the need for 2016-2017 years which was originally planned in the NFM but due to the change of the NFM launch date was moved within the extension period; In addition overspending in HPHE resulted due to the 6 months extension period PR procured additional lab supplies to cover TB centre need.\nCommitment:  PR - EUR 15,028 – MGIT test procurement (signed contract) to be paid in the year 2017 and EUR 106,307 – Commitment for the construction works of prefabricated TB DOT Centre.  SR – EUR 1,303 HR costs for December, 2016. Payments were made in January 2017.\n",{"$f":"(E37)+1242279.06033019","v":1646826.2684167512},1681604.4321566015,{"$f":"I37-J37","v":-34778.163739850279},"Overspending of EUR (-34,778) – All activities were performed as planned. Actual Savings, occurred due to lower procurement costs of lab supplies, available stocks and average consumption rates at SR level, was reduced by new activities implemented during the year 2016 in agreement with TGF.  The latter relates to: construction of new prefabricated TB DOT Center, Procurement of 19 GeneXpert machines and cartridges to meet the need for 2016-2017 years which was originally planned in the NFM but due to the change of the NFM launch date was moved within the extension period; In addition overspending in HPHE resulted due to the 6 months extension period PR procured additional lab supplies to cover TB centre need.\nCommitment:  PR - EUR 15,028 – MGIT test procurement (signed contract) to be paid in the year 2017 and EUR 106,307 – Commitment for the construction works of prefabricated TB DOT Centre.  SR – EUR 1,303 HR costs for December, 2016. Payments were made in January 2017.\n"]
[3,"TB Treatment","To ensure quality treatment of all forms of TB","Quality Treatment of all forms of TB, including M/XDR-TB",1364060.1749041299,894277.88668033166,{"$f":"E38-F38","v":469782.28822379827},"Saving of EUR 469,782 - All activities were performed in line with approved work plan. Saving in procurement of SLD include: recalculation of needs; tendency of decreasing prevalence of TB; BDQ Donation program provided the medicine free-of-charge; General tendency of decreasing cost of TB medicines through GDF; Commitment to NFM Grant in the amount of USD 428,004 will be financed from the saving. \nCommitments PR : EUR 698 – remaining Payment for the quality control of pharmaceuticals.\n",{"$f":"(E38)+5123348.78576098","v":6487408.9606651105},3555198.8115758426,{"$f":"I38-J38","v":2932210.1490892679},"Saving of EUR 2,932,210 - Net saving mainly derived from procurement of SLD and its relevant PSM costs, that include several reasons: recalculation of needs; tendency of decreasing prevalence of TB; BDQ Donation program provided the medicine free-of-charge; General tendency of decreasing cost of TB medicines through GDF; The latter saving was used to cover new activities implemented by PR in agreement with TGF, 6 months no cost extension and commitment to TB NFM grant in the amount of USD 428,004. Also procurement of Side effect drugs resulted in savings due to lower unit cost and by State budget financing. \nCommitments PR: EUR 698 – remaining Payment for the quality control of pharmaceuticals.\n"]
[4,"TB Treatment","To ensure adherence to TB treatment by intensive patient support and follow up ","Patient Support",365916.93287337595,380529.69113048428,-14612.758257108333,"Overspending EUR (-14,613) - Cash incentive scheme is functioning well. Savings occurred mainly due to budget assumptions used to project cash incentives. Actual compliance was not 100%, also number of patients was less than projected/budgeted. State budget participation (Cash incentives for 225 MDR patients) also was driver for saving. Actual Incentives paid by SR was also less than budgeted. But due to the 6 months no cost extension period actual expenses occurred greater than budgeted.\nCommitment – PR EUR 17,364 – Payment for Cash Incentives (Sensitive & MDR) for December 2016; EUR 1,929 fuel cost provided to SR for December, 2016. Payment was made in January 2017; SR – EUR 4,629 LS costs for December, 2016. Payments were made in January 2017.\n",{"$f":"(E39)+1576406.06505682","v":1942322.9979301959},1048558.9985616519,893763.99936854397,"Saving EUR 893,764 - Cash incentive scheme is functioning well. Actual cost of Cash incentives  (Sensitive & MDR) covered period June 2014 – November 2016 and was less than budgeted. The following are the reasons for saving: Sensitive - budgeted amount was calculated for 1 year period covering 70% of all sensitive patients with 100% adherence (both installments). Actually patients enrolled in January - May, 2014 did not fit for being beneficiary of the scheme as approved scheme was enrolling patients starting June 1. MDR - budgeted amount was calculated for the entire treatment course (15 months) covering 75% of MDR patients from the 2012, 2013, 2014 cohorts, with100% adherence (all weeks on outpatient treatment).  Actually, 5 months were covered, payments started in August, there was no 100% compliance in many cases and number of patients was less than projected/budgeted. \nCommitment – PR EUR 17,364 – Payment for Cash Incentives (Sensitive & MDR) for December 2016; EUR 1,929 fuel cost provided to SR for December, 2016. Payment was made in January 2017; SR – EUR 4,629 LS costs for December, 2016. Payments were made in January 2017.\n"]
[5,"Supportive Environment","Project management - PR","Supportive environment: Program management and administration",71849.832207699976,431835.20235535636,{"$f":"E40-F40","v":-359985.37014765642},"Overspending of EUR 359,985 - PR Office is fully functional. Drivers of overspending were: Project Management costs attributed to HIV Grant during Extension period, was covered from TB grant, 6 months no cost extension period and new activities implemented in agreement with TGF (transition plan, projects on country-wide advocacy, communication and social mobilization campaign using Georgian Orthodox Church and project aiming increasing the TB awareness in educational institutions (schools and universities) and seminars for media\nCommitment PR: – EUR 23,290 – cost for Transitions plan payable in January 2017; EUR 310 –fuel cost for December, 2016. Payment was made in January 2017; EUR 64,548 Payments transferred to the year 2017 for ERP system development and procurement of infrastructure equipment, to accommodate ERP system development;\n",{"$f":"(E40)+492248.073034801","v":564097.90524250094},729623.73364585964,{"$f":"I40-J40","v":-165525.8284033587},"Overspending of EUR 165,526 - PR Office is fully functional. Drivers of overspending were: Project Management costs attributed to HIV Grant during Extension period, was covered from TB grant, 6 months no cost extension period and new activities implemented in agreement with TGF (transition plan, projects on country-wide advocacy, communication and social mobilization campaign using Georgian Orthodox Church and project aiming increasing the TB awareness in educational institutions (schools and universities) and seminars for media\nCommitment PR: – EUR 23,290 – cost for Transitions plan payable in January 2017; EUR 310 –fuel cost for December, 2016. Payment was made in January 2017; EUR 64,548 Payments transferred to the year 2017 for ERP system development and procurement of infrastructure equipment, to accommodate ERP system development;\n"]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E41-F41","v":0},null,0,0,{"$f":"I41-J41","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E42-F42","v":0},null,0,0,{"$f":"I42-J42","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E45-F45","v":0},null,0,0,{"$f":"I45-J45","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E46-F46","v":0},null,0,0,{"$f":"I46-J46","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E47-F47","v":0},null,0,0,{"$f":"I47-J47","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E52-F52","v":0},null,0,0,{"$f":"I52-J52","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E53-F53","v":0},null,0,0,{"$f":"I53-J53","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E54-F54","v":0},null,0,0,{"$f":"I54-J54","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E59-F59","v":0},null,0,0,{"$f":"I59-J59","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E62-F62","v":0},null,0,0,{"$f":"I62-J62","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E63-F63","v":0},null,0,0,{"$f":"I63-J63","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E64-F64","v":0},null,0,0,{"$f":"I64-J64","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E67-F67","v":0},null,0,0,{"$f":"I67-J67","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E68-F68","v":0},null,0,0,{"$f":"I68-J68","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E69-F69","v":0},null,0,0,{"$f":"I69-J69","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E74-F74","v":0},null,0,0,{"$f":"I74-J74","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E75-F75","v":0},null,0,0,{"$f":"I75-J75","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E76-F76","v":0},null,0,0,{"$f":"I76-J76","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E79-F79","v":0},null,0,0,{"$f":"I79-J79","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E80-F80","v":0},null,0,0,{"$f":"I80-J80","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E81-F81","v":0},null,0,0,{"$f":"I81-J81","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E89-F89","v":0},null,0,0,{"$f":"I89-J89","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E90-F90","v":0},null,0,0,{"$f":"I90-J90","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E91-F91","v":0},null,0,0,{"$f":"I91-J91","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E93-F93","v":0},null,0,0,{"$f":"I93-J93","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E94-F94","v":0},null,0,0,{"$f":"I94-J94","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E95-F95","v":0},null,0,0,{"$f":"I95-J95","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E97-F97","v":0},null,0,0,{"$f":"I97-J97","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E100-F100","v":0},null,0,0,{"$f":"I100-J100","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E101-F101","v":0},null,0,0,{"$f":"I101-J101","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E102-F102","v":0},null,0,0,{"$f":"I102-J102","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E105-F105","v":0},null,0,0,{"$f":"I105-J105","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E106-F106","v":0},null,0,0,{"$f":"I106-J106","v":0}]
[null,"Please Select…",null,"please select…",0,0,{"$f":"E107-F107","v":0},null,0,0,{"$f":"I107-J107","v":0}]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
[null,"Please Select…",null,"please select…",0,0,0,null,0,0,0]
["TOTAL",null,null,null,{"$f":"SUM(E36:E110)","v":2324385.0368528333},{"$f":"SUM(F36:F110)","v":2792099.1796567799},{"$f":"SUM(G36:G110)","v":-467714.14280394575},null,{"$f":"SUM(I36:I110)","v":11182991.918927174},{"$f":"SUM(J36:J110)","v":7518591.3462029994},{"$f":"SUM(K36:K110)","v":3664400.5727241761}]
[]
[]
[]
[]
["C- BREAKDOWN* BY IMPLEMENTING ENTITY",null,null,null,"Current Reporting Period",null,null,null,"Cumulative Reporting Period"]
["#","PR/SR","Name","Type of\nImplementing Entity"," \nBudget","\nExpenditures","Variance","Reason for Variance","Cumulative Budget","Cumulative Expenditure","Variance","Reason for Variance"]
[1,"PR","National Center for Disease Control and Public Health","Other Government",2101107.5592226866,2448490.0245514293,{"$f":"E118-F118","v":-347382.46532874275},"The net variance of EUR (-347,382) is derived from the following components:\nPositive Variance EUR 622,424 includes: \nEUR 1,171 - Actual unit price of fuel turned to be less than projected/budgeted. From the programmatic point of view, activities were performed as planned, though required quantity of fuel was less, despite the 6 months no cost extension period.\nEUR 533,221- Saving in procurement of SLD include: recalculation of needs; tendency of decreasing the prevalence of TB; BDQ Donation program provided the medicine free-of-charge; General tendency of decreasing cost of TB medicines through GDF; The saving was reallocated partly for no-cost extension and partly for different new activities initiated by PR in agreement with TGF.\nEUR 42,779 – Actual PSM costs related to SLD and procurement of GeneXperts was less than budgeted.\nEUR 45,252- Actual cost for Cash Incentives (Sensitive & MDR) was less than budgeted due to actual number of patients (slightly less than projected). Most importantly, budget was made assuming max (100%) compliance to treatment. Reimbursed period covers December 2015- November 2016. The savings were reduced due to no cost extension period.\nNegative Variance EUR 969,806 includes: \nEUR 459,253 – overspending in HPHE resulted due to the 6 months extension period PR procured additional lab supplies to cover TB centre needs and launched new activities in agreement with TGF. \nEUR 4,668 – Procurement of printing of statistical forms for TB Centre (reallocation request approved on 06/02/2015) \nEUR 6,106- HR costs for cash incentive administration was higher than budgeted due to 6 months no-cost extension.\nEUR 9,585 – Actual cost for GLC mission was greater than budgeted due to FX rate change.\nEUR 131,395 – Construction of prefabricated TB DOT center was not budgeted under IE and funds were reallocated from savings, in addition procurement of mobile phones for VOT.\nEUR 358,799 - Project management actual costs were higher than budgeted due to the following reasons: 6 months no cost extension, HR costs for HIV grant compensated under TB grant (1Q2Q2016); new activities implemented in agreement to TGF such as: transition plan (reallocation request approved on 09/02/16), attending ECHO training and Estonia Study tour (reallocation request approved on 23/08/16 and 02/03/2016) ; projects on country-wide advocacy, communication and social mobilization campaign using Georgian Orthodox Church and project aiming increasing the TB awareness in educational institutions (schools and universities) and seminars for media. (Reallocation request approved on 28/02/2016).\nCommitments to be reimbursed during the 6 months close-out period from the savings under TB SSF grant are following- Total EUR 635,296  includes:\nEUR 2,297– SRs fuel costs for December, payment transferred to January 2017.\nEUR 17,364 – Committed payment for Cash Incentives (Sensitive & MDR) for December 2016; \nEUR 88,148 – Commitments for:  PR fuel cost for December 2016, payable in January 2017;  cost for Transitions plan  payable in January 2017; Payments transferred  to the year 2017  for  ERP system development and procurement of infrastructure equipment, to accommodate ERP system development; \nEUR 698 – remaining Payment for the quality control of pharmaceuticals.\nEUR 106,307 – Commitment for the construction works of prefabricated  TB DOT Centre.\nEUR 15,028 – Contract signed for MGIT Test Systems upon request of TB Centre.\nEUR 405,455 – Commitment to the TB NFM Grant in the amount of USD 428,004  \n",{"$f":"(E118)+8042499.32321101","v":10143606.882433696},6616291.882153634,{"$f":"I118-J118","v":3527315.0002800617},"The net variance of EUR 3,527,315 is derived from the following components:\nSavings – Total EUR 3,891,627 includes:  \nEUR 56,090 - Actual unit price of fuel turned to be less than projected/budgeted. From the programmatic point of view, activities were performed as planned, though required quantity of fuel was less; Fuel cost budgeted under line 4.7 (b) was cancelled due to the following factor: the adherence data is collected and monitored on a regular basis by regional coordinators with further submission to the TB Centre. Activity related to the on site monitoring of the cash incentive scheme was abolished, considering that it is being performed under the current set-up of the scheme. \nEUR 122,297 - Procurement of lab supplies and respirators (HPHE) caused saving, due to the following factors: 1. Local procurement with competitive bidding with preceding market assessment derived significantly cheaper unit costs compared to the budgeted amounts; 2. Available stock; 3. Re-calculation of average consumption rates; Resulted Savings were reduced by new activities implemented by PR in agreement with TGF and 6 months no cost extension.\nEUR 766,568- Actual cost of Cash incentives  (Sensitive & MDR) covered period June 2014 – November 2016 and was less than budgeted. The following are the reasons for saving:\nSensitive - budgeted amount was calculated for 1 year period covering 70% of all sensitive patients with 100% adherence (both installments). Actually patients enrolled in January - May, 2014 did not fit for being beneficiary of the scheme as approved scheme was enrolling patients starting June 1. \nMDR - budgeted amount was calculated for the entire treatment course (15 months) covering 75% of MDR patients from the 2012, 2013, 2014 cohorts, with100% adherence (all weeks on outpatient treatment).  Actually, 5 months were covered, payments started in August, there was no 100% compliance in many cases and number of patients was less than projected/budgeted. \nEUR 2,632,371– Net saving mainly derived from procurement of SLD, that include several reasons: recalculation of needs; tendency of decreasing prevalence of TB; BDQ Donation program provided the medicine free-of-charge; General tendency of decreasing cost of TB medicines through GDF; The latter saving was used to cover  new activities implemented by PR in agreement with TGF,  6 months no cost extension and commitment to TB NFM grant in the amount of USD 428,004. Also procurement of Side effect drugs resulted in savings due to lower unit cost and by State budget financing. \nEUR 268,492 - Actual PSM costs related to SLD and procurement of Genxperts was less than budgeted.\nEUR 45,809 – Saving in Project Management costs such as Audit cost, Fuel, supervisions occured less than budgeted, FX rate Change had also effect. \nOverspending – Total EUR 364,312 includes:  \nEUR 3,517 – Procurement of printing of statistical forms for TB Centre (reallocation request approved on 06/02/2015) ;\nEUR 131,109 – Construction of prefabricated TB DOT center was not budgeted under IE and funds were reallocated from savings, in addition procurement of mobile phones for VOT.\nEUR 17,708 – Actual cost for GLC mission was greater than budgeted due to FX rate change.\nEUR 1,830- HR costs for cash incentive administration was higher than budgeted due to 6 months no-cost extension.\nEUR 210,148 - Project management actual costs were higher than budgeted due to the following reasons: 6 months no cost extension, HR costs for HIV grant compensated under TB grant (1Q2Q2016); new activities implemented in agreement to TGF such as: transition plan (reallocation request approved on 09/02/16), attending ECHO training and Estonia Study tour (reallocation request approved on 23/08/16 and 02/03/2016) ; projects on country-wide advocacy, communication and social mobilization campaign using Georgian Orthodox Church and project aiming increasing the TB awareness in educational institutions (schools and universities) and seminars for media. (Reallocation request approved on 28/02/2016).\nCommitments to be reimbursed during the 6 months close-out period from the savings under TB SSF grant are following- Total EUR 635,296  includes:\nEUR 2,297– SRs fuel costs for December, payment transferred to January 2017.\nEUR 17,364 – Committed payment for Cash Incentives (Sensitive & MDR) for December 2016; \nEUR 88,148 – Commitments for:  PR fuel cost for December 2016, payable in January 2017;  cost for Transitions plan  payable in January 2017; Payments transferred  to the year 2017  for  ERP system development and procurement of infrastructure equipment, to accommodate ERP system development; \nEUR 698 – remaining Payment for the quality control of pharmaceuticals.\nEUR 106,307 – Commitment for the construction works of prefabricated  TB DOT Centre.\nEUR 15,028 – Contract signed for MGIT Test Systems upon request of TB Centre.\nEUR 405,455 – Commitment to the TB NFM Grant in the amount of USD 428,004  \n"]
[2,"SR","National Center for Tuberculosis and Lung Diseases","Other Government",223277.47763014823,343609.14506224322,{"$f":"E119-F119","v":-120331.66743209498},"The reporting period relates to the activities performed by the TB center for January 2016 - December 2016, but according to the contract, SR received reimbursement for December 2015 -November 2016 services (EUR 313,447 ) and advance payment (EUR 19,257). The latter was deducted from the payment made by PR in January 2017 to cover services performed in December 2016.\nDue to 6 months no cost-extension period actual expenses reimbursed by SR were higher than budgeted resulting in Net Variance of (-120,332 EUR). \nCommitments EUR 30,046- December service cost, out of which EUR 19,257 advance payment was deducted and reimbursed in January 2017.\n",{"$f":"(E119)+816107.558863334","v":1039385.0364934823},902299.45400627947,{"$f":"I119-J119","v":137085.58248720283},"The Budget relates to the activities performed by the TB Center in April 2014-December 2016.  During the cumulative period SR received payment for April 2014-Novemebr 2016 services in the amount of EUR 890,121 and advance payment with remaining balance of EUR 19,257, The latter was deducted from the payment made by PR in January 2017 to cover services performed in December 2016.  SR performed all budgeted programatic activities and faced Savings. The Major part of savings was absorbed by 6 months no cost extension. \nThe Positive variance in the amount of EUR 137,086 related to TB Center performance includes mainly unspent vehicle maintenance costs; less transportation incentives for patients; TA and ME costs were less than budgeted.\nCommitments EUR 30,046- December service cost, out of which EUR 12,178 was spent by SR in December from  advance payment.\n"]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,{"$f":"E124-F124","v":0},null,0,0,{"$f":"I124-J124","v":0}]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,{"$f":"E131-F131","v":0},null,0,0,{"$f":"I131-J131","v":0}]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,{"$f":"E134-F134","v":0},null,0,0,{"$f":"I134-J134","v":0}]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,{"$f":"E137-F137","v":0},null,0,0,{"$f":"I137-J137","v":0}]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,{"$f":"E157-F157","v":0},null,0,0,{"$f":"I157-J157","v":0}]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,"Please Select …",null,"Please Select…",0,0,0,null,0,0,0]
[null,null,null,"TOTAL",{"$f":"SUM(E118:E160)","v":2324385.0368528347},{"$f":"SUM(F118:F160)","v":2792099.1696136724},{"$f":"SUM(G118:G160)","v":-467714.13276083773},null,{"$f":"SUM(I118:I160)","v":11182991.918927178},{"$f":"SUM(J118:J160)","v":7518591.3361599138},{"$f":"SUM(K118:K160)","v":3664400.5827672645}]
[]
[]
[]
[]
["* The sum of all three breakdowns should be equal (A- Budget Line-item, B- Program Activity, C- Implementing Entity)."]
["** For the purposes of this report, the SDA Program management and administration should be included in the Supportive Environment Macro Category."]
[]
["D- ADDITIONAL INFORMATION"]
["Please disclose any relevant information concerning the information in the above tables. Refer to the Guidelines for Completing the Template if required."]
[]
[]
[]
[]
[]
[]
["E- DISBURSEMENTS BREAKDOWN BY IMPLEMENTING ENTITY",null,null,null,"Cumulative Reporting Period"]
["#","Name","Type of\nImplementing Entity","Cumulative Disbursements","Comments"]
[1,"National Center for Tuberculosis and Lung Diseases","Other Government",{"$f":"'Budget Variance_2E'!K10","v":909378.36658432567},"The actual disbursements paid to SR covers period April 2014-November 2016 and advance payment carried forward and deducted from payment made in January 2017. Diff-ce between disbursed amount by PR and EFR expenditure spent by SR amounts EUR 7,079 and represents cash balance at SR level per Bank Statement"]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"Please Select…",0]
[null,null,"TOTAL",{"$f":"SUM(D179:D205)","v":909378.36658432567}]

{"sheet":"LFA EFR_7B","index":19,"n_rows":206,"n_cols":30,"rows_kept":206,"cut":false,"hidden":false,"merged":[[169,0,169,15],[170,0,174,15],[176,4,176,15],[192,5,192,14],[168,0,168,15],[177,5,177,14],[178,5,178,14],[179,5,179,14],[180,5,180,14],[181,5,181,14],[182,5,182,14],[183,5,183,14],[184,5,184,14],[185,5,185,14],[186,5,186,14],[187,5,187,14],[115,4,115,10],[115,11,115,15],[27,1,27,3],[28,1,28,3],[29,1,29,3],[30,0,30,2],[33,4,33,10],[161,0,163,4],[26,1,26,3],[21,1,21,3],[21,19,21,20],[21,24,21,25],[22,1,22,3],[22,19,22,20],[22,24,22,25],[23,1,23,3],[23,19,23,20],[23,24,23,25],[24,1,24,3],[25,1,25,3],[33,11,33,15],[110,0,110,3],[111,0,113,4],[18,1,18,3],[18,19,18,20],[18,24,18,25],[19,1,19,3],[20,1,20,3],[20,19,20,20],[20,24,20,25],[16,1,16,2],[16,19,16,20],[16,24,16,25],[17,1,17,3],[17,19,17,20],[17,24,17,25],[8,11,9,11],[12,4,14,10],[15,4,15,10],[15,11,15,15],[15,24,15,25],[15,19,15,20],[8,0,8,1],[0,0,0,6],[3,0,3,1],[3,2,3,3],[3,6,4,10],[4,0,4,1],[4,2,4,3],[5,0,5,1],[5,2,5,3],[6,0,6,1],[6,2,6,3],[7,0,7,1],[7,2,7,3],[8,6,9,6],[188,5,188,14],[190,5,190,14],[189,5,189,14],[191,5,191,14],[193,5,193,14],[194,5,194,14],[195,5,195,14],[196,5,196,14],[197,5,197,14],[203,5,203,14],[204,5,204,14],[198,5,198,14],[199,5,199,14],[200,5,200,14],[201,5,201,14],[202,5,202,14]]}
["Ongoing Progress Update and Disbursement Request"]
["Section 7B: LFA - Enhanced Financial Reporting"]
[]
["Country",null,{"$f":"CoverSheet!D5","v":"Georgia"},null,null,null,"PLEASE REFER TO THE \"GUIDANCE FOR COMPLETION OF THE ENHANCED FINANCIAL REPORTING TEMPLATE\" DOCUMENT TO ASSIST YOU IN COMPLETING THE TEMPLATE"]
["Grant No.",null,{"$f":"CoverSheet!D7","v":"GEO-T-NCDC"}]
["PR",null,{"$f":"CoverSheet!D8","v":"NCDC"},null,null,null,"TO BE COMPLETED ONLY ONCE A YEAR "]
["Currency",null,{"$f":"CoverSheet!D11","v":"EUR"}]
["Disease(Component)",null,{"$f":"CoverSheet!D6","v":"Tuberculosis"},null,null,null,null,null,"dd-mm-yyyy",null,null,null,null,"dd-mm-yyyy"]
[null,null,null,null,null,null,"Current Reporting Period","Start Date:",null,null,null,"Cumulative Reporting Period","Start Date:"]
[null,null,null,null,null,null,null,"End Date:",null,null,null,null,"End Date:"]
[null,null,null,null,null,null,null,null,null,null,"The end date for the current reporting period and cumulative reporting period must be the same"]
[null,null,{"$f":"CONCATENATE(\"EFR\",SUBSTITUTE(SUBSTITUTE(C8,\"/\",\"\"),\" \",\"\"))","v":"EFRTuberculosis"}]
[null,null,{"$f":"CONCATENATE(\"SDA\",SUBSTITUTE(SUBSTITUTE(C8,\"/\",\"\"),\" \",\"\"))","v":"SDATuberculosis"},null,"The \"TOTAL\" rows in Table A, B and C will have a RED background if the amounts in each table do not agree. If the Totals for each Table agrees, these rows will have a YELLOW background. "]
[]
[]
["A- BREAKDOWN* BY  EXPENDITURE CATEGORY",null,null,null,"Current Reporting Period",null,null,null,null,null,null,"Cumulative Reporting Period",null,null,null,null,null,null,null,{"$f":"IF('[3]PR_Programmatic Progress_1A'!R15=\"Select\",\"Please select currency on Page\n 'PR_Programmatic Achievement (1)'\", \"All amounts are in: \"&'[3]PR_Programmatic Progress_1A'!R15)","v":"All amounts are in: "},null,"Budget for Reporting Period","Actual Cash Outflow for Reporting Period","Variance","Reason for Variance",null,"Cumulative Budget through period of Progress Update","Cumulative Actual Cash Outflow through period of Progress Update","Variance","Reason for Variance"]
["#","Category",null,null," \nBudget for Reporting Period","LFA Adjustment on Budget","\nActual Expenditure","LFA Adjustment on Actual Expenditure","Budget v/s Actuals Variance","Absorption Capacity","LFA comments on the Principal Recipient's explanation of variances","Cumulative Budget","Cumulative Expenditure","Cumulative Budget v/s Variance","Absorption Capacity","LFA comments on the Principal Recipient's explanation of variances",null,null,null,"1. Total PR cash outflow vs. budget",null,{"$f":"V18+V19","v":0},{"$f":"W18+W19","v":0},{"$f":"IF(V17=\"\",IF(W17=\"\",\"\",V17-W17),V17-W17)","v":0},null,null,{"$f":"AA18+AA19","v":0},{"$f":"AB18+AB19","v":0},{"$f":"IF(AA17=\"\",IF(AB17=\"\",\"\",AA17-AB17),AA17-AB17)","v":0}]
[1,"Human Resources",null,null,{"$f":"'PR EFR_7A'!E18","v":135454.14007096039},0,{"$f":"'PR EFR_7A'!F18","v":336623.29575276905},0,{"$f":"(E18+F18)-(G18+H18)","v":-201169.15568180865},{"$f":"IF(AND((E18+F18)=0,(G18+H18)=0),\"N/A\",IF(AND((E18+F18)=0,(G18+H18)<>0),\"Not Budgeted\",(G18+H18)/(E18+F18)))","v":2.4851458624773088},null,{"$f":"E18+F18","v":135454.14007096039},{"$f":"G18+H18","v":336623.29575276905},{"$f":"L18-M18","v":-201169.15568180865},{"$f":"IF(AND(L18=0,M18=0),\"N/A\",IF(AND(L18=0,M18<>0),\"Not Budgeted\",M18/L18))","v":2.4851458624773088},null,null,null,null,"    1a. PR's total expenditures",null,{"$f":"'[3]PR_Total PR Cash Outflow_3A'!C13","v":0},{"$f":"'[3]PR_Total PR Cash Outflow_3A'!D13","v":0},{"$f":"IF(V18=\"\",IF(W18=\"\",0,V18-W18),V18-W18)","v":0},null,null,{"$f":"'[3]PR_Total PR Cash Outflow_3A'!H13","v":0},{"$f":"'[3]PR_Total PR Cash Outflow_3A'!I13","v":0},{"$f":"IF(AA18=\"\",IF(AB18=\"\",0,AA18-AB18),AA18-AB18)","v":0}]
[2,"Technical Assistance",null,null,{"$f":"'PR EFR_7A'!E19","v":13420},0,{"$f":"'PR EFR_7A'!F19","v":134674.38309510172},0,{"$f":"(E19+F19)-(G19+H19)","v":-121254.38309510172},{"$f":"IF(AND((E19+F19)=0,(G19+H19)=0),\"N/A\",IF(AND((E19+F19)=0,(G19+H19)<>0),\"Not Budgeted\",(G19+H19)/(E19+F19)))","v":10.03534896386749},null,{"$f":"E19+F19","v":13420},{"$f":"G19+H19","v":134674.38309510172},{"$f":"L19-M19","v":-121254.38309510172},{"$f":"IF(AND(L19=0,M19=0),\"N/A\",IF(AND(L19=0,M19<>0),\"Not Budgeted\",M19/L19))","v":10.03534896386749},null,null,null,null,"    1b. Disbursements to sub-recipients",null,{"$f":"'[3]PR_Total PR Cash Outflow_3A'!C14","v":0},{"$f":"'[3]PR_Total PR Cash Outflow_3A'!D14","v":0},{"$f":"IF(V19=\"\",IF(W19=\"\",0,V19-W19),V19-W19)","v":0},null,null,{"$f":"'[3]PR_Total PR Cash Outflow_3A'!H14","v":0},{"$f":"'[3]PR_Total PR Cash Outflow_3A'!I14","v":0},{"$f":"IF(AA19=\"\",IF(AB19=\"\",0,AA19-AB19),AA19-AB19)","v":0}]
[3,"Training",null,null,{"$f":"'PR EFR_7A'!E20","v":3000},0,{"$f":"'PR EFR_7A'!F20","v":40894.170165158233},0,-37894.170165158233,13.631390055052744,null,{"$f":"E20+F20","v":3000},{"$f":"G20+H20","v":40894.170165158233},-37894.170165158233,13.631390055052744]
[4,"Health Products and Health Equipment",null,null,{"$f":"'PR EFR_7A'!E21","v":447048.89307732024},0,{"$f":"'PR EFR_7A'!F21","v":906301.40601168922},0,-459252.51293436898,2.0272981771032774,null,447048.89307732024,906301.40601168922,-459252.51293436898,2.0272981771032774,null,null,null,null,null,null,"Budget for Reporting Period*","Actual Cash Outflow for Reporting Period","Variance","Reason for Variance",null,"Cumulative Budget through period of Progress Update","Cumulative Actual Cash Outflow through period of Progress Update","Variance","Reason for Variance"]
[5,"Medicines and Pharmaceutical Products",null,null,{"$f":"'PR EFR_7A'!E22","v":1151470.3529311728},0,{"$f":"'PR EFR_7A'!F22","v":618248.93913535285},0,533221.41379581997,0.53692128291583341,null,1151470.3529311728,618248.93913535285,533221.41379581997,0.53692128291583341,null,null,null,null,"2. Total pharmaceutical & health product expenditures vs. budget",null,{"$f":"V23+V24","v":0},{"$f":"W23+W24","v":0},{"$f":"IF(V22=\"\",IF(W22=\"\",\"\",V22-W22),V22-W22)","v":0},null,null,{"$f":"AA23+AA24","v":0},{"$f":"AB23+AB24","v":0},{"$f":"IF(AA22=\"\",IF(AB22=\"\",\"\",AA22-AB22),AA22-AB22)","v":0}]
[6,"Procurement and Supply Management Costs",null,null,{"$f":"'PR EFR_7A'!E23","v":126085.14813311728},0,{"$f":"'PR EFR_7A'!F23","v":83306.395973095248},0,42778.752160022035,0.66071537533621816,null,126085.14813311728,83306.395973095248,42778.752160022035,0.66071537533621816,null,null,null,null,"    2a.  Medicines and pharmaceutical products",null,{"$f":"'[3]PR_Total PR Cash Outflow_3A'!C18","v":0},{"$f":"'[3]PR_Total PR Cash Outflow_3A'!D18","v":0},{"$f":"IF(V23=\"\",IF(W23=\"\",0,V23-W23),V23-W23)","v":0},null,null,{"$f":"'[3]PR_Total PR Cash Outflow_3A'!H18","v":0},{"$f":"'[3]PR_Total PR Cash Outflow_3A'!I18","v":0},{"$f":"IF(AA23=\"\",IF(AB23=\"\",0,AA23-AB23),AA23-AB23)","v":0}]
[7,"Infrastructure and Other Equipment",null,null,{"$f":"'PR EFR_7A'!E24","v":7864.1829071233315},0,{"$f":"'PR EFR_7A'!F24","v":191331.93945546373},0,-183467.7565483404,24.329538327771644,null,7864.1829071233315,191331.93945546373,-183467.7565483404,24.329538327771644,null,null,null,null,"    2b.  Health products and health equipment",null,{"$f":"'[3]PR_Total PR Cash Outflow_3A'!C19","v":0},{"$f":"'[3]PR_Total PR Cash Outflow_3A'!D19","v":0},{"$f":"IF(V24=\"\",IF(W24=\"\",0,V24-W24),V24-W24)","v":0},null,null,{"$f":"'[3]PR_Total PR Cash Outflow_3A'!H19","v":0},{"$f":"'[3]PR_Total PR Cash Outflow_3A'!I19","v":0},{"$f":"IF(AA24=\"\",IF(AB24=\"\",0,AA24-AB24),AA24-AB24)","v":0}]
[8,"Communication Materials",null,null,{"$f":"'PR EFR_7A'!E25","v":0},0,{"$f":"'PR EFR_7A'!F25","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[9,"Monitoring & Evaluation",null,null,{"$f":"'PR EFR_7A'!E26","v":43629.711687670308},0,{"$f":"'PR EFR_7A'!F26","v":68099.668239627354},0,-24469.956551957046,1.5608553347115566,null,43629.711687670308,68099.668239627354,-24469.956551957046,1.5608553347115566]
[10,"Living Support to Clients/Target Populations",null,null,{"$f":"'PR EFR_7A'!E27","v":338856.12},0,{"$f":"'PR EFR_7A'!F27","v":334025.07212382997},0,4831.0478761700215,0.98574307031500563,null,338856.12,334025.07212382997,4831.0478761700215,0.98574307031500563]
[11,"Planning and Administration",null,null,{"$f":"'PR EFR_7A'!E28","v":53317.403837406266},0,{"$f":"'PR EFR_7A'!F28","v":74082.557869228986},0,-20765.15403182272,1.3894629621342209,null,53317.403837406266,74082.557869228986,-20765.15403182272,1.3894629621342209]
[12,"Overheads",null,null,{"$f":"'PR EFR_7A'!E29","v":4239.0842080638377},0,{"$f":"'PR EFR_7A'!F29","v":4511.3446318040151},0,-272.26042374017743,1.0642262362286334,null,4239.0842080638377,4511.3446318040151,-272.26042374017743,1.0642262362286334]
[13,"Other",null,null,{"$f":"'PR EFR_7A'!E30","v":0},0,{"$f":"'PR EFR_7A'!F30","v":7.3832481543831818E-3},0,-7.3832481543831818E-3,"Not Budgeted",null,0,7.3832481543831818E-3,-7.3832481543831818E-3,"Not Budgeted"]
[null,null,null,"TOTAL",{"$f":"SUM(E18:E30)","v":2324385.0368528343},{"$f":"SUM(F18:F30)","v":0},{"$f":"SUM(G18:G30)","v":2792099.1798363691},{"$f":"SUM(H18:H30)","v":0},{"$f":"SUM(I18:I30)","v":-467714.14298353402},{"$f":"G31/E31","v":1.2012205962299642},null,{"$f":"SUM(L18:L30)","v":2324385.0368528343},{"$f":"SUM(M18:M30)","v":2792099.1798363691},-467714.14298353402,{"$f":"M31/L31","v":1.2012205962299642}]
[]
[]
["B- BREAKDOWN* BY PROGRAM ACTIVITY",null,null,null,"Current Reporting Period",null,null,null,null,null,null,"Cumulative Reporting Period"]
["#","Macro-category","Objectives","Service Delivery Area"," \nBudget for Reporting Period","LFA Adjustment on Budget","\nActual Expenditure","LFA Adjustment on Actual Expenditure","Budget v/s Actuals Variance","Absorption Capacity","LFA comments on the Principal Recipient's explanation of variances","Cumulative Budget","Cumulative Expenditure","Variance","Absorption Capacity","LFA comments on the Principal Recipient's explanation of variances"]
[{"$f":"'PR EFR_7A'!A36","v":1},{"$f":"'PR EFR_7A'!B36","v":"Supportive Environment"},{"$f":"'PR EFR_7A'!C36","v":"To strengthen the National TB Control Program management, coordination, monitoring and evaluation"},{"$f":"'PR EFR_7A'!D36","v":"Program Management, M&E, Capacity Building"},{"$f":"'PR EFR_7A'!E36","v":118010.8887810669},0,{"$f":"'PR EFR_7A'!F36","v":175168.73426270066},0,{"$f":"(E36+F36)-(G36+H36)","v":-57157.845481633762},{"$f":"IF(AND((E36+F36)=0,(G36+H36)=0),\"N/A\",IF(AND((E36+F36)=0,(G36+H36)<>0),\"Not Budgeted\",(G36+H36)/(E36+F36)))","v":1.4843438268452724},null,{"$f":"E36+F36","v":118010.8887810669},{"$f":"G36+H36","v":175168.73426270066},{"$f":"L36-M36","v":-57157.845481633762},{"$f":"IF(AND(L36=0,M36=0),\"N/A\",IF(AND(L36=0,M36<>0),\"Not Budgeted\",M36/L36))","v":1.4843438268452724}]
[{"$f":"'PR EFR_7A'!A37","v":2},{"$f":"'PR EFR_7A'!B37","v":"TB Detection"},{"$f":"'PR EFR_7A'!C37","v":"To improve diagnosis of TB including M/XDR-TB"},{"$f":"'PR EFR_7A'!D37","v":"Improving diagnosis"},{"$f":"'PR EFR_7A'!E37","v":404547.20808656118},0,{"$f":"'PR EFR_7A'!F37","v":910287.66522790666},0,-505740.45714134548,2.2501395313872292,null,404547.20808656118,{"$f":"G37+H37","v":910287.66522790666},{"$f":"L37-M37","v":-505740.45714134548},2.2501395313872292]
[{"$f":"'PR EFR_7A'!A38","v":3},{"$f":"'PR EFR_7A'!B38","v":"TB Treatment"},{"$f":"'PR EFR_7A'!C38","v":"To ensure quality treatment of all forms of TB"},{"$f":"'PR EFR_7A'!D38","v":"Quality Treatment of all forms of TB, including M/XDR-TB"},{"$f":"'PR EFR_7A'!E38","v":1364060.1749041299},0,{"$f":"'PR EFR_7A'!F38","v":894277.88668033166},0,469782.28822379827,0.65560002640146287,null,1364060.1749041299,{"$f":"G38+H38","v":894277.88668033166},469782.28822379827,0.65560002640146287]
[{"$f":"'PR EFR_7A'!A39","v":4},{"$f":"'PR EFR_7A'!B39","v":"TB Treatment"},{"$f":"'PR EFR_7A'!C39","v":"To ensure adherence to TB treatment by intensive patient support and follow up "},{"$f":"'PR EFR_7A'!D39","v":"Patient Support"},{"$f":"'PR EFR_7A'!E39","v":365916.93287337595},0,{"$f":"'PR EFR_7A'!F39","v":380529.69113048428},0,-14612.758257108333,1.0399346325472318,null,365916.93287337595,380529.69113048428,-14612.758257108333,1.0399346325472318]
[{"$f":"'PR EFR_7A'!A40","v":5},{"$f":"'PR EFR_7A'!B40","v":"Supportive Environment"},{"$f":"'PR EFR_7A'!C40","v":"Project management - PR"},{"$f":"'PR EFR_7A'!D40","v":"Supportive environment: Program management and administration"},{"$f":"'PR EFR_7A'!E40","v":71849.832207699976},0,{"$f":"'PR EFR_7A'!F40","v":431835.20235535636},0,-359985.37014765642,6.0102464972642986,null,71849.832207699976,431835.20235535636,-359985.37014765642,6.0102464972642986]
[{"$f":"'PR EFR_7A'!A41","v":0},{"$f":"'PR EFR_7A'!B41","v":"Please Select…"},{"$f":"'PR EFR_7A'!C41","v":0},{"$f":"'PR EFR_7A'!D41","v":"please select…"},{"$f":"'PR EFR_7A'!E41","v":0},0,{"$f":"'PR EFR_7A'!F41","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A42","v":0},{"$f":"'PR EFR_7A'!B42","v":"Please Select…"},{"$f":"'PR EFR_7A'!C42","v":0},{"$f":"'PR EFR_7A'!D42","v":"please select…"},{"$f":"'PR EFR_7A'!E42","v":0},0,{"$f":"'PR EFR_7A'!F42","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A43","v":0},{"$f":"'PR EFR_7A'!B43","v":"Please Select…"},{"$f":"'PR EFR_7A'!C43","v":0},{"$f":"'PR EFR_7A'!D43","v":"please select…"},{"$f":"'PR EFR_7A'!E43","v":0},0,{"$f":"'PR EFR_7A'!F43","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A44","v":0},{"$f":"'PR EFR_7A'!B44","v":"Please Select…"},{"$f":"'PR EFR_7A'!C44","v":0},{"$f":"'PR EFR_7A'!D44","v":"please select…"},{"$f":"'PR EFR_7A'!E44","v":0},0,{"$f":"'PR EFR_7A'!F44","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A45","v":0},{"$f":"'PR EFR_7A'!B45","v":"Please Select…"},{"$f":"'PR EFR_7A'!C45","v":0},{"$f":"'PR EFR_7A'!D45","v":"please select…"},{"$f":"'PR EFR_7A'!E45","v":0},0,{"$f":"'PR EFR_7A'!F45","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A46","v":0},{"$f":"'PR EFR_7A'!B46","v":"Please Select…"},{"$f":"'PR EFR_7A'!C46","v":0},{"$f":"'PR EFR_7A'!D46","v":"please select…"},{"$f":"'PR EFR_7A'!E46","v":0},0,{"$f":"'PR EFR_7A'!F46","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A47","v":0},{"$f":"'PR EFR_7A'!B47","v":"Please Select…"},{"$f":"'PR EFR_7A'!C47","v":0},{"$f":"'PR EFR_7A'!D47","v":"please select…"},{"$f":"'PR EFR_7A'!E47","v":0},0,{"$f":"'PR EFR_7A'!F47","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A48","v":0},{"$f":"'PR EFR_7A'!B48","v":"Please Select…"},{"$f":"'PR EFR_7A'!C48","v":0},{"$f":"'PR EFR_7A'!D48","v":"please select…"},{"$f":"'PR EFR_7A'!E48","v":0},0,{"$f":"'PR EFR_7A'!F48","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A49","v":0},{"$f":"'PR EFR_7A'!B49","v":"Please Select…"},{"$f":"'PR EFR_7A'!C49","v":0},{"$f":"'PR EFR_7A'!D49","v":"please select…"},{"$f":"'PR EFR_7A'!E49","v":0},0,{"$f":"'PR EFR_7A'!F49","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A50","v":0},{"$f":"'PR EFR_7A'!B50","v":"Please Select…"},{"$f":"'PR EFR_7A'!C50","v":0},{"$f":"'PR EFR_7A'!D50","v":"please select…"},{"$f":"'PR EFR_7A'!E50","v":0},0,{"$f":"'PR EFR_7A'!F50","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A51","v":0},{"$f":"'PR EFR_7A'!B51","v":"Please Select…"},{"$f":"'PR EFR_7A'!C51","v":0},{"$f":"'PR EFR_7A'!D51","v":"please select…"},{"$f":"'PR EFR_7A'!E51","v":0},0,{"$f":"'PR EFR_7A'!F51","v":0},0,0,"N/A",null,0,0,{"$f":"L51-M51","v":0},"N/A"]
[{"$f":"'PR EFR_7A'!A52","v":0},{"$f":"'PR EFR_7A'!B52","v":"Please Select…"},{"$f":"'PR EFR_7A'!C52","v":0},{"$f":"'PR EFR_7A'!D52","v":"please select…"},{"$f":"'PR EFR_7A'!E52","v":0},0,{"$f":"'PR EFR_7A'!F52","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A53","v":0},{"$f":"'PR EFR_7A'!B53","v":"Please Select…"},{"$f":"'PR EFR_7A'!C53","v":0},{"$f":"'PR EFR_7A'!D53","v":"please select…"},{"$f":"'PR EFR_7A'!E53","v":0},0,{"$f":"'PR EFR_7A'!F53","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A54","v":0},{"$f":"'PR EFR_7A'!B54","v":"Please Select…"},{"$f":"'PR EFR_7A'!C54","v":0},{"$f":"'PR EFR_7A'!D54","v":"please select…"},{"$f":"'PR EFR_7A'!E54","v":0},0,{"$f":"'PR EFR_7A'!F54","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A55","v":0},{"$f":"'PR EFR_7A'!B55","v":"Please Select…"},{"$f":"'PR EFR_7A'!C55","v":0},{"$f":"'PR EFR_7A'!D55","v":"please select…"},{"$f":"'PR EFR_7A'!E55","v":0},0,{"$f":"'PR EFR_7A'!F55","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A56","v":0},{"$f":"'PR EFR_7A'!B56","v":"Please Select…"},{"$f":"'PR EFR_7A'!C56","v":0},{"$f":"'PR EFR_7A'!D56","v":"please select…"},{"$f":"'PR EFR_7A'!E56","v":0},0,{"$f":"'PR EFR_7A'!F56","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A57","v":0},{"$f":"'PR EFR_7A'!B57","v":"Please Select…"},{"$f":"'PR EFR_7A'!C57","v":0},{"$f":"'PR EFR_7A'!D57","v":"please select…"},{"$f":"'PR EFR_7A'!E57","v":0},0,{"$f":"'PR EFR_7A'!F57","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A58","v":0},{"$f":"'PR EFR_7A'!B58","v":"Please Select…"},{"$f":"'PR EFR_7A'!C58","v":0},{"$f":"'PR EFR_7A'!D58","v":"please select…"},{"$f":"'PR EFR_7A'!E58","v":0},0,{"$f":"'PR EFR_7A'!F58","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A59","v":0},{"$f":"'PR EFR_7A'!B59","v":"Please Select…"},{"$f":"'PR EFR_7A'!C59","v":0},{"$f":"'PR EFR_7A'!D59","v":"please select…"},{"$f":"'PR EFR_7A'!E59","v":0},0,{"$f":"'PR EFR_7A'!F59","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A60","v":0},{"$f":"'PR EFR_7A'!B60","v":"Please Select…"},{"$f":"'PR EFR_7A'!C60","v":0},{"$f":"'PR EFR_7A'!D60","v":"please select…"},{"$f":"'PR EFR_7A'!E60","v":0},0,{"$f":"'PR EFR_7A'!F60","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A61","v":0},{"$f":"'PR EFR_7A'!B61","v":"Please Select…"},{"$f":"'PR EFR_7A'!C61","v":0},{"$f":"'PR EFR_7A'!D61","v":"please select…"},{"$f":"'PR EFR_7A'!E61","v":0},0,{"$f":"'PR EFR_7A'!F61","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A62","v":0},{"$f":"'PR EFR_7A'!B62","v":"Please Select…"},{"$f":"'PR EFR_7A'!C62","v":0},{"$f":"'PR EFR_7A'!D62","v":"please select…"},{"$f":"'PR EFR_7A'!E62","v":0},0,{"$f":"'PR EFR_7A'!F62","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A63","v":0},{"$f":"'PR EFR_7A'!B63","v":"Please Select…"},{"$f":"'PR EFR_7A'!C63","v":0},{"$f":"'PR EFR_7A'!D63","v":"please select…"},{"$f":"'PR EFR_7A'!E63","v":0},0,{"$f":"'PR EFR_7A'!F63","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A64","v":0},{"$f":"'PR EFR_7A'!B64","v":"Please Select…"},{"$f":"'PR EFR_7A'!C64","v":0},{"$f":"'PR EFR_7A'!D64","v":"please select…"},{"$f":"'PR EFR_7A'!E64","v":0},0,{"$f":"'PR EFR_7A'!F64","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A65","v":0},{"$f":"'PR EFR_7A'!B65","v":"Please Select…"},{"$f":"'PR EFR_7A'!C65","v":0},{"$f":"'PR EFR_7A'!D65","v":"please select…"},{"$f":"'PR EFR_7A'!E65","v":0},0,{"$f":"'PR EFR_7A'!F65","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A66","v":0},{"$f":"'PR EFR_7A'!B66","v":"Please Select…"},{"$f":"'PR EFR_7A'!C66","v":0},{"$f":"'PR EFR_7A'!D66","v":"please select…"},{"$f":"'PR EFR_7A'!E66","v":0},0,{"$f":"'PR EFR_7A'!F66","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A67","v":0},{"$f":"'PR EFR_7A'!B67","v":"Please Select…"},{"$f":"'PR EFR_7A'!C67","v":0},{"$f":"'PR EFR_7A'!D67","v":"please select…"},{"$f":"'PR EFR_7A'!E67","v":0},0,{"$f":"'PR EFR_7A'!F67","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A68","v":0},{"$f":"'PR EFR_7A'!B68","v":"Please Select…"},{"$f":"'PR EFR_7A'!C68","v":0},{"$f":"'PR EFR_7A'!D68","v":"please select…"},{"$f":"'PR EFR_7A'!E68","v":0},0,{"$f":"'PR EFR_7A'!F68","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A69","v":0},{"$f":"'PR EFR_7A'!B69","v":"Please Select…"},{"$f":"'PR EFR_7A'!C69","v":0},{"$f":"'PR EFR_7A'!D69","v":"please select…"},{"$f":"'PR EFR_7A'!E69","v":0},0,{"$f":"'PR EFR_7A'!F69","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A70","v":0},{"$f":"'PR EFR_7A'!B70","v":"Please Select…"},{"$f":"'PR EFR_7A'!C70","v":0},{"$f":"'PR EFR_7A'!D70","v":"please select…"},{"$f":"'PR EFR_7A'!E70","v":0},0,{"$f":"'PR EFR_7A'!F70","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A71","v":0},{"$f":"'PR EFR_7A'!B71","v":"Please Select…"},{"$f":"'PR EFR_7A'!C71","v":0},{"$f":"'PR EFR_7A'!D71","v":"please select…"},{"$f":"'PR EFR_7A'!E71","v":0},0,{"$f":"'PR EFR_7A'!F71","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A72","v":0},{"$f":"'PR EFR_7A'!B72","v":"Please Select…"},{"$f":"'PR EFR_7A'!C72","v":0},{"$f":"'PR EFR_7A'!D72","v":"please select…"},{"$f":"'PR EFR_7A'!E72","v":0},0,{"$f":"'PR EFR_7A'!F72","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A73","v":0},{"$f":"'PR EFR_7A'!B73","v":"Please Select…"},{"$f":"'PR EFR_7A'!C73","v":0},{"$f":"'PR EFR_7A'!D73","v":"please select…"},{"$f":"'PR EFR_7A'!E73","v":0},0,{"$f":"'PR EFR_7A'!F73","v":0},0,0,"N/A",null,0,0,{"$f":"L73-M73","v":0},"N/A"]
[{"$f":"'PR EFR_7A'!A74","v":0},{"$f":"'PR EFR_7A'!B74","v":"Please Select…"},{"$f":"'PR EFR_7A'!C74","v":0},{"$f":"'PR EFR_7A'!D74","v":"please select…"},{"$f":"'PR EFR_7A'!E74","v":0},0,{"$f":"'PR EFR_7A'!F74","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A75","v":0},{"$f":"'PR EFR_7A'!B75","v":"Please Select…"},{"$f":"'PR EFR_7A'!C75","v":0},{"$f":"'PR EFR_7A'!D75","v":"please select…"},{"$f":"'PR EFR_7A'!E75","v":0},0,{"$f":"'PR EFR_7A'!F75","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A76","v":0},{"$f":"'PR EFR_7A'!B76","v":"Please Select…"},{"$f":"'PR EFR_7A'!C76","v":0},{"$f":"'PR EFR_7A'!D76","v":"please select…"},{"$f":"'PR EFR_7A'!E76","v":0},0,{"$f":"'PR EFR_7A'!F76","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A77","v":0},{"$f":"'PR EFR_7A'!B77","v":"Please Select…"},{"$f":"'PR EFR_7A'!C77","v":0},{"$f":"'PR EFR_7A'!D77","v":"please select…"},{"$f":"'PR EFR_7A'!E77","v":0},0,{"$f":"'PR EFR_7A'!F77","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A78","v":0},{"$f":"'PR EFR_7A'!B78","v":"Please Select…"},{"$f":"'PR EFR_7A'!C78","v":0},{"$f":"'PR EFR_7A'!D78","v":"please select…"},{"$f":"'PR EFR_7A'!E78","v":0},0,{"$f":"'PR EFR_7A'!F78","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A79","v":0},{"$f":"'PR EFR_7A'!B79","v":"Please Select…"},{"$f":"'PR EFR_7A'!C79","v":0},{"$f":"'PR EFR_7A'!D79","v":"please select…"},{"$f":"'PR EFR_7A'!E79","v":0},0,{"$f":"'PR EFR_7A'!F79","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A80","v":0},{"$f":"'PR EFR_7A'!B80","v":"Please Select…"},{"$f":"'PR EFR_7A'!C80","v":0},{"$f":"'PR EFR_7A'!D80","v":"please select…"},{"$f":"'PR EFR_7A'!E80","v":0},0,{"$f":"'PR EFR_7A'!F80","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A81","v":0},{"$f":"'PR EFR_7A'!B81","v":"Please Select…"},{"$f":"'PR EFR_7A'!C81","v":0},{"$f":"'PR EFR_7A'!D81","v":"please select…"},{"$f":"'PR EFR_7A'!E81","v":0},0,{"$f":"'PR EFR_7A'!F81","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A82","v":0},{"$f":"'PR EFR_7A'!B82","v":"Please Select…"},{"$f":"'PR EFR_7A'!C82","v":0},{"$f":"'PR EFR_7A'!D82","v":"please select…"},{"$f":"'PR EFR_7A'!E82","v":0},0,{"$f":"'PR EFR_7A'!F82","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A83","v":0},{"$f":"'PR EFR_7A'!B83","v":"Please Select…"},{"$f":"'PR EFR_7A'!C83","v":0},{"$f":"'PR EFR_7A'!D83","v":"please select…"},{"$f":"'PR EFR_7A'!E83","v":0},0,{"$f":"'PR EFR_7A'!F83","v":0},0,0,"N/A",null,0,0,{"$f":"L83-M83","v":0},"N/A"]
[{"$f":"'PR EFR_7A'!A84","v":0},{"$f":"'PR EFR_7A'!B84","v":"Please Select…"},{"$f":"'PR EFR_7A'!C84","v":0},{"$f":"'PR EFR_7A'!D84","v":"please select…"},{"$f":"'PR EFR_7A'!E84","v":0},0,{"$f":"'PR EFR_7A'!F84","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A85","v":0},{"$f":"'PR EFR_7A'!B85","v":"Please Select…"},{"$f":"'PR EFR_7A'!C85","v":0},{"$f":"'PR EFR_7A'!D85","v":"please select…"},{"$f":"'PR EFR_7A'!E85","v":0},0,{"$f":"'PR EFR_7A'!F85","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A86","v":0},{"$f":"'PR EFR_7A'!B86","v":"Please Select…"},{"$f":"'PR EFR_7A'!C86","v":0},{"$f":"'PR EFR_7A'!D86","v":"please select…"},{"$f":"'PR EFR_7A'!E86","v":0},0,{"$f":"'PR EFR_7A'!F86","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A87","v":0},{"$f":"'PR EFR_7A'!B87","v":"Please Select…"},{"$f":"'PR EFR_7A'!C87","v":0},{"$f":"'PR EFR_7A'!D87","v":"please select…"},{"$f":"'PR EFR_7A'!E87","v":0},0,{"$f":"'PR EFR_7A'!F87","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A88","v":0},{"$f":"'PR EFR_7A'!B88","v":"Please Select…"},{"$f":"'PR EFR_7A'!C88","v":0},{"$f":"'PR EFR_7A'!D88","v":"please select…"},{"$f":"'PR EFR_7A'!E88","v":0},0,{"$f":"'PR EFR_7A'!F88","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A89","v":0},{"$f":"'PR EFR_7A'!B89","v":"Please Select…"},{"$f":"'PR EFR_7A'!C89","v":0},{"$f":"'PR EFR_7A'!D89","v":"please select…"},{"$f":"'PR EFR_7A'!E89","v":0},0,{"$f":"'PR EFR_7A'!F89","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A90","v":0},{"$f":"'PR EFR_7A'!B90","v":"Please Select…"},{"$f":"'PR EFR_7A'!C90","v":0},{"$f":"'PR EFR_7A'!D90","v":"please select…"},{"$f":"'PR EFR_7A'!E90","v":0},0,{"$f":"'PR EFR_7A'!F90","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A91","v":0},{"$f":"'PR EFR_7A'!B91","v":"Please Select…"},{"$f":"'PR EFR_7A'!C91","v":0},{"$f":"'PR EFR_7A'!D91","v":"please select…"},{"$f":"'PR EFR_7A'!E91","v":0},0,{"$f":"'PR EFR_7A'!F91","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A92","v":0},{"$f":"'PR EFR_7A'!B92","v":"Please Select…"},{"$f":"'PR EFR_7A'!C92","v":0},{"$f":"'PR EFR_7A'!D92","v":"please select…"},{"$f":"'PR EFR_7A'!E92","v":0},0,{"$f":"'PR EFR_7A'!F92","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A93","v":0},{"$f":"'PR EFR_7A'!B93","v":"Please Select…"},{"$f":"'PR EFR_7A'!C93","v":0},{"$f":"'PR EFR_7A'!D93","v":"please select…"},{"$f":"'PR EFR_7A'!E93","v":0},0,{"$f":"'PR EFR_7A'!F93","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A94","v":0},{"$f":"'PR EFR_7A'!B94","v":"Please Select…"},{"$f":"'PR EFR_7A'!C94","v":0},{"$f":"'PR EFR_7A'!D94","v":"please select…"},{"$f":"'PR EFR_7A'!E94","v":0},0,{"$f":"'PR EFR_7A'!F94","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A95","v":0},{"$f":"'PR EFR_7A'!B95","v":"Please Select…"},{"$f":"'PR EFR_7A'!C95","v":0},{"$f":"'PR EFR_7A'!D95","v":"please select…"},{"$f":"'PR EFR_7A'!E95","v":0},0,{"$f":"'PR EFR_7A'!F95","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A96","v":0},{"$f":"'PR EFR_7A'!B96","v":"Please Select…"},{"$f":"'PR EFR_7A'!C96","v":0},{"$f":"'PR EFR_7A'!D96","v":"please select…"},{"$f":"'PR EFR_7A'!E96","v":0},0,{"$f":"'PR EFR_7A'!F96","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A97","v":0},{"$f":"'PR EFR_7A'!B97","v":"Please Select…"},{"$f":"'PR EFR_7A'!C97","v":0},{"$f":"'PR EFR_7A'!D97","v":"please select…"},{"$f":"'PR EFR_7A'!E97","v":0},0,{"$f":"'PR EFR_7A'!F97","v":0},0,0,"N/A",null,0,0,{"$f":"L97-M97","v":0},"N/A"]
[{"$f":"'PR EFR_7A'!A98","v":0},{"$f":"'PR EFR_7A'!B98","v":"Please Select…"},{"$f":"'PR EFR_7A'!C98","v":0},{"$f":"'PR EFR_7A'!D98","v":"please select…"},{"$f":"'PR EFR_7A'!E98","v":0},0,{"$f":"'PR EFR_7A'!F98","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A99","v":0},{"$f":"'PR EFR_7A'!B99","v":"Please Select…"},{"$f":"'PR EFR_7A'!C99","v":0},{"$f":"'PR EFR_7A'!D99","v":"please select…"},{"$f":"'PR EFR_7A'!E99","v":0},0,{"$f":"'PR EFR_7A'!F99","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A100","v":0},{"$f":"'PR EFR_7A'!B100","v":"Please Select…"},{"$f":"'PR EFR_7A'!C100","v":0},{"$f":"'PR EFR_7A'!D100","v":"please select…"},{"$f":"'PR EFR_7A'!E100","v":0},0,{"$f":"'PR EFR_7A'!F100","v":0},0,{"$f":"(E100+F100)-(G100+H100)","v":0},{"$f":"IF(AND((E100+F100)=0,(G100+H100)=0),\"N/A\",IF(AND((E100+F100)=0,(G100+H100)<>0),\"Not Budgeted\",(G100+H100)/(E100+F100)))","v":"N/A"},null,{"$f":"E100+F100","v":0},0,0,{"$f":"IF(AND(L100=0,M100=0),\"N/A\",IF(AND(L100=0,M100<>0),\"Not Budgeted\",M100/L100))","v":"N/A"}]
[{"$f":"'PR EFR_7A'!A101","v":0},{"$f":"'PR EFR_7A'!B101","v":"Please Select…"},{"$f":"'PR EFR_7A'!C101","v":0},{"$f":"'PR EFR_7A'!D101","v":"please select…"},{"$f":"'PR EFR_7A'!E101","v":0},0,{"$f":"'PR EFR_7A'!F101","v":0},0,0,{"$f":"IF(AND((E101+F101)=0,(G101+H101)=0),\"N/A\",IF(AND((E101+F101)=0,(G101+H101)<>0),\"Not Budgeted\",(G101+H101)/(E101+F101)))","v":"N/A"},null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A102","v":0},{"$f":"'PR EFR_7A'!B102","v":"Please Select…"},{"$f":"'PR EFR_7A'!C102","v":0},{"$f":"'PR EFR_7A'!D102","v":"please select…"},{"$f":"'PR EFR_7A'!E102","v":0},0,{"$f":"'PR EFR_7A'!F102","v":0},0,0,"N/A",null,0,{"$f":"G102+H102","v":0},0,"N/A"]
[{"$f":"'PR EFR_7A'!A103","v":0},{"$f":"'PR EFR_7A'!B103","v":"Please Select…"},{"$f":"'PR EFR_7A'!C103","v":0},{"$f":"'PR EFR_7A'!D103","v":"please select…"},{"$f":"'PR EFR_7A'!E103","v":0},0,{"$f":"'PR EFR_7A'!F103","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A104","v":0},{"$f":"'PR EFR_7A'!B104","v":"Please Select…"},{"$f":"'PR EFR_7A'!C104","v":0},{"$f":"'PR EFR_7A'!D104","v":"please select…"},{"$f":"'PR EFR_7A'!E104","v":0},0,{"$f":"'PR EFR_7A'!F104","v":0},0,0,"N/A",null,0,0,{"$f":"L104-M104","v":0},"N/A"]
[{"$f":"'PR EFR_7A'!A105","v":0},{"$f":"'PR EFR_7A'!B105","v":"Please Select…"},{"$f":"'PR EFR_7A'!C105","v":0},{"$f":"'PR EFR_7A'!D105","v":"please select…"},{"$f":"'PR EFR_7A'!E105","v":0},0,{"$f":"'PR EFR_7A'!F105","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A106","v":0},{"$f":"'PR EFR_7A'!B106","v":"Please Select…"},{"$f":"'PR EFR_7A'!C106","v":0},{"$f":"'PR EFR_7A'!D106","v":"please select…"},{"$f":"'PR EFR_7A'!E106","v":0},0,{"$f":"'PR EFR_7A'!F106","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A107","v":0},{"$f":"'PR EFR_7A'!B107","v":"Please Select…"},{"$f":"'PR EFR_7A'!C107","v":0},{"$f":"'PR EFR_7A'!D107","v":"please select…"},{"$f":"'PR EFR_7A'!E107","v":0},0,{"$f":"'PR EFR_7A'!F107","v":0},0,0,"N/A",null,0,0,{"$f":"L107-M107","v":0},"N/A"]
[{"$f":"'PR EFR_7A'!A108","v":0},{"$f":"'PR EFR_7A'!B108","v":"Please Select…"},{"$f":"'PR EFR_7A'!C108","v":0},{"$f":"'PR EFR_7A'!D108","v":"please select…"},{"$f":"'PR EFR_7A'!E108","v":0},0,{"$f":"'PR EFR_7A'!F108","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A109","v":0},{"$f":"'PR EFR_7A'!B109","v":"Please Select…"},{"$f":"'PR EFR_7A'!C109","v":0},{"$f":"'PR EFR_7A'!D109","v":"please select…"},{"$f":"'PR EFR_7A'!E109","v":0},0,{"$f":"'PR EFR_7A'!F109","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A110","v":0},{"$f":"'PR EFR_7A'!B110","v":"Please Select…"},{"$f":"'PR EFR_7A'!C110","v":0},{"$f":"'PR EFR_7A'!D110","v":"please select…"},{"$f":"'PR EFR_7A'!E110","v":0},0,{"$f":"'PR EFR_7A'!F110","v":0},0,0,"N/A",null,0,0,0,"N/A"]
["TOTAL",null,null,null,{"$f":"SUM(E36:E110)","v":2324385.0368528333},{"$f":"SUM(F36:F110)","v":0},{"$f":"SUM(G36:G110)","v":2792099.1796567799},{"$f":"SUM(H36:H110)","v":0},{"$f":"SUM(I36:I110)","v":-467714.14280394575},{"$f":"G111/E111","v":1.2012205961527016},null,{"$f":"SUM(L36:L110)","v":2324385.0368528333},{"$f":"SUM(M36:M110)","v":2792099.1796567799},{"$f":"SUM(N36:N110)","v":-467714.14280394575},{"$f":"M111/L111","v":1.2012205961527016}]
[]
[]
[]
[]
["C- BREAKDOWN* BY IMPLEMENTING ENTITY",null,null,null,"Current Reporting Period",null,null,null,null,null,null,"Cumulative Reporting Period"]
["#","PR/SR","Name","Type of\nImplementing Entity"," \nBudget for Reporting Period","LFA Adjustment on Budget","\nActual Expenditure","LFA Adjustment on Actual Expenditure","Budget v/s Actuals Variance","Absorption Capacity","LFA comments on the Principal Recipient's explanation of variances","Cumulative Budget","Cumulative Expenditure","Variance","Absorption Capacity","LFA comments on the Principal Recipient's explanation of variances"]
[{"$f":"'PR EFR_7A'!A118","v":1},{"$f":"'PR EFR_7A'!B118","v":"PR"},{"$f":"'PR EFR_7A'!C118","v":"National Center for Disease Control and Public Health"},{"$f":"'PR EFR_7A'!D118","v":"Other Government"},{"$f":"'PR EFR_7A'!E118","v":2101107.5592226866},0,{"$f":"'PR EFR_7A'!F118","v":2448490.0245514293},0,{"$f":"(E118+F118)-(G118+H118)","v":-347382.46532874275},{"$f":"IF(AND((E118+F118)=0,(G118+H118)=0),\"N/A\",IF(AND((E118+F118)=0,(G118+H118)<>0),\"Not Budgeted\",(G118+H118)/(E118+F118)))","v":1.1653330234351535},null,{"$f":"E118+F118","v":2101107.5592226866},{"$f":"G118+H118","v":2448490.0245514293},{"$f":"L118-M118","v":-347382.46532874275},{"$f":"IF(AND(L118=0,M118=0),\"N/A\",IF(AND(L118=0,M118<>0),\"Not Budgeted\",M118/L118))","v":1.1653330234351535}]
[{"$f":"'PR EFR_7A'!A119","v":2},{"$f":"'PR EFR_7A'!B119","v":"SR"},{"$f":"'PR EFR_7A'!C119","v":"National Center for Tuberculosis and Lung Diseases"},{"$f":"'PR EFR_7A'!D119","v":"Other Government"},{"$f":"'PR EFR_7A'!E119","v":223277.47763014823},0,{"$f":"'PR EFR_7A'!F119","v":343609.14506224322},0,-120331.66743209498,1.5389332981959802,null,223277.47763014823,343609.14506224322,{"$f":"L119-M119","v":-120331.66743209498},1.5389332981959802]
[{"$f":"'PR EFR_7A'!A120","v":0},{"$f":"'PR EFR_7A'!B120","v":"Please Select …"},{"$f":"'PR EFR_7A'!C120","v":0},{"$f":"'PR EFR_7A'!D120","v":"Please Select…"},{"$f":"'PR EFR_7A'!E120","v":0},0,{"$f":"'PR EFR_7A'!F120","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A121","v":0},{"$f":"'PR EFR_7A'!B121","v":"Please Select …"},{"$f":"'PR EFR_7A'!C121","v":0},{"$f":"'PR EFR_7A'!D121","v":"Please Select…"},{"$f":"'PR EFR_7A'!E121","v":0},0,{"$f":"'PR EFR_7A'!F121","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A122","v":0},{"$f":"'PR EFR_7A'!B122","v":"Please Select …"},{"$f":"'PR EFR_7A'!C122","v":0},{"$f":"'PR EFR_7A'!D122","v":"Please Select…"},{"$f":"'PR EFR_7A'!E122","v":0},0,{"$f":"'PR EFR_7A'!F122","v":0},0,0,"N/A",null,0,0,{"$f":"L122-M122","v":0},"N/A"]
[{"$f":"'PR EFR_7A'!A123","v":0},{"$f":"'PR EFR_7A'!B123","v":"Please Select …"},{"$f":"'PR EFR_7A'!C123","v":0},{"$f":"'PR EFR_7A'!D123","v":"Please Select…"},{"$f":"'PR EFR_7A'!E123","v":0},0,{"$f":"'PR EFR_7A'!F123","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A124","v":0},{"$f":"'PR EFR_7A'!B124","v":"Please Select …"},{"$f":"'PR EFR_7A'!C124","v":0},{"$f":"'PR EFR_7A'!D124","v":"Please Select…"},{"$f":"'PR EFR_7A'!E124","v":0},0,{"$f":"'PR EFR_7A'!F124","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A125","v":0},{"$f":"'PR EFR_7A'!B125","v":"Please Select …"},{"$f":"'PR EFR_7A'!C125","v":0},{"$f":"'PR EFR_7A'!D125","v":"Please Select…"},{"$f":"'PR EFR_7A'!E125","v":0},0,{"$f":"'PR EFR_7A'!F125","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A126","v":0},{"$f":"'PR EFR_7A'!B126","v":"Please Select …"},{"$f":"'PR EFR_7A'!C126","v":0},{"$f":"'PR EFR_7A'!D126","v":"Please Select…"},{"$f":"'PR EFR_7A'!E126","v":0},0,{"$f":"'PR EFR_7A'!F126","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A127","v":0},{"$f":"'PR EFR_7A'!B127","v":"Please Select …"},{"$f":"'PR EFR_7A'!C127","v":0},{"$f":"'PR EFR_7A'!D127","v":"Please Select…"},{"$f":"'PR EFR_7A'!E127","v":0},0,{"$f":"'PR EFR_7A'!F127","v":0},0,0,"N/A",null,0,0,{"$f":"L127-M127","v":0},"N/A"]
[{"$f":"'PR EFR_7A'!A128","v":0},{"$f":"'PR EFR_7A'!B128","v":"Please Select …"},{"$f":"'PR EFR_7A'!C128","v":0},{"$f":"'PR EFR_7A'!D128","v":"Please Select…"},{"$f":"'PR EFR_7A'!E128","v":0},0,{"$f":"'PR EFR_7A'!F128","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A129","v":0},{"$f":"'PR EFR_7A'!B129","v":"Please Select …"},{"$f":"'PR EFR_7A'!C129","v":0},{"$f":"'PR EFR_7A'!D129","v":"Please Select…"},{"$f":"'PR EFR_7A'!E129","v":0},0,{"$f":"'PR EFR_7A'!F129","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A130","v":0},{"$f":"'PR EFR_7A'!B130","v":"Please Select …"},{"$f":"'PR EFR_7A'!C130","v":0},{"$f":"'PR EFR_7A'!D130","v":"Please Select…"},{"$f":"'PR EFR_7A'!E130","v":0},0,{"$f":"'PR EFR_7A'!F130","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A131","v":0},{"$f":"'PR EFR_7A'!B131","v":"Please Select …"},{"$f":"'PR EFR_7A'!C131","v":0},{"$f":"'PR EFR_7A'!D131","v":"Please Select…"},{"$f":"'PR EFR_7A'!E131","v":0},0,{"$f":"'PR EFR_7A'!F131","v":0},0,0,"N/A",null,0,0,{"$f":"L131-M131","v":0},"N/A"]
[{"$f":"'PR EFR_7A'!A132","v":0},{"$f":"'PR EFR_7A'!B132","v":"Please Select …"},{"$f":"'PR EFR_7A'!C132","v":0},{"$f":"'PR EFR_7A'!D132","v":"Please Select…"},{"$f":"'PR EFR_7A'!E132","v":0},0,{"$f":"'PR EFR_7A'!F132","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A133","v":0},{"$f":"'PR EFR_7A'!B133","v":"Please Select …"},{"$f":"'PR EFR_7A'!C133","v":0},{"$f":"'PR EFR_7A'!D133","v":"Please Select…"},{"$f":"'PR EFR_7A'!E133","v":0},0,{"$f":"'PR EFR_7A'!F133","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A134","v":0},{"$f":"'PR EFR_7A'!B134","v":"Please Select …"},{"$f":"'PR EFR_7A'!C134","v":0},{"$f":"'PR EFR_7A'!D134","v":"Please Select…"},{"$f":"'PR EFR_7A'!E134","v":0},0,{"$f":"'PR EFR_7A'!F134","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A135","v":0},{"$f":"'PR EFR_7A'!B135","v":"Please Select …"},{"$f":"'PR EFR_7A'!C135","v":0},{"$f":"'PR EFR_7A'!D135","v":"Please Select…"},{"$f":"'PR EFR_7A'!E135","v":0},0,{"$f":"'PR EFR_7A'!F135","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A136","v":0},{"$f":"'PR EFR_7A'!B136","v":"Please Select …"},{"$f":"'PR EFR_7A'!C136","v":0},{"$f":"'PR EFR_7A'!D136","v":"Please Select…"},{"$f":"'PR EFR_7A'!E136","v":0},0,{"$f":"'PR EFR_7A'!F136","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A137","v":0},{"$f":"'PR EFR_7A'!B137","v":"Please Select …"},{"$f":"'PR EFR_7A'!C137","v":0},{"$f":"'PR EFR_7A'!D137","v":"Please Select…"},{"$f":"'PR EFR_7A'!E137","v":0},0,{"$f":"'PR EFR_7A'!F137","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A138","v":0},{"$f":"'PR EFR_7A'!B138","v":"Please Select …"},{"$f":"'PR EFR_7A'!C138","v":0},{"$f":"'PR EFR_7A'!D138","v":"Please Select…"},{"$f":"'PR EFR_7A'!E138","v":0},0,{"$f":"'PR EFR_7A'!F138","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A139","v":0},{"$f":"'PR EFR_7A'!B139","v":"Please Select …"},{"$f":"'PR EFR_7A'!C139","v":0},{"$f":"'PR EFR_7A'!D139","v":"Please Select…"},{"$f":"'PR EFR_7A'!E139","v":0},0,{"$f":"'PR EFR_7A'!F139","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A140","v":0},{"$f":"'PR EFR_7A'!B140","v":"Please Select …"},{"$f":"'PR EFR_7A'!C140","v":0},{"$f":"'PR EFR_7A'!D140","v":"Please Select…"},{"$f":"'PR EFR_7A'!E140","v":0},0,{"$f":"'PR EFR_7A'!F140","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A141","v":0},{"$f":"'PR EFR_7A'!B141","v":"Please Select …"},{"$f":"'PR EFR_7A'!C141","v":0},{"$f":"'PR EFR_7A'!D141","v":"Please Select…"},{"$f":"'PR EFR_7A'!E141","v":0},0,{"$f":"'PR EFR_7A'!F141","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A142","v":0},{"$f":"'PR EFR_7A'!B142","v":"Please Select …"},{"$f":"'PR EFR_7A'!C142","v":0},{"$f":"'PR EFR_7A'!D142","v":"Please Select…"},{"$f":"'PR EFR_7A'!E142","v":0},0,{"$f":"'PR EFR_7A'!F142","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A143","v":0},{"$f":"'PR EFR_7A'!B143","v":"Please Select …"},{"$f":"'PR EFR_7A'!C143","v":0},{"$f":"'PR EFR_7A'!D143","v":"Please Select…"},{"$f":"'PR EFR_7A'!E143","v":0},0,{"$f":"'PR EFR_7A'!F143","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A144","v":0},{"$f":"'PR EFR_7A'!B144","v":"Please Select …"},{"$f":"'PR EFR_7A'!C144","v":0},{"$f":"'PR EFR_7A'!D144","v":"Please Select…"},{"$f":"'PR EFR_7A'!E144","v":0},0,{"$f":"'PR EFR_7A'!F144","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A145","v":0},{"$f":"'PR EFR_7A'!B145","v":"Please Select …"},{"$f":"'PR EFR_7A'!C145","v":0},{"$f":"'PR EFR_7A'!D145","v":"Please Select…"},{"$f":"'PR EFR_7A'!E145","v":0},0,{"$f":"'PR EFR_7A'!F145","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A146","v":0},{"$f":"'PR EFR_7A'!B146","v":"Please Select …"},{"$f":"'PR EFR_7A'!C146","v":0},{"$f":"'PR EFR_7A'!D146","v":"Please Select…"},{"$f":"'PR EFR_7A'!E146","v":0},0,{"$f":"'PR EFR_7A'!F146","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A147","v":0},{"$f":"'PR EFR_7A'!B147","v":"Please Select …"},{"$f":"'PR EFR_7A'!C147","v":0},{"$f":"'PR EFR_7A'!D147","v":"Please Select…"},{"$f":"'PR EFR_7A'!E147","v":0},0,{"$f":"'PR EFR_7A'!F147","v":0},0,0,"N/A",null,0,0,{"$f":"L147-M147","v":0},"N/A"]
[{"$f":"'PR EFR_7A'!A148","v":0},{"$f":"'PR EFR_7A'!B148","v":"Please Select …"},{"$f":"'PR EFR_7A'!C148","v":0},{"$f":"'PR EFR_7A'!D148","v":"Please Select…"},{"$f":"'PR EFR_7A'!E148","v":0},0,{"$f":"'PR EFR_7A'!F148","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A149","v":0},{"$f":"'PR EFR_7A'!B149","v":"Please Select …"},{"$f":"'PR EFR_7A'!C149","v":0},{"$f":"'PR EFR_7A'!D149","v":"Please Select…"},{"$f":"'PR EFR_7A'!E149","v":0},0,{"$f":"'PR EFR_7A'!F149","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A150","v":0},{"$f":"'PR EFR_7A'!B150","v":"Please Select …"},{"$f":"'PR EFR_7A'!C150","v":0},{"$f":"'PR EFR_7A'!D150","v":"Please Select…"},{"$f":"'PR EFR_7A'!E150","v":0},0,{"$f":"'PR EFR_7A'!F150","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A151","v":0},{"$f":"'PR EFR_7A'!B151","v":"Please Select …"},{"$f":"'PR EFR_7A'!C151","v":0},{"$f":"'PR EFR_7A'!D151","v":"Please Select…"},{"$f":"'PR EFR_7A'!E151","v":0},0,{"$f":"'PR EFR_7A'!F151","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A152","v":0},{"$f":"'PR EFR_7A'!B152","v":"Please Select …"},{"$f":"'PR EFR_7A'!C152","v":0},{"$f":"'PR EFR_7A'!D152","v":"Please Select…"},{"$f":"'PR EFR_7A'!E152","v":0},0,{"$f":"'PR EFR_7A'!F152","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A153","v":0},{"$f":"'PR EFR_7A'!B153","v":"Please Select …"},{"$f":"'PR EFR_7A'!C153","v":0},{"$f":"'PR EFR_7A'!D153","v":"Please Select…"},{"$f":"'PR EFR_7A'!E153","v":0},0,{"$f":"'PR EFR_7A'!F153","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A154","v":0},{"$f":"'PR EFR_7A'!B154","v":"Please Select …"},{"$f":"'PR EFR_7A'!C154","v":0},{"$f":"'PR EFR_7A'!D154","v":"Please Select…"},{"$f":"'PR EFR_7A'!E154","v":0},0,{"$f":"'PR EFR_7A'!F154","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A155","v":0},{"$f":"'PR EFR_7A'!B155","v":"Please Select …"},{"$f":"'PR EFR_7A'!C155","v":0},{"$f":"'PR EFR_7A'!D155","v":"Please Select…"},{"$f":"'PR EFR_7A'!E155","v":0},0,{"$f":"'PR EFR_7A'!F155","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A156","v":0},{"$f":"'PR EFR_7A'!B156","v":"Please Select …"},{"$f":"'PR EFR_7A'!C156","v":0},{"$f":"'PR EFR_7A'!D156","v":"Please Select…"},{"$f":"'PR EFR_7A'!E156","v":0},0,{"$f":"'PR EFR_7A'!F156","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A157","v":0},{"$f":"'PR EFR_7A'!B157","v":"Please Select …"},{"$f":"'PR EFR_7A'!C157","v":0},{"$f":"'PR EFR_7A'!D157","v":"Please Select…"},{"$f":"'PR EFR_7A'!E157","v":0},0,{"$f":"'PR EFR_7A'!F157","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A158","v":0},{"$f":"'PR EFR_7A'!B158","v":"Please Select …"},{"$f":"'PR EFR_7A'!C158","v":0},{"$f":"'PR EFR_7A'!D158","v":"Please Select…"},{"$f":"'PR EFR_7A'!E158","v":0},0,{"$f":"'PR EFR_7A'!F158","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A159","v":0},{"$f":"'PR EFR_7A'!B159","v":"Please Select …"},{"$f":"'PR EFR_7A'!C159","v":0},{"$f":"'PR EFR_7A'!D159","v":"Please Select…"},{"$f":"'PR EFR_7A'!E159","v":0},0,{"$f":"'PR EFR_7A'!F159","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[{"$f":"'PR EFR_7A'!A160","v":0},{"$f":"'PR EFR_7A'!B160","v":"Please Select …"},{"$f":"'PR EFR_7A'!C160","v":0},{"$f":"'PR EFR_7A'!D160","v":"Please Select…"},{"$f":"'PR EFR_7A'!E160","v":0},0,{"$f":"'PR EFR_7A'!F160","v":0},0,0,"N/A",null,0,0,0,"N/A"]
[null,null,null,"TOTAL",{"$f":"SUM(E118:E160)","v":2324385.0368528347},{"$f":"SUM(F118:F160)","v":0},{"$f":"SUM(G118:G160)","v":2792099.1696136724},{"$f":"SUM(H118:H160)","v":0},{"$f":"SUM(I118:I160)","v":-467714.13276083773},{"$f":"G161/E161","v":1.2012205918319421},null,{"$f":"SUM(L118:L160)","v":2324385.0368528347},{"$f":"SUM(M118:M160)","v":2792099.1696136724},{"$f":"SUM(N118:N160)","v":-467714.13276083773},{"$f":"M161/L161","v":1.2012205918319421}]
[]
[]
[]
[]
["* The sum of all three breakdowns should be equal (A- Budget Line-item, B- Program Activity, C- Implementing Entity)."]
["** For the purposes of this report, the SDA Program management and administration should be included in the Supportive Environment Macro Category."]
[]
["D- ADDITIONAL INFORMATION"]
["Please disclose any relevant information concerning the information in the above tables. Refer to the Guidelines for Completing the Template if required."]
[]
[]
[]
[]
[]
[]
["E- DISBURSEMENTS BREAKDOWN BY IMPLEMENTING ENTITY",null,null,null,"Cumulative Reporting Period"]
["#","Name","Type of\nImplementing Entity","Cumulative Disbursements","LFA Adjustment on Cumulative Disbursements","Comments"]
[{"$f":"'PR EFR_7A'!A179","v":1},{"$f":"'PR EFR_7A'!B179","v":"National Center for Tuberculosis and Lung Diseases"},{"$f":"'PR EFR_7A'!C179","v":"Other Government"},{"$f":"'PR EFR_7A'!D179","v":909378.36658432567},0]
[{"$f":"'PR EFR_7A'!A180","v":0},{"$f":"'PR EFR_7A'!B180","v":0},{"$f":"'PR EFR_7A'!C180","v":"Please Select…"},{"$f":"'PR EFR_7A'!D180","v":0},0]
[{"$f":"'PR EFR_7A'!A181","v":0},{"$f":"'PR EFR_7A'!B181","v":0},{"$f":"'PR EFR_7A'!C181","v":"Please Select…"},{"$f":"'PR EFR_7A'!D181","v":0},0]
[{"$f":"'PR EFR_7A'!A182","v":0},{"$f":"'PR EFR_7A'!B182","v":0},{"$f":"'PR EFR_7A'!C182","v":"Please Select…"},{"$f":"'PR EFR_7A'!D182","v":0},0]
[{"$f":"'PR EFR_7A'!A183","v":0},{"$f":"'PR EFR_7A'!B183","v":0},{"$f":"'PR EFR_7A'!C183","v":"Please Select…"},{"$f":"'PR EFR_7A'!D183","v":0},0]
[{"$f":"'PR EFR_7A'!A184","v":0},{"$f":"'PR EFR_7A'!B184","v":0},{"$f":"'PR EFR_7A'!C184","v":"Please Select…"},{"$f":"'PR EFR_7A'!D184","v":0},0]
[{"$f":"'PR EFR_7A'!A185","v":0},{"$f":"'PR EFR_7A'!B185","v":0},{"$f":"'PR EFR_7A'!C185","v":"Please Select…"},{"$f":"'PR EFR_7A'!D185","v":0},0]
[{"$f":"'PR EFR_7A'!A186","v":0},{"$f":"'PR EFR_7A'!B186","v":0},{"$f":"'PR EFR_7A'!C186","v":"Please Select…"},{"$f":"'PR EFR_7A'!D186","v":0},0]
[{"$f":"'PR EFR_7A'!A187","v":0},{"$f":"'PR EFR_7A'!B187","v":0},{"$f":"'PR EFR_7A'!C187","v":"Please Select…"},{"$f":"'PR EFR_7A'!D187","v":0},0]
[{"$f":"'PR EFR_7A'!A188","v":0},{"$f":"'PR EFR_7A'!B188","v":0},{"$f":"'PR EFR_7A'!C188","v":"Please Select…"},{"$f":"'PR EFR_7A'!D188","v":0},0]
[{"$f":"'PR EFR_7A'!A189","v":0},{"$f":"'PR EFR_7A'!B189","v":0},{"$f":"'PR EFR_7A'!C189","v":"Please Select…"},{"$f":"'PR EFR_7A'!D189","v":0},0]
[{"$f":"'PR EFR_7A'!A190","v":0},{"$f":"'PR EFR_7A'!B190","v":0},{"$f":"'PR EFR_7A'!C190","v":"Please Select…"},{"$f":"'PR EFR_7A'!D190","v":0},0]
[{"$f":"'PR EFR_7A'!A191","v":0},{"$f":"'PR EFR_7A'!B191","v":0},{"$f":"'PR EFR_7A'!C191","v":"Please Select…"},{"$f":"'PR EFR_7A'!D191","v":0},0]
[{"$f":"'PR EFR_7A'!A192","v":0},{"$f":"'PR EFR_7A'!B192","v":0},{"$f":"'PR EFR_7A'!C192","v":"Please Select…"},{"$f":"'PR EFR_7A'!D192","v":0},0]
[{"$f":"'PR EFR_7A'!A193","v":0},{"$f":"'PR EFR_7A'!B193","v":0},{"$f":"'PR EFR_7A'!C193","v":"Please Select…"},{"$f":"'PR EFR_7A'!D193","v":0},0]
[{"$f":"'PR EFR_7A'!A194","v":0},{"$f":"'PR EFR_7A'!B194","v":0},{"$f":"'PR EFR_7A'!C194","v":"Please Select…"},{"$f":"'PR EFR_7A'!D194","v":0},0]
[{"$f":"'PR EFR_7A'!A195","v":0},{"$f":"'PR EFR_7A'!B195","v":0},{"$f":"'PR EFR_7A'!C195","v":"Please Select…"},{"$f":"'PR EFR_7A'!D195","v":0},0]
[{"$f":"'PR EFR_7A'!A196","v":0},{"$f":"'PR EFR_7A'!B196","v":0},{"$f":"'PR EFR_7A'!C196","v":"Please Select…"},{"$f":"'PR EFR_7A'!D196","v":0},0]
[{"$f":"'PR EFR_7A'!A197","v":0},{"$f":"'PR EFR_7A'!B197","v":0},{"$f":"'PR EFR_7A'!C197","v":"Please Select…"},{"$f":"'PR EFR_7A'!D197","v":0},0]
[{"$f":"'PR EFR_7A'!A198","v":0},{"$f":"'PR EFR_7A'!B198","v":0},{"$f":"'PR EFR_7A'!C198","v":"Please Select…"},{"$f":"'PR EFR_7A'!D198","v":0},0]
[{"$f":"'PR EFR_7A'!A199","v":0},{"$f":"'PR EFR_7A'!B199","v":0},{"$f":"'PR EFR_7A'!C199","v":"Please Select…"},{"$f":"'PR EFR_7A'!D199","v":0},0]
[{"$f":"'PR EFR_7A'!A200","v":0},{"$f":"'PR EFR_7A'!B200","v":0},{"$f":"'PR EFR_7A'!C200","v":"Please Select…"},{"$f":"'PR EFR_7A'!D200","v":0},0]
[{"$f":"'PR EFR_7A'!A201","v":0},{"$f":"'PR EFR_7A'!B201","v":0},{"$f":"'PR EFR_7A'!C201","v":"Please Select…"},{"$f":"'PR EFR_7A'!D201","v":0},0]
[{"$f":"'PR EFR_7A'!A202","v":0},{"$f":"'PR EFR_7A'!B202","v":0},{"$f":"'PR EFR_7A'!C202","v":"Please Select…"},{"$f":"'PR EFR_7A'!D202","v":0},0]
[{"$f":"'PR EFR_7A'!A203","v":0},{"$f":"'PR EFR_7A'!B203","v":0},{"$f":"'PR EFR_7A'!C203","v":"Please Select…"},{"$f":"'PR EFR_7A'!D203","v":0},0]
[{"$f":"'PR EFR_7A'!A204","v":0},{"$f":"'PR EFR_7A'!B204","v":0},{"$f":"'PR EFR_7A'!C204","v":"Please Select…"},{"$f":"'PR EFR_7A'!D204","v":0},0]
[{"$f":"'PR EFR_7A'!A205","v":0},{"$f":"'PR EFR_7A'!B205","v":0},{"$f":"'PR EFR_7A'!C205","v":"Please Select…"},{"$f":"'PR EFR_7A'!D205","v":0},0]
[null,null,"TOTAL",{"$f":"SUM(D179:D205)","v":909378.36658432567},{"$f":"SUM(E179:E205)","v":0}]

{"sheet":"Annual Cash Forecast_8A","index":20,"n_rows":19,"n_cols":16,"rows_kept":19,"cut":false,"hidden":false,"merged":[[0,0,0,7]]}
["Ongoing Progress Update and Disbursement Request"]
["Section 8A: The Global Fund Annual Forecast Template"]
["Summary Breakdown by Cost Category"]
[]
["Cost Categories","Budget for Forecast Period","Unspent from previous periods","Budget for the Buffer Period","Total Budget available (including the buffer)","Adjustment for the  Forecast Period (based on implementable activities)","Adjustment for the Buffer Period","Total Principal Recipient Forecast (including Buffer)","Comments",null,"Local Fund Agent Adjustment on PR Budget","Local Fund Agent Adjustment on Budget for the Buffer Period","Local Fund Agent Adjustment on the Forecast","Local Fund Agent Adjustment on the Buffer Forecast","Local Fund Agent - Adjusted Forecast (including the buffer)","Comments"]
["Human Resources (HR)",null,{"$f":"'PR EFR_7A'!K18","v":-114596.18578960083},null,{"$f":"B6+C6+D6","v":-114596.18578960083},148027.88228208473,null,{"$f":"E6+F6+G6","v":33431.696492483898},"Commitments from TB SSF Grant to be paid until 30 June 2017 in agreement with TGF",null,null,null,null,null,{"$f":"K6+L6+H6+M6+N6","v":33431.696492483898}]
["Technical Assistance",null,{"$f":"'PR EFR_7A'!K19","v":-17035.711061719368},null,{"$f":"B7+C7+D7","v":-17035.711061719368},17898.273695935546,null,{"$f":"E7+F7+G7","v":862.56263421617768},null,null,null,null,null,null,{"$f":"K7+L7+H7+M7+N7","v":862.56263421617768}]
["Training",null,{"$f":"'PR EFR_7A'!K20","v":-27000.913040565443},null,-27000.913040565443,47749.581616084412,null,20748.668575518968,null,null,null,null,null,null,20748.668575518968]
["Health Products and Health Equipment",null,{"$f":"'PR EFR_7A'!K21","v":122297.21252811351},null,122297.21252811351,283157.68625499588,null,405454.89878310938,null,null,null,null,null,null,405454.89878310938]
["Medicines and Pharmaceutical Products",null,{"$f":"'PR EFR_7A'!K22","v":2632370.9406609526},null,2632370.9406609526,-2631673.0165378335,null,697.9241231190972,null,null,null,null,null,null,697.9241231190972]
["Procurement and Supply Management Costs",null,{"$f":"'PR EFR_7A'!K23","v":268492.41574702994},null,268492.41574702994,-97637.705653973157,null,170854.71009305678,null,null,null,null,null,null,170854.71009305678]
["Infrastructure and Other Equipment",null,{"$f":"'PR EFR_7A'!K24","v":-144442.41344877932},null,-144442.41344877932,144442.41344877938,null,5.8207660913467407E-11,null,null,null,null,null,null,5.8207660913467407E-11]
["Communication Materials",null,{"$f":"'PR EFR_7A'!K25","v":0},null,0,367.9228346456693,null,367.9228346456693,null,null,null,null,null,null,367.9228346456693]
["Monitoring & Evaluation",null,{"$f":"'PR EFR_7A'!K26","v":45992.314207788353},null,45992.314207788353,-22450.853542268705,null,23541.460665519648,null,null,null,null,null,null,23541.460665519648]
["Living Support to Clients/Target Populations",null,{"$f":"'PR EFR_7A'!K27","v":883065.64872989559},null,883065.64872989559,-873993.69454235083,null,9071.9541875447612,null,null,null,null,null,null,9071.9541875447612]
["Planning and Administration",null,{"$f":"'PR EFR_7A'!K28","v":5869.9803153130924},null,5869.9803153130924,-5560.1020046478461,null,309.87831066524632,null,null,null,null,null,null,309.87831066524632]
["Overheads",null,{"$f":"'PR EFR_7A'!K29","v":9387.296065027158},null,9387.296065027158,-47361.608878198182,null,-37974.312813171025,"Refundable VAT as of 31/12/2016",null,null,null,null,null,-37974.312813171025]
["Other",null,{"$f":"'PR EFR_7A'!K30","v":-1.0484355212156515E-2},null,-1.0484355212156515E-2,{"$f":"-E18","v":1.0484355212156515E-2},null,0,null,null,null,null,null,null,0]
["Grand Total",{"$f":"SUM(B6:B18)","v":0},{"$f":"SUM(C6:C18)","v":3664400.5744291008},{"$f":"SUM(D6:D18)","v":0},{"$f":"SUM(E6:E18)","v":3664400.5744291008},{"$f":"SUM(F6:F18)","v":-3037033.2105423906},0,627367.36388670863,null,null,{"$f":"SUM(K6:K18)","v":0},{"$f":"SUM(L6:L18)","v":0},0,0,627367.36388670863]

{"sheet":" Request and Recommendation_8B","index":21,"n_rows":49,"n_cols":18,"rows_kept":49,"cut":false,"hidden":false,"merged":[[51,9,55,14],[29,1,30,8],[31,13,31,17],[35,0,35,8],[34,11,34,12],[48,9,48,14],[29,0,32,0],[32,1,32,8],[41,9,41,12],[43,9,43,12],[45,9,45,12],[34,0,34,8],[30,13,30,17],[31,11,31,12],[25,0,26,6],[32,13,32,17],[25,7,26,17],[30,11,30,12],[45,1,45,4],[32,11,32,12],[34,13,34,17],[0,0,0,14],[33,11,33,12],[33,13,33,17],[2,0,2,17],[31,1,31,8],[23,0,24,6],[20,0,20,16],[21,0,21,16],[13,1,13,3],[23,7,24,17],[29,11,29,12],[29,13,29,17]]}
["Ongoing Progress Review and Disbursement Request"]
["Section 8B.  Disbursement Request and Recommendation"]
[]
["Total forecasted net cash expenditures by the Principal Recipient for the period immediately following the period covered by the Progress Update:"]
[" "]
["1.  Period beginning date:",null,null,null,null,{"$f":"CoverSheet!J14","v":"N/A"},null,"end date:",{"$f":"CoverSheet!L14","v":"N/A"},null,"Approved budget amount (PR):",null,{"$f":"'Annual Cash Forecast_8A'!B19","v":0},null,"Forecasted amount  (PR)",{"$f":"'Annual Cash Forecast_8A'!B19+'Annual Cash Forecast_8A'!C19+'Annual Cash Forecast_8A'!F19","v":627367.36388671026}]
[]
[null,null,null,null,null,null,null,null,null,null,"LFA-verified approved budget amount:",null,{"$f":"'Annual Cash Forecast_8A'!B19+'Annual Cash Forecast_8A'!K19","v":0},null,"LFA-adjusted forecasted amount:",{"$f":"P6+'Annual Cash Forecast_8A'!K19+'Annual Cash Forecast_8A'!M19","v":627367.36388671026}]
["2a. Cash buffer period (by default)"]
["  (cash \"buffer\") beginning date:",null,null,null,null,"N/A",null,"end date:","N/A",null,"Approved budget amount (PR):",null,{"$f":"'Annual Cash Forecast_8A'!D19","v":0},null,"Forecasted amount  (PR):",{"$f":"'Annual Cash Forecast_8A'!D19+'Annual Cash Forecast_8A'!G19","v":0}]
[]
[null,null,null,null,null,null,null,null,null,null,"LFA-verified approved budget amount:",null,{"$f":"'Annual Cash Forecast_8A'!D19+'Annual Cash Forecast_8A'!L19","v":0},null,"LFA-adjusted forecasted amount:",{"$f":"P10+'Annual Cash Forecast_8A'!L19+'Annual Cash Forecast_8A'!N19","v":0},null,"PR Total Forecast"]
["2b.  Additional \"buffer\" (discretionary, select only if there is a prior agreement with the FPM) (1)",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"$f":"P6+P10+P17","v":627367.36388671026}]
[null,"Cash \"buffer\" agreed with FPM (2)",null,null,null,"Select ",null,null,null,null,null,null,null,null,null,null,null,"LFA Total Forecast"]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"$f":"P8+P12+P19","v":627367.36388671026}]
[]
["(cash \"buffer\") beginning date",null,null,null,null,{"$f":"I10","v":"N/A"},null,"end date:",{"$f":"IF(F14=\"\",\"\",IF(F14=\"1M\",DATE(YEAR(I10),MONTH(I10)+1,DAY(I10)-1),IF(F14=\"2M\",DATE(YEAR(I10),MONTH(I10)+2,DAY(I10)-1),IF(F14=\"3M\",DATE(YEAR(I10),MONTH(I10)+3,DAY(I10)-1),\"\"))))","v":""},null,"Approved budget amount:",null,null,null,"Forecasted amount:"]
[]
[null,null,null,null,null,null,null,null,null,null,"LFA-verified approved budget amount:",null,null,null,"LFA-adjusted forecasted amount:"]
[]
["(1) Upon agreement with the FPM, additional Cash buffer can be requested if the PU/DR report contains a completed AFR or EFR report or if there is a request from the Secretariat for the PR to complete the report on SR Cash Reconciliation contained in the “SR Cash Reconciliation 2D”, or if there are any additional Global Fund-specific requirements that cannot be delivered within 60 days.  However such requests may or may not be satisfied based on the review of the current PU/DR."]
["(2) When the additional (cash \"buffer\" ) period is 1 or 2 months, the approved budget and forecasted amounts should be calculated as prorated values for the period following the regular buffer period."]
[]
["PR's explanation of any significant variance between forecasted amounts and amounts as originally budgeted.  Please explain any significant variance (based on your judgment) between the forecasted amounts and the amounts as per approved budgets.  Please specify the main factors and related amounts that are the major drivers of the variance. \nNB. Consider the following items when providing the analysis. \n  - Expected timing of payments for any significant budgetary items,\n  - Impact of existing cash balance at SR levels\n  - Current confirmed commitments to be paid during disbursement request period \n  - Current/expected unit prices compared to those in the budget \n  - Change in quantities compared to budget\n  - Exchange rates and inflation\n  - Linkage between budget absorption and programmatic performance to-date.\n\n! The forecast should include any existing commitments (eligible under this grant) as of the end of the reporting period and which are likely to be paid during the disbursement period"]
[]
["LFA comments on PR's explanation of any significant variance between forecasted amounts and amounts as originally budgeted."]
[]
[]
[]
["Less:","3. Cash Balance: End of period covered by Progress Update (Item 5.1 in PRLFA Cash Reconciliation):",null,null,null,null,null,null,null,"PR-reported amounts","PR Comments","LFA-verified amounts",null,"LFA Comments"]
[null,null,null,null,null,null,null,null,null,{"$f":"'PR Cash Reconciliation_2A,B,C'!D31","v":657427.06591089279},null,{"$f":"'PR Cash Reconciliation_2A,B,C'!H31","v":657427.06591089279}]
[null,"4. Cash in Transit for the reporting period (Disbursements to PR & third party disbursements):",null,null,null,null,null,null,null,{"$f":"'PR Cash Reconciliation_2A,B,C'!D42","v":0},null,{"$f":"'PR Cash Reconciliation_2A,B,C'!H42","v":0}]
[null,"5.Cash in Transit after the current reporting period (Disbursements to PR & third party disbursements) :",null,null,null,null,null,null,null,{"$f":"'PR Cash Reconciliation_2A,B,C'!D43","v":0},null,{"$f":"'PR Cash Reconciliation_2A,B,C'!H43","v":0}]
[null,null,null,null,null,null,null,null,null,"PR-requested amount","PR Comments","LFA-verified amounts",null,"LFA Comments"]
["6. Disbursement Request to the Global Fund for the period immediately following the period covered by the Progress Update, plus additional period (cash buffer):",null,null,null,null,null,null,null,null,{"$f":"IF(R13=0,0,IF(R13-J31-J32-J33<0,0,R13-J31-J32-J33))","v":0},null,{"$f":"IF(R15=0,0,IF(R15-L31-L32-L33<0,0,R15-L31-L32-L33))","v":0},{"$f":"IF(T15=0,0,IF(T15-M31-M32-M33<0,0,T15-M31-M32-M33))","v":0}]
[]
["7.  Does the PR's Disbursement Request include funds for health product procurement?",null,null,null,null,null,null,null,null,"N/A"]
["8.  Exchange Rate (used to translate local currency into grant currency)",null,null,null,null,null,null,null,null,"Yes"]
[]
[null,null,null,null,null,"Rates used by the PR",null,"LFA-verified rates",null,"Name of local currency, date and source of the exchange rate, and other comments (if appropriate) "]
[]
[null,"- used to convert Opening Cash Balance",null,null,null,2.6168999999999998,null,0,null,"Exchange rate at the closing date of the previous reporting period (source: www.nbg.gov.ge)"]
[]
[null,"- used to convert Closing Cash Balance",null,null,null,2.794,null,0,null,"Exchange rate at the closing date of the current reporting period (source: www.nbg.gov.ge)"]
[]
[null,"- used to convert Total PR Cash Outflow for the Progress Update Period",null,null,null,0,null,0,null,"Exchange rate at the date of transaction  (source: www.nbg.gov.ge)"]
[]
[]
[null,null,null,null,null,null,null,null,null,"LFA comments on the exchange rates used by the PR"]

{"sheet":"PR Authorization_9A","index":22,"n_rows":14,"n_cols":10,"rows_kept":14,"cut":false,"hidden":false,"merged":[[16,0,16,14],[10,0,10,4],[13,5,13,9],[0,0,0,14],[6,5,6,9],[10,5,10,9],[11,5,11,9],[12,5,12,9],[2,0,2,4],[2,5,2,9],[5,0,5,4],[5,5,5,9],[3,5,3,6],[8,0,8,14]]}
["Ongoing Progress Review and Disbursement Request"]
["Section 9A.  PR Authorization"]
["Grant Name:",null,null,null,null,{"$f":"CoverSheet!D7","v":"GEO-T-NCDC"}]
["Disbursement Request  - Disbursement Period:",null,null,null,null,"Cycle:",null,{"$f":"CoverSheet!J13","v":0},"Number:",{"$f":"CoverSheet!L13","v":"N/A"}]
["Disbursement Request  - Period Covered:",null,null,null,null,"Beginning Date:",null,{"$f":"CoverSheet!J14","v":"N/A"},"End Date:",{"$f":"CoverSheet!L14","v":"N/A"}]
["Currency:",null,null,null,null,{"$f":"CoverSheet!D11","v":"EUR"}]
["Disbursement Request Amount:",null,null,null,null,{"$f":"' Request and Recommendation_8B'!J35","v":0}]
[]
["The undersigned acknowledges that: (i) all the information (programmatic, financial, or otherwise) provided in this Progress Update and Disbursement Request is complete and accurate; (ii) funds disbursed in accordance with this request shall be deposited in the bank account specified in the Facesheet; and (iii) funds disbursed under the Grant Agreement shall be used in accordance with the Grant Agreement."]
[]
["Signed on behalf of the Principal Recipient:\n(signature of Authorized Designated Representative)"]
["Name:",null,null,null,null,"Irma Khonelidze"]
["Title:",null,null,null,null,"Program Director"]
["Date and Place:",null,null,null,null," 05 April 2017 Tbilisi, Georgia"]

{"sheet":"LFA Authorization_9B","index":23,"n_rows":19,"n_cols":10,"rows_kept":19,"cut":false,"hidden":false,"merged":[[13,0,13,14],[21,0,21,14],[0,0,0,14],[4,0,4,4],[4,5,4,9],[7,5,7,9],[8,0,8,4],[8,5,8,9],[10,0,10,14],[12,0,12,14],[11,0,11,14],[15,3,15,5],[16,3,16,5],[17,3,17,5],[18,3,18,5],[7,0,7,4]]}
["Ongoing Progress Review and Disbursement Request"]
["For LFA Use Only"]
["Section 9B.  LFA Authorization"]
[]
["Grant Name:",null,null,null,null,{"$f":"CoverSheet!D7","v":"GEO-T-NCDC"}]
["Disbursement Request  - Disbursement Period:",null,null,null,null,"Cycle:",null,{"$f":"CoverSheet!J13","v":0},"Number:",{"$f":"CoverSheet!L13","v":"N/A"}]
["Disbursement Request  - Period Covered:",null,null,null,null,"Beginning Date:",null,{"$f":"CoverSheet!J14","v":"N/A"},"End Date:",{"$f":"CoverSheet!L14","v":"N/A"}]
["Currency:",null,null,null,null,{"$f":"CoverSheet!D11","v":"EUR"}]
["Disbursement Recommendation Amount:",null,null,null,null,{"$f":"' Request and Recommendation_8B'!L35:M35","v":{"$error":"#VALUE!"}}]
["Summary of the LFA's approach used for verification of financial, programmatic and procurement data and Quality Assurance undertaken by the LFA"]
["In this section the LFA should indicate, as applicable, what percentage of expenditures was verified at PR level, if any expenditures were verified at SR level, how many site visits were made, what tender documentation was verified, and any other material parts of verification procedures in line with the verification approach agreed upfront between the LFA and the Global Fund's Secretariat based on country/grant risks.  As a good practice, the verification approach needs to be reviewed jointly by the LFA and the Secretariat annually."]
[]
[]
["The LFA should sign a printed version of the verified PU/DR and send it to the Secretariat as a pdf file by email, or include an electronic signature in the Excel file to be submitted to the Global Fund."]
[]
["Signed on behalf of the LFA:"]
["Name:"]
["Title:"]
["Date and Place:"]

{"sheet":"PR_Disbursement Request_7","index":24,"n_rows":45,"n_cols":19,"rows_kept":45,"cut":false,"hidden":true,"merged":[[33,7,33,12],[40,8,40,11],[42,8,42,11],[44,1,44,4],[44,8,44,11],[30,0,32,0],[0,0,0,9],[2,0,2,4],[2,5,2,8],[5,5,5,8],[6,3,6,8],[10,0,10,18],[11,0,11,18],[23,0,23,19],[24,0,24,19],[26,0,27,7],[26,8,27,18]]}
["On-going Progress Update and Disbursement Request"]
["DISBURSEMENT REQUEST PERIOD"]
["Grant number:",null,null,null,null,{"$f":"IF(#REF!=\"\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Progress Update - Reporting Period:",null,null,null,null,"Cycle:",{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}},"Number:",{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Progress Update - Period Covered:",null,null,null,null,"Beginning Date:",{"$f":"IF(#REF!=\"\",\"\",#REF!)","v":{"$error":"#REF!"}},"End Date:",{"$f":"IF(#REF!=\"\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Progress Update - Number:",null,null,null,null,{"$f":"IF(#REF!=\"Select\",\"\",#REF!)","v":{"$error":"#REF!"}}]
["Currency:",null,null,{"$f":"IF(#REF!=\"\",\" \",#REF!)","v":{"$error":"#REF!"}}]
[]
["Section 5: Cash Reconciliation and Disbursement Request"]
[]
["B: DISBURSEMENT REQUEST"]
[]
[]
["Total forecasted net cash expenditures by the Principal Recipient for the period immediately following the period covered"]
[" by the Progress Update:"]
["1.  Period beginning date:",null,null,null,{"$f":"IF(CoverSheet!J11=\"\",\"\",CoverSheet!J11)","v":""},null,"end date:",{"$f":"IF(CoverSheet!L11=\"\",\"\",CoverSheet!L11)","v":""},null,"approved budget amount:",null,"forecasted amount:"]
["2a. Cash buffer period (by default)"]
["  (cash \"buffer\") beginning date:",null,null,null,{"$f":"IF(H16=\"\",\"\",H16+1)","v":""},null,"end date:",{"$f":"IF(E18=\"\",\"\",DATE(YEAR(E18),MONTH(E18)+3,DAY(E18)-1))","v":""},null,"approved budget amount:",null,"forecasted amount:"]
[null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,"PR Total Forecast"]
["2b.  Additional \"buffer\" (discretionary, select only if there is a prior agreement with the FPM) (1)",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"$f":"N16+N18+N22","v":0}]
["cash \"buffer\" agreed with FPM (2)",null,"Select "]
["(cash \"buffer\") beginning date",null,null,null,{"$f":"IF(H18=\"\",\"\",H18+1)","v":""},null,"end date:",{"$f":"IF(C21=\"\",\"\",IF(C21=\"1M\",DATE(YEAR(E22),MONTH(E22)+1,DAY(E22)-1),IF(C21=\"2M\",DATE(YEAR(E22),MONTH(E22)+2,DAY(E22)-1),IF(C21=\"3M\",DATE(YEAR(E22),MONTH(E22)+3,DAY(E22)-1),\"\"))))","v":""},null,"approved budget amount:",null,"forecasted amount:"]
[]
["(1) Additional Cash buffer can be requested if the next PU/DR report will contain a completed EFR report or a completed Annex on SR financials, requested by the Secretariat, or if there are any additional GF-specific requirements that cannot be delivered within 45 days. An agreement in principal from the FPM should be obtained prior to requesting an additional cash buffer."]
["(2) When the additional (cash \"buffer\" ) period is 1 or 2 months, the approved budget and forecasted amounts should be calculated as prorated values for the period following the regular buffer period."]
[]
["Please explain any significant variance (based on your judgment) between the forecasted amounts and the amounts as per approved budgets.  Please specify the main factors and related amounts that are the major drivers of the variance. \nNB. Consider the following items when providing the analysis. \n  - Expected timing of payments for any significant budgetary items,\n  - Impact of existing cash balance at SR levels\n  - Current confirmed commitments to be paid during disbursement request period \n  - Current/expected unit prices compared to those in the budget \n  - Change in quantities compared to budget\n  - Exchange rates and inflation\n  - Linkage between budget absorption and programmatic performance to-date.\n\n! The forecast should include any existing commitments (eligible under this grant) as of the end of the reporting period and which are likely to be paid during the disbursement period"]
[]
[]
[]
["Less:","3. Cash Balance: End of period covered by Progress Update (number 10 from PR Cash Reconciliation sheet):",null,null,null,null,null,null,null,null,null,null,null,{"$f":"+'PR Cash Reconciliation_2A,B,C'!#REF!","v":{"$error":"#REF!"}}]
[]
[null,"4.  Cash \"in transit\" disbursed to the PR:"]
[null,"5. Cash \"in transit\" disbursed to third parties by the Global Fund on behalf of the PR",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"$f":"+N31+N33+N34","v":{"$error":"#REF!"}}]
[]
["6.  PR's Disbursement Request to the Global Fund for the period immediately following the period covered by the Progress Update, plus additional period (cash buffer):",null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,null,{"$f":"IF(S20=0,0,IF(S20-S34<0,0,S20-S34))","v":0}]
[]
["7.  Does the PR's Disbursement Request include funds for health product procurement?",null,null,null,null,null,null,null,"Select"]
[]
["8. Exchange Rate (used to translate local currency into grant currency)",null,null,null,null,null,null,null,"Name of local currency, date and source of the exchange rate, and other comments (if appropriate) "]
[null,"- used to convert Opening Cash Balance"]
[]
[null,"- used to convert Closing Cash Balance"]
[]
[null,"- used to convert Total Cash Outflow for the Progress Update Period"]

{"sheet":"Modules","index":25,"n_rows":24,"n_cols":6,"rows_kept":24,"cut":false,"hidden":true,"merged":[]}
[]
[null,"HIVAIDS_Module","HIVTB","Tuberculosis","Malaria","Health Systems Strengthening"]
[null,"Prevention programs for general population","Prevention programs for general population","TB care and prevention","Vector control","HSS - Procurement supply chain management (PSCM)"]
[null,"Prevention programs for MSM and TGs","Prevention programs for MSM and TGs","TB/HIV","Case management","HSS - Health information systems and M&E"]
[null,"Prevention programs for sex workers and their clients","Prevention programs for sex workers and their clients","MDR-TB","Specific prevention interventions (SPI)","HSS - Health and community workforce"]
[null,"Prevention programs for people who inject drugs (PWID) and their partners","Prevention programs for people who inject drugs (PWID) and their partners","HSS - Procurement supply chain management (PSCM)","HSS - Procurement supply chain management (PSCM)","HSS - Service delivery"]
[null,"Prevention programs for other vulnerable populations (please specify)","Prevention programs for other vulnerable populations (please specify)","HSS - Health information systems and M&E","HSS - Health information systems and M&E","HSS - Financial management"]
[null,"Prevention programs for adolescents and youth, in and out of school","Prevention programs for adolescents and youth, in and out of school","HSS - Health and community workforce","HSS - Health and community workforce","HSS - Policy and governance"]
[null,"PMTCT","PMTCT","HSS - Service delivery","HSS - Service delivery","HSS - Healthcare financing"]
[null,"Treatment, care and support","Treatment, care and support","HSS - Financial management","HSS - Financial management","Removing legal barriers to access"]
[null,"TB/HIV","TB care and prevention","HSS - Policy and governance","HSS - Policy and governance","Program management"]
[null,"HSS - Procurement supply chain management (PSCM)","TB/HIV","HSS - Healthcare financing","HSS - Healthcare financing"]
[null,"HSS - Health information systems and M&E","MDR-TB","Removing legal barriers to access","Removing legal barriers to access"]
[null,"HSS - Health and community workforce","HSS - Procurement supply chain management (PSCM)","Community systems strengthening","Community systems strengthening"]
[null,"HSS - Service delivery","HSS - Health information systems and M&E","Program management","Program management"]
[null,"HSS - Financial management","HSS - Health and community workforce","Results-based Financing","Results based Financing"]
[null,"HSS - Policy and governance","HSS - Service delivery"]
[null,"HSS - Healthcare financing","HSS - Financial management"]
[null,"Removing legal barriers to access","HSS - Policy and governance"]
[null,"Community systems strengthening","HSS - Healthcare financing"]
[null,"Program management","Removing legal barriers to access"]
[null,"Results-based Financing","Community systems strengthening"]
[null,null,"Program management"]
[null,null,"Results-based Financing"]

{"sheet":"EFR Data","index":26,"n_rows":48,"n_cols":12,"rows_kept":48,"cut":false,"hidden":true,"merged":[]}
["EFRHIVAIDS",null,null,null,null,"SDAMalaria",null,"SDATuberculosis",null,"SDAHIVAIDS",null,"SDAHealthSystemsStrengthening"]
["Please Select…",null,null,null,null,"please select…",null,"please select…",null,"Please select…",null,"Please select…"]
["Prevention",null,null,null,null,"Prevention:  Behavioral Change Communication - Mass media",null,"Improving diagnosis",null,"Prevention: Behavioral Change Communication - Mass media",null,"HSS: Service delivery"]
["Treatment",null,null,null,null,"Prevention:  Behavioral Change Communication - community outreach",null,"Standardized treatment, patient support and patient charter",null,"Prevention: Behavioral Change Communication - community outreach",null,"HSS: Human resources"]
["Care and Support",null,null,null,null,"Prevention: Insecticide-treated nets (ITNs)",null,"Procurement and supply management",null,"Prevention: Condom distribution",null,"HSS: Community Systems Strengthening"]
["TB/HIV Collaborative Activities",null,null,null,null,"Prevention: Malaria prevention during pregnancy",null,"M&E",null,"Prevention: Counseling and Testing ",null,"HSS: Information system & Operational research"]
["Supportive Environment",null,null,null,null,"Prevention: Vector control (other than ITNs)",null,"TB/HIV",null,"Prevention: PMTCT",null,"HSS: Infrastructure"]
["Health System Strengthening (HSS)",null,null,null,null,"Prevention: other - specify",null,"MDR-TB",null,"Prevention: Post-exposure prophylaxis (PEP)",null,"HSS: Procurement and Supply management"]
[null,null,null,null,null,"Treatment: Prompt, effective anti-malarial treatment",null,"High-risk groups ",null,"Prevention: STI diagnosis and treatment",null,"HSS: other - specify"]
[null,null,null,null,null,"Treatment: Home based management of malaria",null,"HSS (beyond TB)",null,"Prevention: Blood safety and universal precaution",null,"Supportive environment: Program management and administration"]
["EFRMalaria",null,null,null,null,"Treatment: Diagnosis",null,"PAL (Practical Approach to Lung Health)",null,"Treatment: Antiretroviral treatment (ARV) and monitoring"]
["Please Select…",null,null,null,null,"Treatment: other - specify",null,"PPM / ISTC (Public-Public, Public-Private Mix (PPM) approaches and International standards for TB care)",null,"Treatment: Prophylaxis and treatment for opportunistic infections"]
["Prevention",null,null,null,null,"Supportive environment: Monitoring drug resistance",null,"ACSM (Advocacy, communication and social mobilization) ",null,"Care and support: Care and support for the chronically ill"]
["Treatment",null,null,null,null,"Supportive environment: Monitoring insecticide resistance",null,"Community TB care",null,"Care and support: Support for orphans and vulnerable children"]
["Supportive Environment",null,null,null,null,"Supportive environment: Coordination and partnership development (national, community, public-private)",null,"Programme-based operational research",null,"TB/HIV collaborative activities: HIV care and support for HIV-positive TB patients "]
["Health System Strengthening (HSS)",null,null,null,null,"Supportive environment: other - specify",null,"Other:Specify",null,"Supportive environment: Policy development including workplace policy"]
[null,null,null,null,null,"Supportive environment: Program management and administration",null,"Supportive environment: Program management and administration",null,"Supportive environment: Strengthening of civil society and institutional capacity building "]
[null,null,null,null,null,"HSS: Service delivery",null,null,null,"Supportive environment: Stigma reduction in all settings"]
["EFRHealthSystemsStrengthening",null,null,null,null,"HSS: Human resources",null,null,null,"Supportive environment: Program management and administration"]
["Please Select…",null,null,null,null,"HSS: Community Systems Strengthening",null,null,null,"HSS: Service delivery"]
["Health System Strengthening (HSS)",null,null,null,null,"HSS: Information system & Operational research",null,null,null,"HSS: Human resources"]
["Supportive Environment",null,null,null,null,"HSS: Infrastructure",null,null,null,"HSS: Community Systems Strengthening"]
[null,null,null,null,null,"HSS: Procurement and Supply management",null,null,null,"HSS: Information system & Operational research"]
[null,null,null,null,null,"HSS: other - specify",null,null,null,"HSS: Infrastructure"]
[null,null,null,null,null,null,null,null,null,"HSS: Procurement and Supply management"]
[null,null,null,null,null,null,null,null,null,"HSS: Other, specify"]
[]
[]
["EFRTuberculosis"]
["Please Select…"]
["TB Detection"]
["TB Treatment"]
["TB/HIV Collaborative Activities"]
["Supportive Environment"]
["Health System Strengthening"]
[]
[]
[]
[]
["IE"]
["Please Select…"]
["FBO"]
["NGO/CBO/Academic"]
["Private Sector"]
["Ministry Health (MoH)"]
["Other Government"]
["UNDP"]
["Other Multilateral Organization"]

{"sheet":"Checklist","index":27,"n_rows":30,"n_cols":4,"rows_kept":30,"cut":false,"hidden":false,"merged":[[5,0,5,3],[12,0,12,3],[18,0,18,3],[27,0,27,3]]}
["List of supporting documents for PU/DR review"]
[]
["This checklist is included for information and not for completion."]
[]
["List of Latest Approved Documents by functional area","To be made available to the LFA by the PR  ","To be submitted by the LFA to the Secretariat","Comments"]
["M&E"]
["Performance Framework","x"]
["M&E Plan","x"]
["Survey results","x",null,"For Impact/Outcome indicators"]
["M&E Systems Strengthening Assessment","x",null,"If newly available during the reporting period."]
["Other M&E assessments done by partners to assess data quality and M&E system issues.","x",null,"If newly available during the reporting period."]
[]
["Procurement"]
["Consumption reports for pharmaceuticals and health products","x"]
["Supplier invoices","x"]
["Procurement Plan","x"]
["Stock level reports","x"]
[]
["Finance"]
["Approved budgets","x",null,"For the periods covered by Progress Update and Disbursement Request, including the buffer period."]
["Cash books","x"]
["General Ledger ","x"]
["Cash forecasts ","x"]
["Bank statements","x"]
["Bank Reconciliations","x"]
["Annual PR Audit Report, Financial Statements, Management Letters and Responses (if Due)","x"]
["Annual SR Audit Report, Financial Statements, Management Letters and Responses (if Due)","x"]
["General Management"]
["Grant Agreement (including implementation letters)","x"]
["Workplan","x"]

{"sheet":"Memo HIV","index":28,"n_rows":26,"n_cols":10,"rows_kept":26,"cut":false,"hidden":true,"merged":[]}
["Service Delivery Areas","Impact Indicators","IndicatorTypes","Outcome Indicators","DataSources"]
["Please select…","Please select…","Please select…","Please select…","Please select…",null,null,null,null,"Please select…"]
["Prevention: Behavioral Change Communication - Mass media","% of young women and men aged 15-24 who are HIV infected ","impact","% of young people aged 15-24 who had sex with more than one partner in the last year ","National Health Accounts","Please enter a corresponding indicator here…",null,null,null,"Please select disease and Impact/Outcome first"]
["Prevention: Behavioral Change Communication - community outreach","% of adults aged 15-49 who are HIV infected ","outcome","% of young people aged 15-19 who have never had sex ","DHS/DHS+ (Demographic and Health Survey)","Please enter a data source here…"]
["Prevention: Condom distribution","% of adults and children with HIV still alive 12 months after initiation of antiretroviral therapy (extend to 2, 3, 5 years as program matures) ",null,"% of young people aged 15-24 who never had sex in the last year of those who ever had sex","MICS (Multiple Indicator Cluster Survey)","Please enter a SDA here…"]
["Prevention: Counseling and Testing ","% of infants born to HIV infected mothers who are infected ",null,"% of young people aged 15-24 reporting the consistent use of a condom with non-regular sexual partners in the last year ","AIS (AIDS Indicator Survey)"]
["Prevention: PMTCT","% of most-at-risk population(s) (sex workers, clients of sex workers, men who have sex with men, injecting drug users) who are HIV infected ",null,"% of young women and men who had sex before the age of 15 ","SAMS (Service Availibility Mapping Survey)"]
["Prevention: Post-exposure prophylaxis (PEP)","% of HIV seroprevalence among all newly registered TB patients",null,"% of adults and children who are still on treatment after 6 months, 1, 2, 3, 5 years from the initiation of treatment ","BSS (Behavioral and Surveillance Survey)"]
["Prevention: STI diagnosis and treatment",null,null,"% of injecting drug users who have adopted behaviors that reduce transmission of HIV. ","Sentinel surveillance"]
["Prevention: Blood safety and universal precaution",null,null,"% of orphaned children compared to non-orphaned children aged 10-14 who are currently attending school ","Serological surveys"]
["Treatment: Antiretroviral treatment (ARV) and monitoring",null,null,"% of young people aged 15-24 reporting the use of a condom the last time they had sex with a non-regular sexual partner ","Prevalence surveys"]
["Treatment: Prophylaxis and treatment for opportunistic infections",null,null,"% of people expressing accepting attitudes towards PLWHA, of all people surveyed aged 15-49 ","Facility-based survey "]
["Care and support: Care and support for the chronically ill",null,null,"% of female sex workers reporting the use of a condom with every client in the last month ","Key informant survey"]
["Care and support: Support for orphans and vulnerable children",null,null,"% of men who have had sex with a female sex worker in the last year ","Specific surveys (to be defined)"]
["TB/HIV collaborative activities: HIV care and support for HIV-positive TB patients ","TB/HIV collaborative activities: Intensified case-finding among PLWHA",null,"% of men reporting the use of condom the last time they had anal sex with a male partner in the last 6 months ","Civil registration systems (vital/disease specific registration) "]
["Supportive environment: Policy development including workplace policy","TB/HIV collaborative activities: Prevention of TB disease in PLWHA",null,null,"Census"]
["Supportive environment: Strengthening of civil society and institutional capacity building ","TB/HIV collaborative activities: Prevention of HIV in TB patients",null,null,"Health service statistics"]
["Supportive environment: Stigma reduction in all settings","TB/HIV collaborative activities: Prevention of opportunistic infections in PLWHA with TB",null,null,"Patient register"]
["Supportive environment: Program management and administration",null,null,null,"Clinical cohort follow-up studies "]
["HSS: Service delivery","TB/HIV collaborative activities: Provision of antiretroviral treatment for TB patients during TB treatment",null,null,"Community services assessment"]
["HSS: Human resources","HSS: PAL (Practical Approach to Lung Health)",null,null,"Records: laboratory, patient (e.g. treatment cards), training, certification, other (to be specified)"]
["HSS: Community Systems Strengthening",null,null,null,"Operational research"]
["HSS: Information system & Operational research"]
["HSS: Infrastructure"]
["HSS: Procurement and Supply management"]
["HSS: Other, specify"]

{"sheet":"Memo TB","index":29,"n_rows":27,"n_cols":5,"rows_kept":27,"cut":false,"hidden":true,"merged":[]}
["Service Delivery Areas","Impact Indicators","IndicatorTypes","Outcome Indicators","DataSources"]
["please select…","please select…","please select…","please select…","please select…"]
["Improving diagnosis","TB prevalence rate","impact","Case detection","National Health Accounts"]
["Standardized treatment, patient support and patient charter","TB incidence rate","outcome","Treatment success rate","DHS/DHS+ (Demographic and Health Survey)"]
["Procurement and supply management","TB mortality rate",null,"Smear conversion rate","MICS (Multiple Indicator Cluster Survey)"]
["M&E",null,null,null,"AIS (AIDS Indicator Survey)"]
["TB/HIV",null,null,null,"SAMS (Service Availibility Mapping Survey)"]
["MDR-TB",null,null,null,"BSS (Behavioral and Surveillance Survey)"]
["High-risk groups ",null,null,null,"Sentinel surveillance"]
["HSS (beyond TB)",null,null,null,"Serological surveys"]
["PAL (Practical Approach to Lung Health)",null,null,null,"Prevalence surveys"]
["PPM / ISTC (Public-Public, Public-Private Mix (PPM) approaches and International standards for TB care)",null,null,null,"Facility-based survey "]
["ACSM (Advocacy, communication and social mobilization) ",null,null,null,"Key informant survey"]
["Community TB care",null,null,null,"Specific surveys (to be defined)"]
["Programme-based operational research"]
["Other:Specify"]
["Supportive environment: Program management and administration",null,null,null,"Civil registration systems (vital/disease specific registration) "]
[null,null,null,null,"Census"]
[null,null,null,null,"Health service statistics"]
[null,null,null,null,"Patient register"]
[null,null,null,null,"Clinical cohort follow-up studies "]
[null,null,null,null,"Community services assessment"]
[null,null,null,null,"Records: laboratory, patient (e.g. treatment cards), training, certification, other (to be specified)"]
[null,null,null,null,"Operational research"]
[null,null,null,null,"R&R TB system, quarterly report"]
[null,null,null,null,"R&R TB system, yearly management report "]
[null,null,null,null,"Other Surveillance reports, specify"]

{"sheet":"Memo Malaria","index":30,"n_rows":25,"n_cols":5,"rows_kept":25,"cut":false,"hidden":true,"merged":[]}
["Service Delivery Areas","Impact Indicators","IndicatorTypes","Outcome Indicators","DataSources"]
["please select…","please select…","please select…","please select…","please select…"]
["Prevention:  Behavioral Change Communication - Mass media","Death rates associated with Malaria: all-cause under-5 mortality rate in highly endemic areas ","impact","% of U5 children (and other target groups) with malaria/fever receiving appropriate treatment within 24 hours (community/health facility)","National Health Accounts"]
["Prevention:  Behavioral Change Communication - community outreach","Incidence of clinical malaria cases (estimated and/or reported) ","outcome","% of U5 children (and other target group) with uncomplicated malaria correctly managed at health facilities","DHS/DHS+ (Demographic and Health Survey)"]
["Prevention: Insecticide-treated nets (ITNs)","Anaemia prevalence in children under 5 years of age",null,"% of U5 children (and other target groups) admitted with severe malaria and correctly managed at health facilities","MICS (Multiple Indicator Cluster Survey)"]
["Prevention: Malaria prevention during pregnancy","Prevalence of malaria parasite infection ",null,"% of children U5 sleeping under an ITN the previous night","MIS (Malaria Indicator Survey)"]
["Prevention: Vector control (other than ITNs)","Laboratory-confirmed malaria cases seen in heath facilities",null,"% of households with at least one ITN","SAMS (Service Availibility Mapping Survey)"]
["Prevention: other - specify","Laboratory-confirmed malaria deaths seen in health facilities",null,"% of pregnant women (and other target groups) sleeping under an ITN the previous night","BSS (Behavioral and Surveillance Survey)"]
["Treatment: Prompt, effective anti-malarial treatment","Malaria-attributed deaths in sentinel demographic surveillance sites",null,"% of pregnant women on Intermittent preventive treatment (IPT) according to national policy (specific to Sub-Saharian Africa)","Sentinel surveillance"]
["Treatment: Home based management of malaria","API (Annual Parasite Index) (specific to Latin America and Asia)",null,"% of households in malaria areas protected by IRS","MOH (routine HIS or HMIS)"]
["Treatment: Diagnosis",null,null,null,"RBM (Roll Back Malaria)"]
["Treatment: other - specify",null,null,null,"Serological surveys"]
["Supportive environment: Monitoring drug resistance",null,null,null,"Prevalence surveys"]
["Supportive environment: Monitoring insecticide resistance",null,null,null,"Facility-based survey "]
["Supportive environment: Coordination and partnership development (national, community, public-private)",null,null,null,"Key informant survey"]
["Supportive environment: other - specify",null,null,null,"Specific surveys (to be defined)"]
["Supportive environment: Program management and administration",null,null,null,"Civil registration systems (vital/disease specific registration) "]
["HSS: Service delivery",null,null,null,"Census"]
["HSS: Human resources",null,null,null,"Health service statistics"]
["HSS: Community Systems Strengthening",null,null,null,"Patient register"]
["HSS: Information system & Operational research",null,null,null,"Clinical cohort follow-up studies "]
["HSS: Infrastructure",null,null,null,"Community services assessment"]
["HSS: Procurement and Supply management",null,null,null,"Records: laboratory, patient (e.g. treatment cards), training, certification, other (to be specified)"]
["HSS: other - specify",null,null,null,"Operational research"]
[null,null,null,null,"Questionnaire"]